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ABSTRACT 
             The study of the immune system has provided insight in the mechanism of 
protection induced by vaccination; primarily that most clinically protective vaccines 
are potent in generating neutralizing antibody responses. However, vaccination fails 
to protect against a wide range of acquired chronic infections caused by viruses, such 
as HIV, HBV and HCV. One of the major reasons for weak responses to therapeutic 
vaccine is the impaired function of effector T cells resulting from viral persistence. 
Although IL-2 can potently increase effect function of viral specific T cells, systemic 
administration of IL-2 induces organ pathology and expansion of Treg cells.  
             In this study, we have now developed a novel vaccine delivery system IL-2-
nanoAPC delivering antigen-MHC complexes (pMHC), co-stimulatory molecules 
and IL-2 to antigen specific T cells. NanoAPC are derived from the endoplasmic 
reticulum (ER) membranes of human B cell line 721.221 engineered with selected 
HLA allele and IL-2 as the ER retention proteins. The IL-2-nanoAPC interacted with 
antigen specific T cells, induced immune synapses and expression of high affinity 
IL-2 receptor and enhanced effector function of antigen specific T cells, but did not 
affect bystander T cells and Foxp3
+
 Treg cells. Together with pMHC, co-stimulatory 
molecules, the selective delivery of IL-2 not only increased the CD4 and CD8 T cell 
responses to viral antigens but also enhanced TCR proximal signalling and 
suppressed expression of PD1 molecules on IFNγ producing effector CD8 T cells. 
We also found that the co-induction of T helper responses by IL-2-nanoAPC in a 
mixed culture could increase CD8 T cell responses to viral antigen. The IL-2-
nanoAPC effectively induced responses of CD4 and CD8 T cells from chronic HBV 
patients. The results demonstrate that selective delivery of IL-2, together with pMHC 
and co-stimulatory molecules, by nanoAPC to antigen specific T cells has potential 
to recover anti-viral immune responses in chronic HBV patients.  
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INTRODUCTION 
            The plague of Athens in 430BCE is the earliest trail of immunity recorded by 
Thucydides. He noted that if the people that had recovered from a previous bout of 
the disease could nurse the sick without contracting the illness a second time (Figure 
1.1).  
 
Figure 1.1 Plague of Athens (430BC). 
            Couples of milleniums later, Edward Jenner (1749-1823) who is credited as 
the founder of immunology generated a vaccine against smallpox in 1798. However, 
the similar evidence also existed in traditional Chinese medicine. In 1000 AD the 
ancient Chinese custom suggest to use the powders made from the crusty skin lesions 
of patients recovered from smallpox inhaled by children to protect the disease.  Even 
earlier, in AD 649, Sun Simiao, a famous Chinese doctor recorded that covers the 
people with the sick dog’s brain (Cao, 2008) (Figure 1.2). Although they did not 
have any knowledge of the existence of pathogens, their experiences introduce 
concepts of vaccines and the foundation of immunology. 
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Figure 1.2 the discovery of vaccination. 
Left, Dr Jenner discovered that milkmaids who came into contact with cowpox seemed to be 
immune from contracting smallpox. He inoculated a young boy with pus from cowpox 
blisters found on the hand of a milkmaid (in Latin cow = vacca, hence the term vaccination) 
to generate an immune response which crossreacted and offered protection against smallpox.  
Right Bei Ji Qian Jin Yao Fang by Sun Simiao (581–682), published circa AD 649 and the 
related description of preventing the recurrence of rabies by "covering the people with the 
sick dog's brain" (red line) (Cao, 2008). 
            Then move to 19
th
-century the discoveries of Robert Koch showed that 
specific diseases were caused by specific pathogens. In the 1880s Luis Pasteur 
prepared a vaccine against rabies to treat a boy bitten by a rabid dog. Together with 
Koch and Jenner’s experience, in the early of 1890s, Emil von Behring and 
Shibasaburo Kitasato (Figure 1.3) discovered that the serum of the animals immune to 
diphtheria or tetanus contained a specific antitoxic activity can protect against the 
toxin from the diphtheria or tetanus. This protection is due to specific antibody, which 
binds to the specific protein to neutralize their activity. Overall, the understanding of 
these mechanisms gave birth to immunology. 
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Figure 1.3 Emil von Behring and Shibasaburo Kitasato 
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1. The immune system. 
          The immune system, a system of biological structures and processes within an 
organism that protects against disease. The system consists of tissues organs, cells 
and molecules that work together to detect, distinguish and eliminate harmful 
pathogens by orchestrated mechanisms that are collectively called the Immune 
Response. 
1.1 The cellular mediators of the immune system 
           All the cells in the immune system are derived from multipotent 
hematopoietic stem cells in the bone marrow. Before they give rise to all the blood 
cell types, they need to switch from highly undifferentiated progenitor cell to two 
different types of less differentiating plasticity stem cells, the common myeloid 
progenitor and the common lymphoid progenitor. The myeloid progenitor 
differentiates into platelets, erythrocytes (red blood cells), granulocytes, 
macrophages and myeloid dendritic cells (DC). The lymphoid progenitor 
differentiates into the T cells, B cells and Natural Killer cells (NK cells) (Figure1.4).  
            Granulocytes, also known as polymorphonuclear leukocytes, are a type of 
white blood cells which own their name by the presence of granulues in their 
cytoplasm. They are characterised by a short life span and are detected in increased 
numbers during immune responses. There are three types of granulocytes, neutrphils 
eosinophils and basophils, which are distinguished by the different staining 
properties of the granules. Granulocytes are part of the innate immune system; their 
role is principally phagocytic, as neutrophil is the most important cells in innate 
immune response, and also it provide as potent phagocytic cells, together with 
macrophages and dendritic cells.   
            T and B lymphocytes are distinguished from the other leukocytes, because of 
antigen receptors, and also differentiation from each other by maturation site. After T 
and B cells mature, they are circulate between the blood and the peripheral lymphoid 
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tissues to recognise the specific antigen. This characteristic makes them the principal 
mediators of an organised adaptive immune response launched against a specific 
pathogen. Unlike T and B cells, NK cells lack antigen specificity and are thought to 
recognise a missing self state through sets of activating and inhibitory receptors. 
 
Figure 1.4 Origin of cells of the immune system. 
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All the cells of the immune system originate from a common pluripotent hematopoietic 
progenitor of the bone marrow. These highly undifferentiated cells divide to produce a 
common lymphoid progenitor that gives rise to NK cells, B and T lymphocytes, and a 
common myeloid progenitor that gives rise to erythrocytes (red blood cells), granulocytes 
(polymprphonuclear leukocytes), megakaryote (cells that produce platelets), macrophages 
and dendritic cells. 
1.2 Other mediators of the immune system 
            Immunoglobulin also known as antibody is antigen recognition molecules of 
B cells. With similar structure, these proteins are produced by naïve B cells and 
activated plasma cell. Membrane bound immunoglobulin serves as B cell receptor 
(BCR). Immunoglobulin for the specific antigen is secreted as antibody by plasma 
cells. They have the capacity to bind specific pathogens or the toxic products. 
            Cytokines are secreted small proteins made by various cells in the body, 
which change the behaviour of cells through binding to specific receptors. Each cell 
type can produce only certain cytokines and in response to certain stimuli. Some 
cytokines have overlapping functions and some have opposite. Cytokines facilitate 
cell growth, chemotaxis, activation and enhance cytotoxicity. Interleukins (IL) are 
group of cytokines that are produced by leucocytes and act on leucocytes.  
Chemokines are small chemoattractant proteins which bind to their receptors 
on leukocytes and induce directed chemotaxis. Normally the cytokine and chemokines 
released by activated macrophages initiate the process known as inflammation. And 
also they response to an activating stimulus which create a certain environment at the 
site of infection which helps the target antigen to the specific antigen presenting cells 
(APC), this initiates APC maturation, triggers cell migration to the  peripheral 
lymphoid organs and regulates differentiation of T cells and antibody mediated 
immunity. The most important cytokines in innate immunity are TNF-α, IL-1, IL-10, 
IL-12, IFNα, β and γ, in adaptive immunity these are IL-2, IL-4, IL-5, TGF-β, IL-10 
and IFNγ 
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1.3 The structure of the immune system. 
            Immune system is the organs, tissues, cells and molecules involved in both 
innate immunity and adaptive immunity. Lymphoid organs can be generally divided 
into central or primary lymphoid organs, where lymphocytes are generated. 
Peripheral or secondary lymphoid organs, is where adaptive immune response are 
initiated and lymphocytes are maintained. The central lymphoid organs are the bone 
marrow and the thymus where B cells and T cells develop respectively. The 
peripheral lymphoid organs are spleen, lymph nodes and lymphoid tissues associated 
with mucosa which are found in various locations in the body such as the 
gastrointestinal tract, thyroid, breast, lung, salivary glands, eye and skin. The 
lymphoid organs are interconnected and link with the blood via the lymphatic system. 
Peripheral lymphoid tissues are dynamic structures highly involved in the immune 
response and their appearance and function is finely coordinated. 
1.4 The immune response. 
            The immune response consists of processes in which our body recognizes and 
defends itself against bacteria, viruses, and substances that appear foreign and 
harmful.  
1.4.1 Innate immune response. 
            Innate immunity is the front line of host defence. It is assumed to be rapid, 
non-specific and identical qualitatively and quantitatively each time the same 
pathogen is encountered (Lanier and Sun, 2007). Similar like adaptive immune 
systems the innate immunity has ability to distinguish between self and non-self 
molecules. Innate immunity relies on receptors such as toll-like receptors (TLR) that 
recognize conserved patterns on different classes of pathogens to trigger an 
inflammatory response which limits pathogen invasion (Janeway and Medzhitov 
2002) (Akira, et al. 2006) (Cooper and Alder 2006). Innate immunity largely 
involves three types of leukocytes, granulocytes, dendritic cells and macrophages 
which bind to pathogens internalise them finally to be killed. Because they use 
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primitive non-specific recognition systems they can bind to a variety of microbial 
products and induce phagocytosis (Janeway et al, 2001). And also the innate immune 
system provides a humeral response via cytokine such as IL-1 to activate the B cells 
to produce antibody. So  innate immune response largely involve professional 
antigen presenting cells, macrophages, dendritic cells and B cells, which can trigger 
adaptive immunity (Figure 1.5). 
 
Figure 1.5 Innate immunity is critical to adaptive immune response. 
Innate immunity is based on the recognition of invariable pathogen associated molecular 
patterns (PAMPs) by Toll-like receptors, and on phagocytosis. If the innate response fails to 
eliminate the pathogen, activated antigen presenting cells bearing this antigen trigger an 
adaptive immune response; they travel to the secondary lymphoid tissues where they present 
antigenic peptides and co-stimulatory signals to naïve T cells. After engaging antigen and 
costimulatory molecules, naïve T cells will be activated, expand and finally differentiated to 
effector T cells.   
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1.4.2 Adaptive immune response. 
            Adaptive immune response is the response of antigen-specific lymphocytes to 
antigen, including the development of immunological memory. B cells are one of the 
major cell types involved in adaptive immune responses. By production of antibodies, 
B cells mediate the humoral response. The antibodies produced by antigen specific B 
cells bind to pathogens and eliminate the pathogens by three main ways: a) They 
inhibit the toxic effects or infectivity of pathogens by binding to them (neutralisation). 
b) By coating the pathogen they enable phagocytic cells to recognise and kill it 
(opsonization). c) Antibodies can also trigger complement activation, which strongly 
enhances opsonization and directly lyses some bacteria (Janeway et al, 2001). 
            T cells are essential component of adaptive immune responses and have a 
wider range of activities. They are divided into two categories based on coreceptor 
molecules, the CD8
+
 T cells and the CD4
+
 T cells.  These two subclasses serve 
different functions upon activation.  CD8
+
 T cells differentiate into cytotoxic T cells 
which act by direct killing of the infected cell, either by delivering cytotoxic proteins 
or by triggering the target cell to apoptosis (Lim et al, 2000). CD4
+
 T cells 
differentiate into helper T cells which activate other cells; they either activate 
macrophages to kill pathogens (T helper I) or they activate B cells to produce 
antibody (T helper 2) (Janeway et al, 2001). T cells can only recognise antigenic 
peptide when in the form of complex with MHC molecules on the surface of antigen 
presenting cells to the two different subsets of T cells. MHC class I present peptides 
to CD8
+
 T cells and MHC class II presents peptides to CD4
+
 T cells (Moss and 
Khanna, 1999).  
            T cell activation requires T cell receptor recognition of peptide/MHC ligands 
on antigen presenting cells, plus co-stimulation resulting from the interaction of 
various molecules on T cells with complementary molecules on antigen-presenting 
cells (mainly dendritic cells) (Chambers and Allison, 1997). Contact with these 
ligands drives T cells to proliferate and differentiate into effector T cells (Figure 1.6).  
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Figure 1.6 Adaptive immune response. 
The humoral branch of the immune system comprises B-lymphocytes (left), which after 
interaction with virus differentiate into antibody-secreting plasma cells. The cellular 
response (right) starts with antigen presentation via MHC I (black) and II (blue) molecules 
by dendritic cells, which then leads to activation, proliferation and differentiation of antigen-
specific T cells (CD4 or CD8). These cells gain effector cell function to help directly, 
release cytokines, or mediate cytotoxicity following recognition of antigen.  
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1.4.3 Thymocytes differentiation and central tolerance 
1.4.3.1 Thymocytes differentiation 
T cell maturation in thymus is strictly controlled process. T cell arise from 
hematopoietic stem cells, migrate to the thymus (Starr et al., 2003). The thymus is an 
organ that supports the differentiation and selection of T cells (Takahama, 2006). 
Figure 1.7 shows the overall scheme of the T cell development within the thymus. 
 
Figure 1.7 Overall summary of T cell development in the Thymus 
Lymphoid Progenitors arise in the bone marrow and migrate to the thymus. In 
the thymus these cells lose the potential for B cell and natural killer cell development 
(Michie et al., 2000). The progenitor upon entry, lack expression of CD4 and CD8 
and are called double negative (DN). DN thymocytes can be subdivided further into 
four sequential stages of differentiation, which are identified by their surface 
expression of CD44 and CD25: DN1, CD44
+
CD25
-
; DN2, CD44
+
CD25
+
; DN3, 
CD44
-
CD25
+
; and DN4;CD44
-
CD25
-
 (Godfrey et al., 1993). As the cells progress 
from DN2 to DN4 stages, they express the pre-T cell receptors (pre-TCR), which is 
composed of the non-rearranging pre-Tα chain and a rearranged TCR β-chain, 
forming a pre-TCR complex (von Boehmer and Fehling, 1997). Only the cells that 
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succeed in in-frame rearrangement of the gene encoding the TCR β-chain are 
selected for further differentiation beyond this DN3 stage.  
In the thymic cortex, the successful expression of the pre-TCR complex on 
the thymocytes along with the interaction of Notch molecules with their legends such 
as delta-like (DII) 1 and delta-like 4 (DII 4) initiate the signals for further 
development to double positive (DP) thymocytes that express the TCRαβ antigen 
receptors. This is the first checkpoint of T cell development at the DN3 stage 
(Takahama, 2006). During the transition of DN4 to DP the pre-TCR expression leads 
to substantial cell proliferation. From the large number of DP thymocytes, the DP 
thymocytes that are best suited to function in the host environment is permitted to 
mature and migrate to peripheral lymphoid tissues. This selection is characterised by 
four processes; death by neglect, negative selection, positive selection and lineage-
specific development (Figure 1.8) 
 
Figure 1.8 Positive selection processes, negative selection process  
Death by neglect is initiated when there is too little signalling between the 
TCR and the self-peptide-MHC ligands, which results in delayed apoptosis. Too 
much signalling can promote acute apoptosis, which is caused in negative selection. 
Positive selection occurs when the signalling is at an intermediate level, where TCR 
signalling initiates effective maturation (Germain, 2002).  
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Positively selected DP thymocytes are induced to differentiate into single 
positive thymocytes, which are CD4
+
CD8
-
 or CD4
-
CD8
+
 (Hollander and Peterson, 
2009). These thymocytes spend approximately 12 days in the medulla before 
travelling to the cortex. During this period the SP thymocytes go through a 
maturation process. This is accompanied by further deletion of self-reactive 
thymocytes that have escaped negative selection in the cortex. This process is 
particularly important in central tolerance to tissue specific antigens (Kyewski and 
Derbinski, 2004).   
As well as the deletion mechanism that ensures self-tolerance, it is also 
thought that the medulla is the place for the production of regulatory T cells 
(Takahama, 2006). Treg cells have emerged to play a critical role in suppressing the 
response of the immune system to self-antigen (Kuhn et al., 2009). 
1.4.3.2 Central tolerance 
            Central tolerance is tolerance to self antigens that is established during 
lymphoid cell development in central lymphoid organs. It is associated with the 
deletion of autoreactive clones. For T cells, this occurs in the thymus. Central 
tolerance mechanisms eliminate newly formed strongly autoreactive lymphocytes 
before they migrate to peripheral lymphoid organs. However, some self-reactive T 
lymphocytes escape central tolerance because some of the cognate self-antigens are 
not expressed in thymus. These autoreactive cells are inactivated in the periphery. It 
is unlikely that mechanisms of tolerance would be sufficient to compensate for the 
failure to remove self-reactive lymphocytes during their primary development. It is 
important that there is some mechanism to prevent auto reactivity of the T cells after 
they have emigrated from the thymus. This is achieved through the T cell tolerance 
process. Although most of the self-reactive T cells are eliminated in the thymus, 
negative selection has limitations and additional mechanisms of tolerance are 
required to limit autoimmunity (Bandyopadhyay et al, 2007). Therefore the self-
reactive T cells that escape the negative selection must be kept under control in the 
periphery. To simplify the tolerance process the peripheral tolerance can be divided 
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into those that act directly on the responding T cell and those that evoke additional 
subsets of cells, including dendritic cells and regulatory cells (Walker and Abbas, 
2002) (Figure 1.9). 
 
Figure 1.9 Central-tolerance mechanisms 
The affinity of the TCR for self-peptide–MHC ligands is the crucial parameter that drives 
developmental outcome in the thymus. Progenitors that have no affinity or very low affinity 
die by neglect. This is thought to be the fate of most thymocytes. If the TCR has a low 
affinity for self-peptide–MHC, then the progenitor survives and differentiates, a process that 
is known as positive selection. If the progenitor has a high affinity for self-peptide–MHC, 
then several outcomes are possible. (Kristin et al, 2005) 
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2. The Major Histocompatibility complex (MHC)  
2.1 MHC genes and molecule. 
            The protective function of T cells depends on their ability to recognize cells 
that are harboring pathogens or the internalized pathogens or their products. They are 
glycoproteins present on the cell surface of host cells. The MHC molecules which are 
proteins involved in antigen presentation to T cells by delivering and displaying 
antigenic peptide on the surface of cell membranes.  
            The MHC is a cluster of genes on human chromosome 6 or mouse 
chromosome 17. The Human Leukocyte Antigen (HLA) is the genetic designation 
for the human MHC. It extends over 4 centimorgans of DNA and contains over 200 
genes, more than 40 of which encode leukocyte antigens. The rest are an assortment 
of genes that are not evolutionary related to the HLA genes themselves, although 
some are involved with them functionally (Klein and Sato, 2000). Some of them 
which have nothing to do with immune recognition which has been suggested that 
these phenotypes are due to accumulated mutations or genetic divergence. The MHC 
genes that are involved in the immune response are the MHC class I and class II 
genes. 
 In the genetic organisation of the MHC in human and mouse, there are three 
classes I α chain genes in humans, called HLA-A, -B and –C (the gene for β2-
microglobulin is located in a different chromosome). There are also three pairs of 
MHC class II α- and β-chain genes, called HLA-DR, -DP and –DQ. However in 
many cases the HLA-DR cluster contains an extra β-chain gene whose product can 
pair with DRα chain. This means that the three sets of genes can give rise to four 
types of MHC class II molecule (Beck and Trowsdale, 1999). The expression of 
MHC alleles is codominant. The class II region also include the TAP, LMP, DM, and 
DO genes. 
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            All the MHC class I and II molecules can present peptides to T cells (Figure 
2.1), MHC class I molecules are expressed on all nucleated cells. By contrast, MHC 
class II expression is restricted in the professional antigen presenting cells, namely B 
cells, macrophages and dendritic cells. To compete with rapidly evolving pathogens 
the MHC is highly polygenic and polymorphic. These are important features as they 
allow the immune system the ability to present a wide array of peptides, preventing 
one disease wiping out the entire species. Much is known about MHC-peptide 
complexes, but each molecule binds a different range of peptides. Thus the presence 
of several different genes of each MHC class means that any individual is equipped 
to present a much broader range of peptides than if only one MHC molecule of each 
class was expressed at the cell surface (Janeway et al, 2001). In this way the host has 
a much greater chance to recognise and eliminate pathogens.  
 
Figure 2.1 The MHC molecule bind to the T cell receptor 
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The MHC class I molecule (left) on most cells binds to the T-cell receptor (TCR) and CD8 
receptor. The MHC Class II molecule (right) on immune cells binds to the TCR and CD4 
receptor on other immune cells. 
2.2. MHC polymorphism 
An outstanding feature of the MHC molecules is their extensive 
polymorphism. There are multiple variants of each gene within a population as a 
whole; the MHC genes are in fact the most polymorphic genes known. There is 
unwarranted satisfaction with the view that MHC polymorphism evolved because 
there was a selective advantage in having a variety of MHC proteins to bind a variety 
of peptide subsets for presentation to T cells (Forsdyke, 1991).  
There are more that 200 alleles of some human MHC class I and II genes, 
each allele being present at a relatively high frequency in the population. So there is 
only a small chance that an individual will be homozygous at a specific MHC locus. 
Thus the extensive polymorphism at each locus has the potential to double the 
number of different MHC molecules expressed in an individual and thereby increases 
the diversity already available through polygeny.  
Allelic variation occurs at specific sites within the MHC molecules (Figure 
2.2). The polymorphic residues are found at the peptide-binding groove. More 
specifically, diversity occurs at the α1 and α2 domains of class I molecules and β1 
domain of class II molecules. Among the polymorphic residues there are several 
conserved residues within the antigen-binding sites. It has been demonstrated by 
Geluk et al (1993) that these reside is crucial for peptide binding and recognition by 
the T cell receptor, and has been conserved for over 30 million years!  
MHC polymorphism appears to have been strongly selected by evolutionary 
pressures. Because selectively neutral polymorphisms are not expected to be 
maintained for long periods of time, the long persistence of MHC polymorphisms is 
evidence that they are selectively maintained (Hughes and Yeager, 1998). Evidence 
from the house mouse (Mus) suggests that the extreme diversity of genes of the 
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MHC results from three different forms of selection: i) pathogen driven selection 
(hypotheses of heterozygote advantage and rare allele advantage), ii) sexual selection 
(hypotheses of mating preferences, infertility and foetal loss and scarcity of 
homozygotes) and iii) inbreeding depression, the most important being the first one 
(Potts and Wakeland 1993) (Jeffery and Bangham, 2000) (Grosberg and Hart,2000) 
(Gruen and Weissman, 1997).     
 
      Figure 2.2. Allelic variation occurs at specific sites within MHC molecules. 
2.3 The structure of MHC molecules. 
As mentioned before, the overall structure of the two classes of MHC 
molecules is very similar. However they bear some critical differences that allow 
them to serve their distinct functions in antigen presentation.     
2.4 MHC class I molecule.    
            There are three components consist of the structure of a mature MHC class I 
molecules which is a heterodimer of the polymorphic heavy chain (HC) 
noncovalently associated with β-2microglobulin (β2m), where does not span the 
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membrane and then loaded with the antigenic peptide, all of which are essential for 
the formation and stability of a functional MHC class I complex. The heavy chain 
(43kDa) α chain, a transmembrane glycoprotein, folds into three different structural 
domains (α-1, α-2, α-3), a transmembrane segment and a cytoplasmic tail. The 
folding of α1 and α2 domains creates a long cleft or groove, which accommodates 
the peptide antigens (Klein and Sato, 2000). The peptides that can bind to a given 
MHC molecule have the same or very similar amino acid residues (‘anchor’ residues) 
at two or three particular positions alone the peptides in the MHC molecule (Bouvier 
and Wiley, 1994). MHC ckass I molecules bind short peptides if 8-10 amino acids by 
both ends. 
 
Figure 2.3 MHC class I.  
Scematic representation shows the MHC class I molecule is a heterodimer of a 
transmembrane α chain bound non-covalently to β2-microglobulin, which does not span the 
membrane. The α1 and α2 segments of the heavy chain fold together to create the peptide-
binding site. 
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2.5 MHC class II molecule. 
The MHC class II molecule (Figure2.4) is composed of two transmembrane 
glycoprotein chain, α and β, which are both encoded within the MHC region of the 
genome. Each chain has two domains and the two chains together form a compact 
four-domain compact structure, similar to that of MHC class I molecule (Fremont et 
al, 1996). The two domains forming the peptide-binding cleft are contributed by 
different chains and are therefore not joined by a covalent bond (Klein and Sato, 
2000). The major difference between the two molecules is that for MHC class II the 
membrane distal domains are not joined by covalent bonds, thus forming a peptide-
binding groove that is open at both ends. As a result, the peptide ends are not bound 
into pockets, but instead the peptide lies in an extended conformation between the 
two chains and binds by interactions along the length of the binding groove. Because 
the peptide is bound by its backbone and allowed to emerge from both ends of the 
binding groove, the length of the peptides that bind to MHC class II molecules are at 
least 13 amino acids long and can be much longer than of those that bind to MHC 
class I molecules, in most cases between 13-17 amino acids long (Rammensee, 1995) 
(Sofra, 2009). Similarly to MHC class I molecules, the sites of major polymorphism 
in the MHC class II molecule that determine antigen binding are located in the 
peptide binding cleft; different allelic variants of MHC class II molecules bind 
different peptides. However, the more open structure of the MHC class II peptide-
binding site and the greater length of the peptides bound in it allow greater flexibility 
in peptide binding (Sofra, 2009). 
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Figure 2.4 MHC class II.  
Schematic representation shows MHC class II is formed by two transmembrane 
glycoprotein chains, which are not covalently bound. Thus, the peptide binding site that is 
formed is open at both ends. 
 
2.6 Peptide-MHC complex. 
            MHC molecules assemble with short antigenic peptides to form antigenic 
peptide MHC complexes. TCR interacts both the antigenic peptides and MHC to 
respond effectively to antigen under MHC restriction. As mentioned before the 
mature MHC molecules consist of three components: the polymorphic heavy chain 
(HC), (light chain) and the antigenic peptide which is a necessary and integral part of 
a stable MHC molecule structure; this serves to prevent random peptide exchanges at 
the cell surface, thus making the peptide/MHC complex a reliable indicator of 
infection or of uptake of a specific antigen. 
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MHC class I molecules are translocated during synthesis into the lumen of 
Endoplasmic reticuculum (ER). Here the chains must fold correctly and assemble 
with each other if necessary, before the complete protein can be transported to the 
cell surface. Thus the peptide-binding site of the MHC class I molecule is formed in 
the lumen of ER and is never exposed to the cytosol. Newly synthesized MHC class I 
molecules are held in the ER until they form stable peptide/MHC class I complexes 
(Townsend et al, 1989), so antigenic peptides are transported into the lumen of ER. 
The antigenic fragments derive from proteins found in the cytosol and they are 
formed by degradation of larger proteins by the proteasome, which is protein 
degradation machines located in the nucleus and the cytoplasm, before they enter the 
ER through the transporters associated with antigen processing (TAP). The TAP 
transporter is responsible for antigenic peptide translocation. This is a heterodimer of 
TAP1 and TAP2 proteins, which are members of the ATP-binding cassette (ABC) 
superfamily and are characterised by the ABC unit. ABC proteins mediate ATP-
dependent transport of ions, sugars, amino acids, and peptides across membranes in 
many types of cells, including bacteria (Klein et al, 1999). 
            In the ER, every step of the assembly and forming of the MHC class I 
molecule undergoes extensive quality control by a wide array of chaperones and 
specific proteins. Thus there is a recognition point on class I heavy chain molecules 
single N-linked glycan for the ER membrane chaperone calnexin and soluble 
chaperone calreticulin, both of which aid in the proper folding and retention of the 
class I molecules (Amy et al, 2002). Initially, partly folded MHC class I α chains 
bind to a chaperone protein, calnexin, and form a complex that binds to β2m. The 
MHC class I α: β2m dimmer is then released from calnexin to become associated 
with the loading complex, which consists of the chaperone molecules calreticulin and 
Erp57, the transporters associated with antigen processing (TAP1 and TAP2) and 
tapasin as the specific chaperone only located at the membrane of the ER. Tapasin 
bridges TAP and MHC class I to facilitate the delivery of suitable TAP-associated 
peptides and their loading on the MHC class I. A stable peptide/MHC class I 
complex is then allowed to travel to the cell surface (Figure 2.5). 
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Figure 2.5. Degradation and Transport of antigens that bind to MHC class I molecules 
Schematic representation of peptide loading mechanism on MHC class I molecules. 
Peptides generated by the immunoproteasome are transported through the ER membrane by 
TAP. Tapasin links TAP to MHC class I heavy-chain/β2- microglobulin dimers to facilitate 
peptide loading onto MHC class I. Other components of the loading complex, such as 
calreticulin (Crt) and ERp57, ensure correct folding and assembly of the MHC class I with 
the peptide. 
            Conversely, MHC class II antigen presentation pathway is geared towards the 
presentation of extracellulaely derived antigens or antigens generated within the 
endolysosomal pathway. MHC class II expression is confined only in a small subset 
of antigen presenting cells grouped as professional APC, which include macrophage, 
B cells and dendritic cell. Like MHC class I, MHC class II molecule is also 
translated into ER, but class II molecules has to transport to the lysosome associated 
endosomal compartment with a third transmemebrane glycoprotein invariant chain 
(Ii), which protects the peptide binding site and targets delivery of MHC class II 
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molecules to the acidic endosomal compartment. As a molecular chaperone for class 
II this invariant chain also provide targeting information in its cytoplasmic N 
terminus to direct the next step for class II /Ii complex (Amy et al, 2002). Once they 
arrive in the endosomal compartment, the MHC class II will form stable complexes 
with antigenic peptides derived from extracellular proteins before it is allowed to 
reach the cell surface. After transport into the acidified vesicle, acid proteases such as 
cathepsin S sequentially cleave the invariant chain leaving only the short fragment, 
called CLIP that blocks the MHC class II α: β peptide binding groove. The class II-
associated invariant chain peptide (CLIP) remains bound to the MHC class II 
molecule until it encounters suitable peptides; upon peptide competition it is 
dissociated or displaced to allow peptide binding to MHC class II. There are other 
proteins also playing an important role called HLA-DM (DM) which form a similar 
structure of that class II molecule. It like the tapasin with class I molecules, DM 
stable class II molecule and confer upon the class II molecule with high affinity bind 
with peptide into the peptide-binding groove.  Finally stable peptide/MHC class II 
complexes travel to the cell membrane where they are presented to T cells. This 
process is slower than class I; new synthesized peptide/MHC class II molecules 
present to cell surface approximate 2-4 hours (Figure 2.6).  
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Figure 2.6. Antigen degradation, transport and binding to MHC class II molecules 
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3. T cell activation 
            T cell activation is initiated by interaction of the TCR-CD3 complex with a 
processed antigenic peptide bound to either a class I (CD8
+
 cells)  or class II (CD4
+
 
cells) MHC molecule on the surface of an antigen presenting cell. CD8
+
 and CD4
+
 
cells also require a co-stimulating boost called B7, and then following activation 
from the APC cells there are a number of substances called cytokines trigger the 
rapid growth and proliferation of more T cells and are thought to increase the 
cytotoxic effects of the CD8
+
 cells. So three signals are required for T cell activation, 
which are peptide- MHC complex binding with TCR, co-stimulate molecule and 
cytokines (Figure 3.1).   
 
Figure 3.1 three signals induce T cell activation  
The outcome of specific antigen recognition by T cells (signal 1) is determined by co-stimulation 
(signal 2) delivered by fully activated APCs and the presence of inflammatory cytokines (signal 3). 
Activation of naïve T cell in the presence of all three signals leads to full effector function.  
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3.1 T cell receptor (TCR).  
            The antigen recognition molecule of T cells is the T cell receptor (TCR) 
located on the plasma membrane of T cell that recognises peptide/MHC 
combinations on antigen presentation cells. TCR is a disulphide-linked heterodimer 
which is formed by two transmembrane glycoprotein chains, α and β, which contain 
highly variable antigen recognition sites (Figure 3.2) A minority of T cells bear an 
alternative but structurally similar receptor made up of a different pair of chain 
designated γ and δ; the function of γ; δ T cells in immune responses is not yet 
entirely clear. 
            The TCR associated with CD3, forming a TCR-CD3 membrane complex. 
CD3 expression in required for membrane expression of α: β and γ: δ TCRs. The 
rearrangement of antigen-recognition segments in TCR gene results in highly 
diversified TCR pool sufficient to recognise a plethora of antigens potentially 
encountered through life time. The α: β chains form extracellular disulfide-linked 
heterodimers responsible for MHC/antigen recognition. The TCR complex is formed 
with various other components that are required for initiating signalling when the 
TCR complex binds to peptide/MHC. These components include various CD3 
molecules which are five invariant polypeptide chains γ, δ, ε, ζ and η chain. These 
chains associate to form three dimmers, γ: ε, δ: ε and a ζ: ζ or a ζ: η. 
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Figure 3.2. T cell receptor  
Schematic representation shows that the T cell receptor is formed by two transmembrane 
glycoprotein chains, the α and β. The extracellular portion of the chains consists of a 
constant region and a viariable region, which is the site of peptide/MHC recognition. 
3.2 Co-stimulatory molecules. 
            Although recognition of antigen: MHC complexes are mediated solely by the 
TCR- CD3 complex, co-stimulatory molecule play an important accessory role to 
fully active T cell. In the absence of co-stimulatory signals with disturb of specific 
signalling through the TCR will lead to T cell non-responsiveness or ‘anergy ’. Co-
stimulatory signals are delivered by co-stimulatory molecules on APCs via their 
cognate receptors on T cells. The two major co-stimulation signals following the 
TCR: CD3: MHC interactions are i) the prototypical CD28 interaction with either 
CD80 (B7.1) or CD86 (B7.2) and ii) the binding of CD40:CD40L (Figure 3.3).  
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                     Figure 3.3. Two major co-stimulation signals 
CD80 and CD86 bind CD28 with equal affinity but are present in differing 
densities on the various APCs (Chambers and Allison, 1997). For this reason the 
resultant T cell response can alter markedly depending to which ligand CD28 binds. 
It must also be noted that upon activation of the T cell a newly expressed CTLA-4 
receptor may also bind the CD86 ligand but with higher affinity, and acts as an 
inhibitory signal leading to deceleration of the activation process (Chambers and 
Allison, 1997). The role of CD28 as a co-stimulatory entity is observed through its 
collaborative actions in ultimately recruiting transcription factors for interleukin-2 
(IL-2) gene expression (Figure 3.4).  
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          Figure 3.4. Co-stimulation signalling control T cell activation 
The CD40: CD40L co-stimulation acts in two directions. It is involved in the 
upregulation of CD80 (B7.1) and CD86 (B7.2) surface expression on the B cell and 
thus in driving the T cell response. Alternatively, CD40 ligand expression by the T 
cell may act upon macrophages to provide the contact dependent macrophage 
response to interferon-γ; although it has been found that tumour-necrosis factor α or 
β can substitute for CD40L in macrophage activation (Janeway et al, 2001). 
3.3 The immunological synapse. 
            The immunological synapse is the interface between an antigen presenting 
cell and a lymphocyte as well as other critically important accessory ligands. This 
structure forms around the site of contact between the T cell and APC as 
consequence of reorganization of T cell membrane proteins. This advance in live 2-
photon-microscopy have revealed that the immunological synapse is an active and 
dynamic structure that allows T cells to recognise and respond to antigenic molecules 
on the surface of APCs. The formation of the immunological synapse is thought to 
take place in three general steps; first, an interaction occurs between the accessory 
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ligands on the T cell, e.g LFA-1, and those on the APC, e.g. ICAM-1 (Sofra, 2009). 
This contact provides a stable structure which allows the T cell to stop and ‘sample’ 
the available peptide/MHC complexes through its TCR. Subsequently, if the TCR 
recognises and binds to the peptide/MHC complex, the entire TCR/peptide/MHC 
structure is transported and becomes the centre of the synapse during which time 
signalling occurs (Figrue 3.5).  
            The immunological synapse requires hours of stable interaction between a T 
cell and an APC to result in effective T cell activation (Garcia et al. 2008). Once 
synapse formation is underway, the size and stability of the assembled cluster are 
determinants of the signal initiation which triggers T cell activation. Thus, the 
molecules involved in the cluster define the fate of T cells following their 
engagement with APC (Sofra, 2009). The function of immunological synapse is still 
in research step, but it is thought to have an important role in regulating signalling, 
and also involved in the directed secretion of cytokines and cytotoxins by effector T 
cells in contact with their target cells. 
 
Figure 3.5. Immunological synapse 
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3.4 T cell activation and immune response to target infected cells  
            The responses of T lymphocytes to cell associated microbial antigens consist 
of a series of sequential steps that result in an increase in the number of antigen 
specific T cells and the conversion of naïve T cells to effector cells. Naïve T 
lymphocytes constantly circulate through peripheral lymphoid organs until 
recognition of specific antigenic peptide in context with MHC on APC. The 
recognition leads to activation and expansion of naïve T cells (Figure 3.6). 
            The activation of naïve T cells leads to their proliferation and the 
differentiation of their progeny into effector T cells. Both of proliferation and 
differentiation depend on the production of cytokines whose multiple functions in 
cell-mediated immunity. Once naïve T cells differentiated into specialized effector T 
cells is associated with their enhanced functional potential to orchestrate pathogen 
clearance. After differentiated into distinct Th cells, the major function for CD4 T 
cells is to produce specific effector cytokines that induce specific type of immune 
responses. So in other words this primary cell-mediated immune response when 
challenged by the same pathogen not only provides a specialized ‘army’ of effector T 
cells, but also generates a state of immunological readiness for protection from 
subsequent challenge with the same pathogen.  
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 Figure 3.6. The recognition of antigens by T cells is MHC restricted.                                
Naïve T cells recognise specific complexes of peptide/MHC. For example, a T cell that has 
a TCR that can recognise antigen x on MHCα would not recognise the same antigen on a 
different MHC (e.g. antigen x on MHCβ), or a different antigen on the same MHC (e.g. 
antigen y on MHCα). 
            The effector T cells act very rapidly when they encounter their specific 
antigen on other cells because of their requirement to recognize peptide antigens 
presented by MHC molecules. And all of them act on other hast cells but not the 
pathogen itself. Subsequently, the effector T cells secrete IL-2, which drives them to 
proliferate and differentiate into armed effector T cells. 
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3.4.1 T cell differentiate 
            On antigen recognition, naïve T cells differentiate into several functional 
classed of effector T cells that are specialized for different activities. There are two 
main functional categories that detect peptide antigens derived from different types 
of pathogen, the cytotoxic CD8
+ 
T cells and the helper CD4
+ 
T cells. Circulating 
effector CD8
+ 
T cells recognize antigenic peptide derived from intracellular 
pathogens in the context of peptide/MHC class I complexes on the APC surface and 
naïve CD8
+
 T cells all differentiate into cytotoxic effector T cells that respond by 
initiating a cytotoxic response towards the antigen presenting cell that synthesized 
the antigenic peptides. Effector CD4
+
 T cells have more flexible repertoire of effector 
activities. After recognition antigens derived from pathogens replicating in 
intracellular vesicles, as well as extracellular bacteria and toxins, in the context of 
peptide/MHC class II complexes on the APC; in response, they can differentiate 
down distinct pathways that generate effector subsets with different immunological 
functions.  
3.4.2 CD4
+ 
effector T cell subsets  
            The naïve CD4
+
 T cell is a multipotential precursor with defined antigen 
recognition specificity, but substantial plasticity for development. It has the ability to 
differentiate into several different subtypes of effector T cells in response to specific 
cytokine environment.  The subsets that were defined first are called TH1, TH2; more 
recently, a third population has been identified and called TH17 cells because its 
signature cytokine IL-17 and several regulatory T cell subsets that have inhibitory 
activity that limits the extent of immune activation (Figure 3.7). 
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Figure 3.7. Cytokines involved in CD4 T cells differentiation, flagship cytokines produced 
by the differentiated CD4 T cells and their effector functions  
            Intracellular bacterial infections tend to stimulate the development of TH1 
cells, which differentiate in the presence of IL-12 and are defined on the basis of 
their production of IL-2, IFNγ and lymphotoxin (Macatonia et al. 1993; Scharton and 
Scott 1993). TH1 cells have the capacity to trigger an inflammatory response and 
support macrophage activation and migration.  These cells provide additional 
activating signals for macrophages that are chronically infected with certain 
pathogens and are unable to destroy them. This is done through producing CD40 
ligand for CD40 macrophage receptor and through IFNγ the generation of cytotoxic 
T cells and the induction of B cells for the production of opsonizing antibodies. 
These effector TH1 cells will generate copious IFNγ when they recognize antigen on 
a target cell, thus reinforcing the signal for the differentiation of more TH1 cells.  
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            Conversely, extracellular antigens tend to stimulate the differentiation of TH2 
cells (also called helper CD4 T cells), which develop in the presence of IL-4. The 
TH2 cells make IL-4, IL-5, IL-13 and other cytokines that help B cell activation, 
production of neutralizing antibodies, control of allergic reactions and expulsion of 
extracellular parasites (Mohrs et al. 2002; Prout et al. 2004). TH2 cells largely 
promote immune response to parasites. They secrete cytokines that promote B cell 
growth: IL-4, IL-5, IL-9 and IL-13. They express CD40 ligand that also induces B 
cell proliferation and isotype switching. Recent evidence has suggested that certain 
protein secreted by activated dendirtic cells can lead to the activation of the IL-4 and 
GATA-3 gene in cells, thus starting a cascade of positive feedback for differentiation 
as TH2 cells as a result of continued IL-4 secretion. Each subset promotes its own 
development and inhibits the development of the other subset via their secreted 
cytokines (Sanders et al. 1988; Gajewski and Fitch 1988), such that in that particular 
environment the induction of one type of response suppresses the induction of the 
other (Mosmann and Coffman 1989).  
            Recently an IL-17-producing subset, known as TH17 cells (Harrington, 
Hatton et al. 2005), has been described. TH17 cell differentiation is driven by TGFβ 
in combination with the pro-inflammatory cytokines IL-6, IL-21, and IL-23 (Zhou, 
Lopes et al. 2008), and it is antagonised by products of the TH1 (e.g. IFNγ) and TH2 
(e.g. IL-4) lineages (McGeachy and Cua 2008), and they express the receptor for 
cytokine IL-23 rather than the receptor for IL-12 expressed by TH1 cells. In addition 
to IL-17, TH17 cells are characterised by their ability to produce IL-22 and IL-17F 
(Boniface et al. 2009). They promote the recruitment of neutrophils and moncytes, 
and this may be their principal role in inflammatory disorders. The commitment to 
the TH17 lineage is thought to be under the control of the transcription factor RORγT, 
which is induced in these conditions and which drives expression of the receptor for 
IL-23. TH17 cells are thought to be an evolved arm of the adaptive immune response 
specialized for enhanced host protection against extracellular bacteria and some fungi 
(Horton et al. 2000) (Stefanelli et al. 2005) (Harrington et al. 2006) particularly at 
mucosal surfaces (Pallone et al. 2009). They are thought to contribute to homeostatic 
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maintenance of mucosal tissues such as the gut (Izcue et al. 2008), and emerging 
information suggests that TH17 cells may also be involved in antiviral immune 
responses by protecting the host against secondary infections involving 
gastrointestinal microbes (Brenchley and Douek 2008). 
            Besides armed effector cells, CD4
+
 T cells can also differentiate into distinct 
regulatory subsets (Treg cells) which found in the periphery are a heterogeneous 
group of cells with different developmental origins. They are CD4
+ 
and also express 
the α chain of the IL-2 receptor (CD25) with high levels of the L-selectin receptor 
CD62L and represent about 10-15% of the CD4 T cells in the human circulation. 
They suppress the proliferation and differentiation of TH or cytotoxic T cells; serve to 
limit potential immunopathology and autoimmunity that may be caused by an over-
exuberant immune response (Sakaguchi. 2000). Treg cells are defined by the 
expression of a forkhead transcription factor, Foxp3, which is essential for 
programming their regulatory effector function. Regulatory T cells can be further 
divided in two categories, the naturally occurring CD4
+
CD25
+ 
subset that develops in 
the thymus (nTregs) and the TGFβ-induced CD4+CD25- subset that differentiates in 
the periphery (iTregs) (Curotto de Lafaille and Lafaille 2009) (Josefowicz and 
Rudensky 2009). Generally, both types exert regulatory function by suppressing 
immune responses via the secretion of specific cytokines, for example by producing 
IL-10 and TGFβ, they inhibit T cell proliferation. Inter-linking mechanisms for CD4+ 
T cell effector and regulatory lineage specification have been described (Veldhoen 
and Stockinger 2006); for example TH17 differentiation depends on the pleiotropic 
cytokine TGFβ, which is also linked to regulatory T cell development and function. 
Low concentrations of TGFβ drive TH17 cell differentiation, while high 
concentrations of TGFβ inhibit TH17 cell development and induce differentiation of 
regulatory T cells. Even after differentiation a helper T cell of a specific lineage can 
convert to another helper phenotype, within a certain cytokine environment. For 
example, iTregs can become IL-17 producing cells in the presence of IL-6 and IL-21, 
TH17 cells can switch to IFNγ producing TH1 cells in the presence of IL-12 or, in the 
presence of IL-4, to IL-4 producing TH1 cells. Treg is involved in controlling 
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adaptive immune responses, so failure of natural Treg function is known to be 
involved in several autoimmune syndormes (Figure 3.8). 
  
Figure 3.8. FOXP3
+
 regulatory T cells in the human immune system (Sakaguchi et al, 2010) 
           One subset of these adaptive regulatory T cells, called TH3, is found in the 
mucosal immune system. TH3 cells produce IL-4, IL-10, and TGFβ which is the main 
reason to distinguish from TH2 cells. TH3 cells may by predominantly of mucosal 
organ and be activated by the mucosal presentation of antigen. Lack of these cells is 
linked to autoimmune disease in the gut and to inflammatory bowel disease 
(Sakaguchi et al. 2006).             
            Other CD4
+
 T cells that may regulate the development and differentiation of 
the helper subtypes are the NKT cells, known as innate-like lymphocytes (ILLs). 
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They require the recombinases RAG-1 and RAG-2 to produce antigen receptors, and 
undergo the process of antigen receptor gene rearrangement; therefore these cells 
belong to adaptive immune system. They arise from the same lymphoid progenitor 
but their development is distinct from that of the other CD4
+
 T cells, since it does not 
depend on the expression of MHC class II. Instead their activation depends on 
relatively invariant CD1 molecules (Silk, Salio et al. 2008) that are induced in 
response to infection. Together with other innate-like lymphocytes, such as the γδ T 
cells, NKT cells are thought to act as intermediates between innate and adaptive 
immunity. 
            After antigen/pathogen is cleared most effector cells die, but a few antigen-
experienced cells remain for long-term protection. These are known as memory T 
and B cells, which guard lymphoid organs and patrol peripheral tissues to mount 
rapid responses on re-exposure to antigen (Sallusto, Lenig et al. 1999). Thus, a 
successful T cell-mediated immune response has the capacity to clear infection and 
establish a state of long-term protective immunity to that particular pathogen. 
3.5 Immunological memory. 
            Immunological memory is the ability to provide a rapid reinduction of 
antigen-specific antibody and effector T cells on subsequent encounters with the 
same pathogen, thus providing long-lasting and often lifelong protection against it. 
Although the mechanisms underlying protective immunological memory are still not 
well understood, the phenomenon has long been recognised and applied to 
vaccination (Figrue 3.9). 
            Long-term protective immunity either naturally derived after an infection or 
after vaccination, involves three key main factors (Rafi Ahmed 13th Congress of 
Immunology): First, it provides the host with pre-existing neutralizing antibodies 
which upon re-infection mediate the initial response. Indeed, it is clear from the early 
days of immunology that antibodies generated by provocation with pathogen can 
protect from reiterated challenge with pathogen as elegantly demonstrated by 
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Kitasato and Behring more than 100 years ago (Behring, 1900), (Dorner and 
Radbruch 2007). Second, it involves long-lived antibody-secreting plasma cells 
(humoral memory) and long-lived memory B cells capable of reacting quickly to a 
recurrent antigenic challenge (reactive memory) (Ahmed and Gray 1996). The third 
key factor of immunological memory is the increased number and longevity of 
memory T cells, which have the capacity to respond quicker and better than T cells in 
a primary immune response; as a result they aid a more rapid and efficient 
elimination of the infectious agent (Sofra, 2009).   
 
Figure 3.9. Immunological memory 
The First encounter with an antigen produces a primary response. Antigen A introduced at 
day 0 encounters little specific antibody in the serum (Red line). After a lag phase antibody 
against antigen A appears; its concentration rises to a plateau and then gradually declines 
which is a typical primary response. After recovering from an infection, a second exposure 
of antigen A, over the ensuing weeks, months, or even years, a very rapid and intense 
secondary respond to A occurs. But this response is specific, because there is only a primary 
response to the new antigen B (Blue line). 
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3.5.1 Memory T lymphocytes 
            There is a small group of antigen specific T cells differentiated into long lived 
memory cells which can survive even after the infection is eradicated and antigens as 
well as the innate immune reaction to the infectious pathogen are no longer present. 
These memory T cells can be found in lymphoid organs in mucosal tissues, and in 
the circulation. There are two subsets of memory T cells. One is central memory cells 
populate in lymphoid organs and responsible for rapid clonal expansion after re-
exposure to antigen. The other called effector memory cells stored in mucosal tissue 
and mediate rapid effector functions on reintroduction of antigen to these sites. 
Memory T cells require signals delivered by certain cytokines like IL-7 to keep them 
stay alive. Although memory T cells cannot continue to produce cytokines to kill 
infected cells, they still have the ability to recognize antigen and then recover rapidly 
on encountering it.  
            To date, it remains to be defined how protective memory is maintained. 
Generally, there are two fundamentally differing views: One that describes memory 
maintenance as an inherent special quality of the immune system independent of 
sustained antigen dependence, and another that illustrates immunological memory as 
a low-level antigen-driven protective immune response. 
3.6 Factors that influence the T cell response. 
            During the T cell response, the survival and proliferation of T cells are 
maintained by antigen, co-stimulatory signals from CD28, and cytokines such as IL-
2. Numerous mechanisms ensure the generation of a useful T cell response, despite 
several obstacles. However, initiation of T cell response is mediated by APC that 
present antigenic peptide-MHC complexes and costimulatory molecules to T cells. 
And then, the correct type of T cell must respond to antigens form the extracellular 
and intracellular compartments which worked out perfectly with the help from the 
specificity of the CD4 and CD8 co-receptors for MHC class II and class I molecules, 
and by the segregation of extracellular and intracellular protein antigens for display 
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by MHC class II and class I molecules, respectively. Third, T cells must interact with 
antigen-bearing APCs long enough to be activated which is accomplished by 
adhesion molecules to stabilize T cell binding to APCs. Fourth, T cells should 
respond to microbial antigens but not to harmless proteins. Microbes take the 
responsibility, because T cell activation requires co-stimulators induced on APCs by 
microbes. Finally, antigen recognition by a small number of T cells must lead to a 
large enough response to be effective, which is calculated by several amplification 
mechanisms that are induced by microbes and activated T cells themselves and lead 
to enhanced T cell activation.      
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4 Professional antigen presenting cells 
4.1 Function of professional APC 
            Cells can present antigen peptide associated with MHC molecule to inactive 
T lymphocytes and activate them for the very first time know as antigen presenting 
cells (APCs). A variety of cells can function as antigen presenting cells to express 
MHC class I, but there is a distinguishing feature group which has unique ability to 
express MHC class II classified as professional antigen presenting cells: dendritic 
cells, macrophages and B lymphocytes.  
             Macrophages must be activated by phagocytoses of particulate antigen 
before they express class II MHC molecules or co-stimulatory membrane molecules 
such as B7. B cells constitutively express class II MHC molecules but must be 
activated before they express co-stimulatory molecules.  Dendritic cells (DC) are the 
most effective of the antigen presenting cells, because these cells constitutively 
express a high level of class II MHC molecules and have co-stimulatory activity, 
they can activate naïve TH cells as discussed later in this chapter (Figure 4.1).  
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Figure 4.1.  Professional antigen presenting cells 
There are three different types of professional antigen presenting cells are shown in different 
models. (From top to bottom).   
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4.2 Dendritic cell biogenesis, function, in vitro generation, antigen loading 
and subtypes. 
DCs represent a unique system of cells that induce, sustain and regulate 
immune responses (Banchereau and Steinman, 1998). Figure 4.2 shows an electron 
microscopic image of a DC. DCs originate in the bone marrow from pluripotent 
CD34
+
 stem cells and migrate to peripheral tissues through the blood. DC progenitors 
give rise to myeloid and lymphoid precursors. DCs are distributed in most tissues and, 
in particular, in tissues that interface with the external environment. There they 
perform sentinel function for incoming pathogens. Langerhans cells, the first DCs 
described, are widely distributed to the skin, esophagus, cervix, and buccal epithelia. 
Interstitial DCs are present in the dermis as well as the interstitium of virtually all 
tissues except for the brain. Furthermore veiled DCs may be found in the afferent 
lymph and interdigitating DCs reside in the cortical zone of the lymph nodes and in 
the spleen (Dannull et al, 2000). The DCs in peripheral tissues are immature but 
capable of actively taking up antigens by three major pathways, micropinocytosis, 
phagocytosis and receptor-mediated endocytosis (Paczesny et al, 2003). 
Macropinocytosis allows uptake of soluble extracellular antigens. In addition, 
phagocytosis or receptor mediated endocytosis may be initiated by direct, 
nonopsonic interaction between pathogen, apoptotic cells, or effete body cells and 
DCs. Receptor mediated uptake may occur via the multilection receptor, the mannose 
receptors, collectins, toll-like receptors, and scavenger receptors (Colino and Snapper, 
2003) (Dannull et al, 2000). Alternatively, antibodies or complement can act as 
bridging molecules between pathogen and Fc-type or complement- type receptor, 
thus leading to opsonic uptake (Dannull et al, 2000). 
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Figure 4.2 Image of a DC 
Following uptake of antigens, DCs induce leukocyte recruitment to the site of 
inflammation through production of chemokines and inflammatory cytokines. 
Antigen uptake induces maturation, which is complex process with the dual role of 
transforming immature DCs in the peripheral tissue into cells that will migrate to the 
secondary lymphoid organs and then act as professional APCs for the priming of 
naïve T cells (Colino and Snapper, 2003). Toward accomplishing migration, 
activated DCs lose their phagocytic capacity and tissue adhesive structures; increase 
their expression of receptors for lymphoid chemokines (i.e. CCR7), and reorganise 
their cytoskeleton for the acquisition of high cellular mobility (Winzler et al, 1997). 
Towards the second goal, DCs strongly upregulate their expression of co-stimulatory 
molecules (i.e. CD40, B7.1, B7.2) and upregulate synthesis and translocation to the 
surface of MHC molecules complexed with processed antigens (Guermonprez et al, 
2002). The ability of DCs to induce a primary immune response is unique among 
APCs. The mature state of DCs ends by apoptotic cell death in the lymph modes, 
which is enhanced by immunoinhibitory cytokines such as IL-10.  
DCs are also important in immune tolerance (Steinnman et al, 2000) 
(Steinman et al, 2002) (Steinman et al, 2003). Two mechanisms were created to 
avoid the immune system attack on the components of self, central and peripheral 
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tolerance, both of which are maintained by DCs. Central tolerance that occurs in the 
thymus is dependent on mature thymic DCs which are essential for deletion of newly 
generated T cells with a receptor that recognises self components (Steinman et al, 
2003). However many self antigens may not access the thymus while others are 
expressed later in life. Hence the need for peripheral tolerance which occurs in 
lymphoid organs and is mediated by immature DCs. Peripheral tolerance involves 
induction of T cell anergy or under certain circumstances deletion. Immature DCs 
within tissues capture the remains of cells that die in the process of physiological 
tissue turnover. As there is no inflammation accompanying this process the DCs 
remain immature. There immature DCs, which lack co-stimulatory molecules, 
migrate to draining lymph nodes where they present the tissue antigens to T cells. T 
cells presented with antigen in the absence of comstimulation either enter into a state 
of anergy or get deleted (Steinman et al, 2002) (Steinman et al, 2000). Immature DCs 
may be critical in development of tolerance towards tumours (Wakkach et al, 2003).  
4.3 Cytokine mediated DC differentiation  
            Dendritic cells are bone marrow derived cells found in most tissues, including 
lymphoid tissues. Two main functional subsets are distinguished. Conventional 
dendritic cells take up antigen in peripheral tissue, are activated by contact with 
pathogens, and travel to the peripheral lymphoid organs, where they are the most 
potent stimulator of T cell responses. Plasmacytoid dendritic cells also take up and 
present antigen, but their main function in an infection is to produce large amounts of 
the antiviral interferons.  Both these types of dendritic cells are distinct from the 
follicular dendritic cell that presents antigen to B cells in lymphoid follicles.   
            A key characteristic of dendritic cell biology is that the cells differentiate or 
mature in distinct ways in response to a spectrum of environmental and endogenous 
stimuli. There is evidence shown either polarized DCs or distinct DC subsets might 
provide T cells with different signals to determent class of immune response.  For 
example, DCs respond to microbial ligands for pattern recognition receptors (e.g. 
pathogen-associated molecular patterns recognised by Toll-like receptors), T cell 
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ligands (e.g. CD40 ligand), innate lymphocytes (e.g. NK cells), and inflammatory 
cytokines (e.g. TNFα) and upon cell contacts with other DCs.   
            In the absence of specific maturation stimuli dendritic cells may differentiate 
by ‘default’ and can induce tolerance when they capture self or harmless 
environmental antigens (Hawiger, Masilamani et al. 2004). Generally, induction of 
tolerance is a consequence of antigen presentation to T cells by phenotypically 
immature dendritic cells that lack co-stimulatory signals and it can be described as T 
cell deletion, T cell anergy or the induction of Tregs (Hawiger et al. 2003). 
            By contrast, in response to infection and inflammation dendritic cells 
differentiate rapidly to a mature state. During maturation antigen uptake is reduced 
(Chen et al. 2000), while antigen processing is upregulated by lowering of the pH in 
endocytic vacuoles, activated lysosomal proteolysis and increased transport of 
peptide/MHC class  II complexes to the cell surface (Trombetta and Mellman 2005). 
Importantly, the maturing dendritic cell membrane undergoes remodelling, dendrites 
are formed and membrane associated co-stimulatory molecules are expressed. 
            The nature of DC maturation, which is regulated by the nature of the stimuli 
received through pattern recognition receptors, and is also dependant on the type of 
DC that is responding to these signals, has a major influence on both DC function 
and subsequent activation of naïve T cells. For example, depending on the type of 
infection maturing dendritic cells selectively polarise CD4
+
 T cell differentiation 
towards TH1 cells to help resist viruses and tumours, or towards TH2 cells in response 
to extracellular bacteria and fungi. 
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5 Infectious immunity 
5.1 Immune responses to viral infection 
The viral infection is any type of infection that caused by a virus, which is 
pathogens composed of a nucleic acid genome enclosed in a protein coat, so it is 
more difficult to kill than bacteria. Viruses can replicate only in a living cell, as they 
do not possess the metabolic machinery for independent life. Viruses can be 
transmitted in numerous ways such as direct contact with infected person, 
swallowing or inhalation. Effective immune response to viruses requires the 
coordinated activation of both innate and adaptive immune modules. 
Innate immune defense against viruses comprises IFN, NK cells and 
macrophages (Male et al, 2006). Interferons are pro-inflammatory cytokines that are 
particularly important in limiting viral infection. Type I interferons, IFNs (α and β), 
can be produced by many different cell as a response to viral infection, when cell 
surface or endocytic PRR recognize viral nucleic acids. Pro-inflammatory cytokines 
such as IL-1 and TNF-α are also potent inducers of IFNα and β production. Most 
nucleated cells have receptors for type I IFNs. IFN binding to virus-infected or 
healthy cell leads to expression of more than 300 genes. However, the key 
mechanisms to prevent viral replication in the cell is activation of enzymes that 
degrade ssRNA, inhibit mRNA translation, increase production of MHC class  I and, 
in the last instance, trigger apoptosis via Bcl-2. IFNs also activate NK and 
macrophages (Male et al, 2006) (Takeuchi and Akira 2009). Cells infected with a 
virus tend to have less MHC class I on their surface, often due to the viral inhibition 
of antigen presenting machinery. NK cells recognize cells that display less MHC 
class I, induce them to undergo apoptosis or kill them by perforin and proteases. NK 
cell also secrete IFNγ (Andoniou et al, 2006). 
Macrophages are ubiquitously present in body tissues and are the first line of 
defense against many pathogens, including viruses. They phagocytize virus-infected 
cells and produce TNF-α and IFNα (Male et al, 2006). 
Adaptive immune response is always required for clearing of viruses. Normally 
it starts when DC present processed viral antigen on MHC class I to CD8 cells in 
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peripheral lymphoid organs, however CD4 cell are also of a great importance in viral 
infection. MHC class I viral antigen presentation can also be carried out by a wide 
variety of cells, not just DC. CD8 cells differentiate into Tc cells, migrate to the site 
of infection, recognize virus-infected cells and kill them in perforin- or granzyme-
dependent manner or by Fas-FasL interactions (Male et al, 2006). CD4 cells 
differentiate into TH1 cells and produce INF-γ that activates macrophages, and TNF-
α. TNF-α mediates INF-dependent mechanism of apoptosis in infected cells (Alberts 
et al, 2008). 
Antibodies are also employed during viral infection. They may act alone or 
with the complement system. They can bind viruses directly and prevent them from 
entering cells or damage the virus itself. In addition, antibodies bind virus-infected 
cell thus marking it for recognition by phagocytes (Male et al, 2006). There are two 
types of viral infection acute infection and chronic infection (Figure 5.1). 
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Figure 5.1 Infectious immunity 
(a) In an acute viral infection, CD8
+
 T cells become activated in response to viral antigen, 
proliferate, acquire the ability to produce cytokines and interferons, and kill virally infected 
cells.  
(b) During a chronic infection, CD8
+
 T cells become exhausted, produce fewer cytokines 
and are less able to kill virally infected cells and control virus levels. (Farrell, 2006) 
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5.2 Acute viral infection and immune responses  
            In acute viral infections, the number of infectious agents rapidly increases 
initiating an innate anti-viral immune response. This takes numerous forms but 
mainly includes interferon production and natural killer (NK) cell activity, which 
occurs early after infection and constitutes the first line of defence (Gregoire, 
Chasson et al. 2007) (Ha, West et al. 2008). As the pathogen is retarded by the 
components of the innate immune system a concurrent adaptive immune response is 
triggered; professional antigen presenting cells, such as DCs, process virally-derived 
antigens, loaded onto MHC, that with the help of co-stimulation result in the 
activation and expansion of specific effector T cells. Four to seven days after 
infection, large numbers of activated cytotoxic T cells appear within the secondary 
lymphoid tissues. At the same time, activated CD4
+ 
T helper cells help B cells to 
produce specific antibody as both the cellular and humoral adaptive response peak. 
Systemic viral load is reduced during this stage. Clearance of the infection coincides 
with elevated cytotoxic T cell activity followed by T cell death as the antigen levels 
fall. The conclusion of the adaptive response is characterised by a dramatic fall in the 
numbers of antigen-specific effector T cells, but, also by elevated serum antibody 
titres that can persist for months and the appearance of antigen-specific memory cells. 
Typical examples of viruses that result in acute infections are smallpox and yellow 
fever virus (Miller, van der Most et al. 2008) (Sofra, 2009).    
            Acute resolving infections leave no residual pathology following an effective 
adaptive immune response, which, ideally, clears the infection and precludes 
potential disease by establishing in the host a state of protective immunity against 
reinfection with the same pathogen. 
5.3 Chronic viral infection and immune responses 
            Consistent to chronic viral infection, there are many virus infection, however 
often fail to resolve and become chronic which can persist for many years, such as 
cytomegalovirus, herpes viruses and mycobacterium tuberculosis, have evolved to 
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coexist with their human hosts, thereby avoiding the generation of efficient 
protective immunity (Thomas Dörner and Andreas Radbruch, 2007). These 
infectious agents may exist within the host in a latent state (contained but not 
eliminated), but when the adaptive immune response is weakened, the pathogen can 
opportunistically reappear as a virulent systemic infection. 
            Despite the protection that T cell effector mechanisms provide during the 
period of acute infection, T cell responses can also be detrimental by destroying 
inoffensive host cells. As a result, the balance between immunoprotection and 
immunopathology becomes a very fragile one, as is well-illustrated in the phenotypes 
of various persistent infections. For example, symptoms in HBV infected patients 
can range from in-apparent infection to very aggressive hepatitis (Zinkernagel 2003). 
5.3.1 Immune defects in chronic infectious diseases  
              There are two issues for immune defection in chronic infection disease 
interacted either the virus or it interaction with immune system. For the virus, they 
can escape from immune surveillance. Some of them focus to destroy the antigen 
present pathway via MHC class I and II dysfunctional which is appeared in the viral 
glycoproteins US2 and US3 from human cytomegalovirus (CMV). US2 can bind to 
MHC class I heavy chain result it dislocation from ER membrane to cytosol, finally 
degraded by proteasome (Wiertz et al, 1996), which is also demonstrated in MHC 
class II molecule (Tomazin et al, 1999). US3 also play function to escape, which can 
associates transiently with MHC class I molecules caused it retention in the ER 
(Gruhler and Fruh 2000). In addition there are also some kinds of virus can be 
latency and reactivation in host which will describe latter.  
             Surprisingly, some of the viruses even contain a special gene which plays a 
niche specific role during chronic infection to evade immunity. These virus encode 
genes contribute to evade immunity during acute or chronic infection (Virgin, 2007b). 
For example which has been demonstrated by Rickinson and Kieff (2007), they 
found that the latency gene in EBV can specialize to prolong the infection of memory 
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B cells and to respond to and regulate B cell activation and differentiation. And also 
they can maintain the viral episome, regulate of B cell antigen receptor signalling and 
regulate of cell cycle and apoptosis (Herbert et al, 2009). The other speciality of 
some persist viruses is that they can select a specific cell type to reside. Like 
genitourinary tract is a particularly place chose by several virus like human T cell 
leukaemia virus (HTKV), human cytomegalovirus (CMV), Kaposi’s sarcoma 
herpesviurs (KSHV) EBV, HIV, LCMV, HSV, and polyomaviruses (Virgin, 2007b), 
which is a difficult place for the immune system to surveillance. 
             In the other hand the immune system also affected by this immune 
suppressed environment which caused by long time inflammation and suppressed 
cytokine or receptor which will lead the T cell and B cell responds deficient which 
will introduce latter. Over all the location, timing, and magnitude of the immune 
response relative to the speed of virus replication and spread are also the major 
determinants of the eventual outcome of viral infection (Herbert et al, 2009). Due to 
the factor that the virus must evade sterilizing immunity, while the immune system 
must adjust to the continuous presence of viral antigen-driven inflammatory 
responses in order to limit viral replication to an acceptable level without untoward 
damage to permanently infected tissues under chronic viral infectious condition, 
there is a dynamic but metastable equilibrium between the virome and the host 
immune defence in chronic viral infection. 
            Major viral mechanisms for chronic infection (Figure 5.2); 
1) Continuous replication: Viruses in this category include HIV, HBV, and HCV in 
humans Continuous replication can generate up to 10
12
 particles per day for HBV 
and HCV (Rehermann and Nascimbeni, 2005). Viruses that persist via continuous 
replication express potentially antigenic viral proteins that are required for viral 
assembly and release, resulting in continuous antigenic stimulation of lymphocytes. 
Continuous replication has other effects on the immune system—low levels of tissue 
damage and stimulation of inflammatory cytokines and co-stimulatory molecules 
may alter the normal immune system. Some viruses, however, are very efficient at 
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avoiding the generation of such inflammatory signals. For example, HBV infection 
can proceed for weeks without any significant induction of either innate or adaptive 
immunity in a “stealth” approach to establishing chronic infection (Wieland and 
Chisari, 2005) (Herbert et al, 2009). 
2) Latency and reactivation: cell latency is neither slow viral replication nor the 
presence of viral nucleic acid without the capacity to reactivate. Latent virusesretreat 
from adaptive immunity into a transcriptionally and antigenically quiescent state. 
Perhaps the most frightening example of this is HIV, which can survive in memory 
CD4 T cells in the proviral state without expressing any proteins that can be 
recognized by the immune system. Similarly, EBV can establish latency in memory 
B cells with undetectable expression of protein- coding RNAs, at least until the 
latently infected cell divides (Hochberg et al., 2004) (Herbert et al, 2009). 
3) Invasion of the genome: the best example is endogenous retroviral elements (ERVs) 
chronically infect in Mammalian genomes which spread vertically from one host 
generation to the next as integrated viral genomes or partial genomes in host 
chromosomes. Some ERVs are replication competent, but many are replication 
defective.  Yet even such defective ERVs can express proteins. Human ERVs from 
over 30 lineages constitute perhaps 8%–9% of the human genome (Virgin, 2007b). 
There are two effects on the immune system. First, they can encode B or T cell 
antigens (Miyazawa et al., 1987) (Wang- Johanning et al., 2008) (Levisetti et al., 
2003). Second, ERV-encoded superantigens can shape the T cell repertoire (Meylan 
et al., 2005) (Sutkowski et al., 2001) (Stauffer et al., 2001) (Herbert et al, 2009).  
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Figure 5.2. Processes of Acute and Chronic Viral Infection 
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Viruses use a range of strategies for acute and chronic infection. (Top) The strategy used 
during acute infection results in the expression of antigens associated with the production of 
new viruses. (Middle) When a virus persists via continuous productive replication, the same 
antigens expressed during acute infection are produced, but the virus has the opportunity to 
evolve under immune selection to produce viruses that express neo-antigens and have 
altered pathogenetic capacities. (Bottom) In contrast to the previous two processes, viruses 
that persist via latency and reactivation can generate antigens associated with productive 
replication but also can enter into transcriptional states in which antigens associated with 
latent infection are expressed. In the most extreme case, no antigens are expressed, resulting 
in immunological silence. There may be more than one latency-associated gene program, 
and it is likely that latency gene programs are cell type specific. When these viruses become 
reactivated, they reinitiate a productive replication program and once again express viral 
antigens associated with the production of new viruses (Herbert et al, 2009). 
             Major mechanisms for the unresponsiveness of immune system; 
             Immune defects in chronic infectious diseases also affect T or B cells 
response. T cell exhaustion (antigen specific T cells fail to respond to antigens) 
which is the major type of T cell dysfunction appeared in chronic infectious diseases. 
These T cells initially develop effector functions, but prolonged or excessive 
stimulation leads to progressive loss of function over time.   
             There are at least four mechanisms to limit T cell responses to persisting 
viruses; first, T cell intrinsic mechanisms including induction of PD1 and CTLA-4 
and altered expression of cytokine receptors such as IL-7R and IL-15R. The 
suppressive receptors, PD1 and CTLA-4 have been found to be induced in antigen 
specific CD8
+
 by  chronic LCMV infection (Barber et al, 2006) and coexpress in 
HIV specific CD4
+
 cells (Kaufmann et al., 2007), while LCMV suppress the 
expression of IL-7R or IL-15R lead to alter TCR and cytokine receptor signal 
transduction (Lang et al, 2005). Second, the expression of immunoregulatory 
cytokines such as IL-10, TGF-β, and possibly additional factors produced by other 
cells in the environment can modulate and suppress vigorous antiviral T cell 
responses. It has been found that LCMV infection induced expression of IL-10 which 
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can induce naïve T cells become iTreg cells, while HCV induces expression of TGF-
β that can impact immune responses during persisting infections (Alatrakchi et al., 
2007). Third, regulatory cells can modulate antiviral effector T cells. Recent research 
shows that Tregs are more often associated with ineffective immune responses 
during chronic infections, including those by Friend leukemia virus (Zelinskyy et al., 
2006), HIV (Kinter et al., 2007) (Nilsson et al., 2006), HCV (Boettler et al, 2005) 
(Ebinuma et al, 2008) (MacDonald et al, 2002), and HBV (Franzese et al, 2005) (Xu 
et al, 2006). The Treg cells could act through cell-to-cell contact, inhibition of APC 
maturation, production of immunoregulatory cytokines, or direct inhibition of CD8 T 
cell effector function. The function of Treg cells functions are enhanced by 
immunosuppressive chemokine and cytokines such as IL-10 and TGFb (Fantini et al, 
2004) (Antonella et al, 2008), thereby creating synergic effect between mechanisms 
that inhibit T cell effectiveness during chronic viral infection (Herbert et al, 2009). 
             Finally, defects of APC function have been found in chronic infectious 
conditions. The quality of T cell stimulation can also be impacted by changes in 
dendritic cell function or number, as well as differences in antigen presentation by 
professional versus nonprofessional APC during persisting viral infection. DC as the 
delegate of APC has been found that monocyte-derived DCs in chronic HCV 
infection do not respond to maturation stimulation, which will maintain their 
immature DCs caused impaired antigen presenting function (Susanne et al, 2001).  
             In addition, defects in memory T cell differentiation during chronic viral 
infections are not just confined to effector functions, but also include a failure to 
develop into self-renewing antigen-independent memory T cells which due to reduce 
expression of CD127 and CD122, the receptor of IL-7 and IL-15 respectively. These 
factors are essential for the maintenance of memory T cells (Shin and Wherry, 2007).  
             Similar to viral mediated T cell defects, the effect function of B cells is also 
reduced in chronic infectious diseases such as deficient responds of B cells during 
HIV infection. There is a study shows that HIV-specific B cells, but not others, have 
a low proliferative capacity and express Fc-receptor-like-4 (FCRL4) that can 
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generate signals that inhibit B cell function (Herbert et al, 2009). There are evidences 
that alterations in B cell responses, B cell tolerance, and the accumulation of 
antibody-antigen immune complexes are associated with chronic viral infections and 
can contribute to disease (Casali and Oldstone, 1983)   
5.3.1.1 Immune responses in acute and chronic HBV infection  
             There are one third of people (about 2 billion) have been infected with 
hepatitis B virus (HBV) among them about 400million people have become 
chronically infected. This virus markedly differs in their virological properties and in 
their immune escape and survival strategies from the other virus. In the acute 
infection, a rapid viral replication associates with a rapid and strong anti-viral 
immune response. HBV DNA is detectable in the circulation under one month after 
infection and keeps control low level of genome equivalents up to 6 weeks until 
HBV DNA and HBV envelope and surface antigen reach to peak. With the injury of 
T cell mediated liver, the serum alanine aminotransferase (ALT) level start to rise 
within 10-15 weeks before most of HBV DNA has been cleared (Rehermann and 
Nasximbeni, 2005). After acute infection, immune memory is established for 
protection of further infection.  
             In contrast to acute infection, the chronic infection has persistent viral load 
with chronic liver inflammation (Chen et al, 2004). Similar like the other chronic 
infection disease, chronic hepatitis B infection associates with immune 
unresponsiveness or low responsiveness (Reignat et al, 2002). The mechanisms for 
the immune unresponsiveness in chronic HBV infection are largely unknown. It has 
been found that HBeAg can induce T cell tolerance in transgenic mice (Chenet et al, 
2004). The development of viral escape mutations in HBeAg was found which affect 
humoral immune responses. However, in chronic hepatitis B, T-cell escape mutants 
are not common (Rehermann et al, 1995) (Rehermann and Nasximbeni, 2005). The 
unresponsiveness of T cells to chronic HBV infection is largely due to the common 
mechanisms discovered in most chronic infectious diseases with high viral load such 
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as over expression of PD1 and CTLA-4 and high levels of inhibitory cytokines 
(Blackburn et al, 2008).  
             Recently, it has been demonstrate that Bim express the highest intracellular 
levels in CTLA-4 high expressed HBV specific CD8
+ 
 T cell in chronic HBV 
infection (Schurich et al, 2011), which suggests that  CTLA-4 may provide a 
pathway for T cell encountering the antigen in liver and then drive it to Bim 
dependent apoptosis. And also they suggested that only treat the patients with 
antiviral therapy is not enough, which will not show any affection after 7-12 months 
later, caused by high level of CTL-4 and Bim (Schurich et al, 2011). So the CLTA-4 
blockade could be one of the therapeutic approaches for chronicle HBV therapy in 
the future.    
5.3.2 T cell tolerance 
            In the T cell compartment, tolerance, or unresponsiveness, to self-antigens is 
maintained by the deletion of immature T cells that recognize these antigens in the 
thymus, and by several mechanisms that are operative in the periphery. Peripheral 
tolerance is attributable to the induction of functional anergy, deletion by apoptosis, 
and the suppressive actions of regulatory T lymphocytes (Treg) (Abbas et al, 2004). 
Self-tolerance of T cells is induced and maintained in different compartments of the 
immune system (Mondino et al, 1996). As mentioned developing T cells can be 
clonally deleted in the thymus as a result of negative selection, which requires the 
presence of relevant antoantigens. Peripheral tolerance is therefore a mechanism 
supplementary to central tolerance. The mechanisms responsible for peripheral CD8
+
 
T cell tolerance can be divided into those acting directly on the responding T cells, 
such as inactivation or deletion of specific T cell (Walker and Abbas2002) (Steinman 
et al 2003) and those that act through additional cells or factors, such as regulatory T 
cells or suppressive cytokines (Sakaguchi et al, 2004) (Hans et al, 2005). In most 
cases in which natural Treg cells participate in responses to infection, these are 
chronic infections. The influence of natural Treg cells may favourably affect the 
outcome or can be harmful to the host, and it most can be infect by the factors which 
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include the stage of infection, dose of the pathogen and genotype and immunological 
status of the host as well as the presence of concomitant disease or other infections. 
In chronic infections, it continually secreted low dose of viral which will finally 
confuse the body to protect it as a part via Treg. As a result there are only non-
responsed antigen specific T cells left in patient body (Figure 5.3). 
 
Figure 5.3 Mechanisms of peripheral T cell tolerance.  
The mechanisms that maintain tolerance in CD4 T cells are illustrated, and compared with a 
normal immune response (Abbas et al, 2004). 
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6. Vaccines 
6.1 Immunity is the ability of an organism to resist infection. 
Vaccination is the best known and the most successful application of 
immunological principles to human health. The first vaccine was named after 
vaccine, the cowpox virus. Jenner pioneered its use 200 years ago. It was the first 
deliberate scientific attempt to prevent an infectious disease (smallpox), but it was 
done in complete ignorance of viruses (or indeed any kind of microbe) and 
immunology. Jenner’s achievement was the realization that infection with a bovine 
analogue of smallpox (vaccinia), which caused cowpox, would provide protective 
immunity against small pox in humans without the risk of significant disease.  
It was not until the work of Pasteur 100 years later that the general principle 
governing vaccination emerged: altered preparations of microbes could be used to 
generate enhanced immunity against the fully virulent organism. During his work on 
chicken cholera he observed that a culture if the responsible bacteria had spoiled and 
failed to induce the disease in some chickens he was infection with the disease. 
Upon reusing these healthy chickens he discovered that he could not infect them, 
even with fresh bacteria; the weakened bacteria had caused the chickens to become 
immune to the disease, even though they had only caused mild symptoms. After 
inoculating the infection being fatal, as usual, the chickens recovered completely. 
Pasteur guessed the recovered animals now might be immune to the disease. He 
applied this immunization method to anthrax, which affected cattle, and aroused 
interest in combating other method to anthrax, which affected cattle, and aroused 
interest in combating other diseases. He publicly claimed he had made the anthrax 
vaccine by exposing the bacillus to oxygen. Pasteur produced the first vaccine for 
rabies by growing the virus in rabbits, and then weakening it by drying the affected 
nerve tissue.  
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The notion of a weak form of a disease causing immunity to the virulent 
version was not new; this had been known for a long time for smallpox. Inoculation 
with smallpox was known to result in far less scarring, and greatly reduces mortality, 
in comparison to the naturally acquired disease. As mentioned earlier Edward Jenner 
had also discovered vaccination, using cowpox to give cross-immunity to smallpox 
(in 1796), and by Pasteur’s time this had generally replaced the use of actual 
smallpox material in inoculation. The difference between smallpox vaccination and 
cholera and anthrax vaccination was that the weakened form of the latter two disease 
organisms had been generated artificially, and so a naturally weak form of the 
disease organism did not need to be found (Figure 6.1). 
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  Figure 6.1 Vaccination 
The term was originally used by Edward Jenner to describe the process of inoculating 
patients with discharge of cowpox to protect them from smallpox. Nowadays vaccination 
applies to the administration of any antigenic material (the vaccine) for the purpose of 
stimulating active immunity to a disease. 
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6.2 Antigens used as vaccines 
           Different vaccination strategies aim to deliver pathogenic protein to antigen 
presenting cells, that will be processed in vivo deliver pathogenic proteins to antigen 
processing pathways. A major drawback of is that proteins are broken down into 
many peptides, very few of which are immunogenic. Peptide vaccination offers a 
solution to this problem, and involves vaccination with characterised T cell specific 
peptide epitopes that stimulate protective immunity. However, it is not possible to 
generate MHC class I specific T cell responses by in vivo immunisation with free 
peptides, as free peptides are diluted and degraded too fast once administered. On the 
other hand, efficient peptide presentation by APCs occurs with endogenously 
processed antigens (Cresswell et al, 2005) (Zhang and Williams, 2006). 
1. Attenuated pathogen. Attenuated live vaccines have been highly successful against 
viruses (e.g. polio, measles, mumps etc) and bacteria (e.g. tuberculosis), generally 
being easier to attenuate the former than the latter. The aim is to diminish the 
pathogen’s virulence while retaining the desired antigens. Attenuated pathogens are 
‘changed’ pathogens in the sense that are less able to grow and cause disease in their 
natural host. ‘Changed’ means that mutations are induced to them. The results of 
attenuation are widely divergent. An example is the divergence between the three 
types of live polio vaccine; Type 1 polio has 57 mutations and has almost never 
reverted to wild type while Type2 and 3 vaccines depend for wild type has occurred, 
in some cases leading to outbreaks of paralytic poliomyelitis. 
2. Killed/inactivated pathogen. Killed vaccines are intact but non-living organisms. 
Some are very effective (rabies and the Salk polio vaccine), some moderately so 
(typhoid, cholera and influenza), some are of debatable value (Plague and typhus) 
and some are controversial on the grounds of toxicity. Some of these will 
undoubtedly be replaced by attenuated or subunit vaccines. 
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3. Inactivated toxins and toxoids. They are the most successful bacterial vaccines. 
Vaccines against tetanus and diphtheria are based on inactivated exotoxins and 
constitute the most successful of all bacterial vaccines.  
4. Subunit vaccines. Aside from toxin-based vaccines which are subunits of their 
respective microorganisms, a number of other vaccines are employed, which make 
use of antigens whether purified from microorganisms or produced by recombinant 
DNA technology. While hepatitis B surface antigen is immunogenic when given with 
alum adjuvant, the bacterial capsular polysaccharides of Neisseria meningitis, 
Streptococcus pneumonia and Haemophilus influenza B give lasting protection 
because helper T cells are not activated by polysaccharide alone. A significant 
improvement in the efficacy of these vaccines has been obtained by chemically 
conjugating the purified polysaccharides to protein carriers (e.g. tetanus or diphtheria 
toxoid), which provide peptide that can be recognised by antigen-specific T cells, 
thus converting a T cell independent response to a T cell dependent anti-
polysaccharide antibody response.  
5. Recombinant vector vaccines. This class of vaccines utilises attenuated versions of 
certain microbes as recombinant vectors to express target antigens from other 
pathogens. Thus the desired gene is incorporated into a vector which can then be 
injected into the patient, allowed to replicate, express the gene and produce large 
amounts of antigen in situ. Vaccinia (Kass et al, 1999) is a convenient vector that is 
large enough to carry several antigens. A number of experimental vaccines using 
recombinant vaccine have been tested (expressing surface protein from HIV, 
influenza, etc), though none are yet in routine use. Many other viruses have also been 
proposed and tested experimentally as vaccine vectors. Viral vector vaccines elicit 
strong humeral and cell mediated immune response, resulting in immunological 
memory. They can be targeted by viral tropisms inducing desired immunity and can 
encode several antigens at the same time. Also they do not interfere with the 
protection produced by other kinds of vaccines and are relatively inexpensive. On the 
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other hand, there is always the risk of reversion to virulence and of pathology caused 
due to immune responses to virus-infected cells.     
Attenuated bacteria have the advantage that they have genomes large enough 
to incorporate many genes from other organisms. They are generally safe and 
reversions can be controlled. Depending on the bacteria used MHC class I and/or II 
antigen processing pathway can be targeted. Some bacteria induce both cell mediated 
and humeral immune responses, including mucosal immunity since some bacteria 
can survive in the gastrointestinal tract, making this technology attractive for oral 
immunisations.  
6. DNA vaccine. A new approach to protect susceptible individuals against a lethal 
disease is the administration of plasmid DNA by direct inoculations with the intent of 
inducing an immune response to the protein encoded therein. The beginning of the 
development of such a vaccine started with the fundamental experiment by Wolf et al 
(1990). They demonstrated that a single intramuscular (i.m.) inoculation of plasmid 
DNA encoding the reporter protein β-galactosidase induces the expression of this 
protein without the use of a delivery vehicle under in vivo conditions. Using 
histochemical staining procedures forβ-galactosidase activity, blue-coloured muscle 
cells were easily detectable at the site of inoculation 7 days after injection. Moreover, 
transfected muscle cells were surrounded by infiltrating leukocytes, indicating the 
activation of a specific immune response against the foreign antigen. Western Blot 
also showed that there wereβ-galactosidase-specific antibodies. 
             Other types of injections tried in DNA vaccination include intradermal (i.d), 
mucosal, and biojector injections as well as direct skin delivery has been reported. 
The majority of DNA vaccination though involves i.m. or i.d. administration. After 
i.m. injection DNA is taken up by myocytes and/or professional APCs with 
subsequent expression of the foreign antigen via the MHC class I pathway. Secreted 
antigens may be ingested by phagocytes and then presented via the MHC class II 
pathway. These exogenous antigens may prime both the induction of antibody 
responses as well as CD4
+
 T cell activation. However activation of naïve CD8
+
 T 
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cells to armed effecter T cells can only occur through MHC class I presentation by 
bone marrow-derived APCs (and not myocytes). 
With the gene gun delivery system, which shoots plasmid DNA on golf 
particles onto skin via helium gas acceleration, it was demonstrated that DNA is 
delivered directly into Langerhans cells. Thereafter, these transfected cells migrate to 
draining lymph nodes presenting the foreign antigen to the immune system (Condon 
et al, 1996). 
In general, DNA vaccines depend upon the delivery route and method of 
delivery. i.m. inoculation drives immune responses mainly towards the Th1 response 
(Raz et al, 1996). However the gene gun method requires much less DNA compared 
to i.m. administration and gives immune responses both of the Th1 and Th2 types 
(But the mechanism is not clear yet) (Feltquate et al, 1997) (Prayaga et al, 1997). 
Initial clinical trials indicate that DNA vaccines are currently tested. 
The two major advantage of DNA vaccine include that they encode multiple 
cell-mediated immune responses. In animal studies the vaccination induced a long 
term protection. Additionally, large-scale manufacturing procedures are available and 
such vaccines are thermostable and nonvirulent. Finally a more simplified and 
effective quality control process is allowed.       
7. Peptide vaccines. Peptide vaccination involves immunisation against usually 
tumours with identified and characterised immunogenic peptides derived from 
antigens associated with tumours. Peptide vaccines are either in the form of free 
peptide administered with adjuvant, peptide-pulsed dendrite cells, or peptides pulsed 
or incorporated in membrane carriers. Detailed discussion of peptide vaccines will 
follow in this chapter.  
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6.3 Adjuvants 
            Some vaccines contain components that enhance their immunogenicity. 
These components, called adjuvants, boost the immune response by providing 
inflammation signals and activate APCs. For example, tetanus toxoid is not 
immunogenic in the absence of adjuvants, and tetanus toxoid vaccines often contain 
aluminium salts, which bind polyvalently to the toxoid by ionic interactions and 
selectively stimulate antibody responses. Pertussis toxin, produced by B. pertussis, 
has adjuvant properties in its own right and, when given mixed as a toxoid with 
tetanus and diphtheria toxoids, not only vaccinates against whooping cough but also 
acts as an adjuvant for the other two toxoids. This mixture makes up the DPT triple 
vaccine given to infants in the first year of life. 
Many important adjuvants are sterile constituents of bacteria, particularly of 
their cell walls. For example Freund’s complete adjuvant, widely used in 
experimental animals to augment antibody response, is an oil and water emulsion 
containing killed mycobacteria. A complex glycolipid, muramyl dipeptide, which can 
be extracted from mycobacterial cell walls or synthesized, contains much of the 
adjuvant activity of whole killed myxobacteria. Other bacterial adjuvants include 
killed B. pertussis, bacterial polusaccharides, bacterial heat shock proteins and 
bacterial DNA. Many of these adjuvants cause quite marked inflammation and are 
not suitable for use in vaccines for humans. 
It is thought that most, if not all, adjuvants act on APCs (especially DCs) and 
this reflects the importance of these cells in initiating an immune response. Tissue 
DCs take up antigens from their environment, then migrate into the lymphoid tissue 
and present these antigens to T cells. They appear to detect the presence of a 
pathogen in two main ways. A) Ligation and activation of receptors for invading 
microorganisms. These include receptors of the complement system, Toll-like 
receptors, and other pattern recognition receptors of the innate immune system. 
There is much that we don’t know about the direct mechanisms of detection of 
infectious agents. For example APCs get powerfully activated by bacterial DNA 
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containing unmethylated CpG dinucleotide motifs, bacterial heat shock proteins and 
muramyl dipeptide and it is not know how they detect them (even though there is 
indirect evidence that many adjuvants use various Toll-like receptors). APCs upon 
direct activation, respond by secreting cytokines and expressing co-stimulatory 
molecules, which in turn stimulate the activation and differentiation of antigen 
specific T cells. B) The second mechanism of stimulation of DCs by invading 
organisms is indirect and involves their activation by cytokine signals derived from 
the inflammatory response triggered by infection. Cytokines such as GM-CSF are 
particularly effective in activation DCs to express co-stimulatory signals and, in the 
context of viral infection; DCs also express IFNα and IL-2. 
Different types of adjuvants promote different kinds of immune response. For 
example, pertussis toxin stimulates mucosal immune responses, which are 
particularly important in defence against organisms entiering through the digestive or 
respiratory tract. Another vaccine approach is coadministering cytokines. For 
example IL-12 has been used as an adjuvant to promote protective immunity against 
the protozoan parasite Leishmania major. 
Apart from boosting the immune response adjuvants have a very important 
role in converting soluble antigens into particulate material, which is more readily 
ingested by APCs such as macrophages. For instance, the antigen can by absorbed on 
particles of the adjuvant (such as alum), made particular by emulsification in mineral 
oils, or incorporated into the colloidal particles of Immune Stimulatory Complexes 
(ISCOMS). This enhances immunogenicity somewhat but such adjuvants are 
relatively weak unless they also contain bacteria or bacterial produces.    
6.4 IL-2 
            IL-2 is a 15,000 kDa α-helical cytokine produced predominately by active 
CD4
+
 and CD8
+
 T cells which can active dendritic cells (DC), natural killer (NK) 
cells and NKT cells. Originally designated T cell growth factor (Morgan et al, 1976), 
IL-2 supports the growth and proliferation of antigen activated T lymphocytes and 
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plays a central role in the cascade of cellular events involved in the immune response 
(Fauci, 1987). IL-2 is rapidly produced by naïve T cell when stimulated by TCR and 
co-stimulatory molecules via APC. As described, upon activation, resting T cells are 
induced to express IL-2 receptors and to secrete IL-2. This autocrine stimulation 
drives the proliferation of activated, receptor-bearing T cells and the generation of 
antigen specific effector T cell types, including cytotoxic, helper and suppressor T 
cells (Figure 6.2). 
 
Figure 6.2 CD28 dependent co-stimulation of activated T cells induces expression of the T 
cell growth factor interleukin-2 and the high affinity IL-2 receptor 
6.4.1 IL-2 receptor 
            The IL-2 receptor is a heterotrimeric protein expressed on the surface of 
certain immune cells which was the first interleukin receptor described by Kendall 
Smith. There are three subunits, IL-2Rα (CD25), IL-2Rβ (CD122), and the common 
gamma chain or γc (CD132). CD122 and CD132 are primarily folded into β-sheet 
structures as low affinity IL-2R (Nelson and Willerford 1998) (Malek, 2008). Once 
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all three subunits form together, they will become high affinity IL-2R. Functional 
structures of IL-2 and IL-2R interaction reveals that each receptor subunit will 
contact with IL-2, most contact will be at the IL-2/CD25 interface. A strong 
interaction between CD25, CD122 and CD132 leads to a stable quaternary complex 
of IL-2, CD25, CD122 and CD132 (Stauber et al, 2006) (Rickert et al, 2005) 
(Thomas R. Malek, 2008). The IL-2 and IL-2R complex on cell surface is transient 
(10 to 20 min) and they are rapidly internalized. However, it requires a few hours for 
IL-2 to drive T cells into cell cycle. It is therefore a continuous expression of IL-2 
and its receptor is essential for IL-2 induced T cell proliferation. (Cantrell and Smith. 
1984) (Malek, 2008). 
            CD25 does not express on naïve T cell. Following TCR and co-stimulatory 
signals, initially a moderate level of CD25 are rapidly induced by after activation of 
transcription factors of NF-κB, NFAT, AP-1, and CREB/AFT, while after interaction 
with IL-2, IL-2R mediates activation of Stat-5 pathway leading to a high level 
expression of CD25. This mechanism is to increase IL-2 binding and hence 
signalling by activate T cells though enhanced capture of IL-2 by CD25 (Kim et al, 
2006) (Malek, 2008). 
The initial encounter with specific antigen in the presence of a co-stimulatory 
signal triggers entry of the T cell into the G1 phase of the cell cycle; at the same time, 
it also induces the synthesis of IL-2 along with the α chain of the IL-2 receptor, also 
known as CD25. Resting T cell express a form of this receptor composed of β and γ 
chains that binds IL-2 with moderate affinity, allowing resting T cells to respond to 
very high concentrations of IL-2. Association of the α chain with the β and γ 
heterodimer creates a receptor with a much higher affinity for IL-2, allowing the cell 
to respond to very low concentrations of IL-2. Binging of IL-2 to the high affinity 
receptor then triggers progression through the rest of the cell cycle (Figure 6.2).    
Activation of CD8
+
 T cells leads to expression of high affinity IL-2 receptor 
in lieu of the moderate affinity receptor in resting T cells. It is the binding of IL-2 to 
its high affinity receptor that initiates cell cycle progression and proliferation. IL-2 
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may act in an autocrine manner and thus stimulate proliferation into thousands of 
antigen specific clones. With continued maturation, the T cell develops into an armed 
effector T cell not requiring co-stimulation to mount an immune attack. 
6.4.2 IL-2 signalling pathway 
             Human IL-2 is a 133 amino acid polypeptide. IL-2 signalling is mediated by 
IL-2R. The IL-2R α chain primarily increases the affinity of ligand binding, whereas 
the β and γ chain participate in both ligand binding and signal transduction. There are 
at least three different pathways in IL-2R signalling system proceeds, which mediate 
the flow of mitogenic and survival promoting signals (Figure 6.3). First pathways 
proceeds through protein tyrosine kinase activity, Ras and the MARK (Mitogen-
Activated Protein Kinase) cascade, leading to expression of the protooncogenes c-
Fos, c-Jun, and Eik1. The Syk, which for the second pathway is responsible for c-
Myc gene induction.  And the final pathway results in BCL2 (B Cell Leukemia-2) 
expression, and progression through a Rho, Pl3k (Phosphoinositide-3 Kinase) and 
Akt/ PKB (Protein Kinase-B) mediated signalling pathway. As the last pathway is 
also involved in IL-2 promoted regulation of actin cytoskeleton organization (Gomez  
et al, 1997) 
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Figure 6.3 IL-2 Signalling pathways 
6.4.3 IL-2 function 
            IL-2 is crucial for in vitro proliferation of T cells and is assumed to be the 
central growth hormone of the immune system. And as most of the data support that 
IL-2 play essential role in immune tolerance, but this idea is overthrow by IL-2 or IL-
2R deficient mice (Sadlack et al, 1995) (Suzuki et al, 1995). This change is occurred 
when T regulatory cell defect was shown to be responsible for the lethal 
autoimmunity associated with IL-2/ IL-2R deficient. Most T cells have the potential 
to secrete IL-2. Treg cells, however, do not produce IL-2, and this represents one of 
their defining features. In contrast to naïve T cells, the IL-2 proximal promoter in 
75 
 
Treg cells does not undergo chromatin remodeling upon TCR activation (Su et al 
2004). Moreover, Foxp3 directly binds to the minimal IL-2 promoter in association 
with NFAT and further downstream in association with AML1/Runx1, contributing 
to active transcriptional repression of IL-2. Recent studies indicate that Treg lineage 
commitment ensues without expression of Foxp3 (Gavin et al 2007) (Lin et al 2007). 
An important function of Foxp3 is to amplify and fix these pre-existing features 
required for the suppressive program. Moreover, paracrine IL-2 was suggested as 
essential for establishing this program (Gavin et al 2007). As the Treg cell 
suppressive program depends on consistent high levels of Foxp3 (Wan et al 2007) 
(Gavin et al 2007), a fundamental role of IL-2 likely lies in its ability to increase 
Foxp3. Another link between IL-2R signaling and expression of important molecules 
for Treg function is the fact that enforced expression of Foxp3, TGF-β, or CTLA-4 
into IL-2- or CD122- deficient T cells controls many aspects of autoimmunity when 
such cells are present in IL-2- or CD122-deficient mice (Hwang et al, 2004) (Carrier 
et al, 2007) (Malek, 2008).  
6.4.2 IL-2 as an adjuvant in different types of vaccination  
            As mentioned adjuvant play a key role in vaccination strategies. In many 
vaccinations delivery system the immune response is significantly boosted by co-
administration of IL-2. IL-2 is responsible for promoting cell division in a resting T 
cell, and it also treat as a key to reverse the tolerance (Essery et al, 1988) (Figure 6.4). 
They were of interest to determine whether IL-2 could reverse tolerance. They 
culture T cells with IL-2 after induction of unresponsiveness. Once the T cells are 
cultured with IL-2 tolerance T cell restore ability to response.    
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Figure 6.4 IL-2 can reverse tolerance of T cells 
            Proliferating T cells also produce a variety of other lymphokines that affect 
other arms of the immune system. B cell specific lymphokines produced by activated 
T cells (interleukins 4, 5, and 6) act in conjunction with T cell help to activate B cells 
and to generate mature antibody producing plasma cells and memory B cells 
(Coffman et al 1988) (Seghal et al. 1987). Another T cell produced lymphokine, 
interferon γ, induces expression of class II histocompatibility antigens on cells of the 
monocyte/macrophage lineages and activates these phagocytic and antigen 
presenting cells (Basham et al, 1984). 
            In view of these direct and indirect actions of IL-2 in the immune response, it 
has been postulated that IL-2 may function as a potent adjuvant to vaccination, to 
increase the specific and durable response to vaccine immunogens.  
           Recombinant human IL-2 (Rosenberg et al, 1984) (Wang et al, 1984) has been 
shown to be biologically active in cells of many mammalian species (Fong and 
Doyle, 1986). Previous work showed that IL-2 can enhance protection against 
Haemophilus pleuropneumonia in seine when IL-2 is administered systemically in 
conjunction with intramuscular H.  pleuropneumonia vaccination (Anderson et al, 
1987). Daily treatment with IL-2, at the time of vaccination and for 4 days thereafter, 
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was substantially more efficacious than a single IL-2 treatment at the time of 
vaccination. It was concluded that the continued presence of IL-2, throughout the 
period of the immune response, is important in the adjuvant effect. This 
interpretation is consistent with the in vivo action of IL-2 during the immune 
response (Fauci, 1987). 
            IL-2 was also used as an adjuvant to inactivated rabbits virus vaccine. The 
National Institutes of Health (NIH) test for rabies vaccine potency (Seligman, 1973) 
was used to study the effect of daily, systemic IL-2 administration on the potency of 
inactivated rabies virus vaccine (Nunberg et al, 1989). Nunberg et al (1989) found 
that daily systemic administration of IL-2 in conjunction with inactivated rabies 
vaccine can increase the potency of vaccination in out bread mice at least 25-fold, as 
measured by survival following challenge with virulent rabies virus. The same study 
revealed that enhanced protection is not correlated with an increase in virus-
neutralising antibody titers and suggested that IL-2 acts to increase the cellular 
immune response to vaccination.  
            In the recent years IL-2 has been used in conjunction with the highly active 
antiretroviral therapy (HAARA) against HIV. As IL-2 is the major T cell growth 
factor that its exogenous administration could help restores immune function in HIV 
positive patients. This assumption led to the development of therapeutic strategies 
aimed at modulating IL-2 signal strength for clinical benefit. Indeed, numerous 
controlled clinical studies in HIV-positive patients with widely varying CD4 counts 
have now demonstrated that when combined with HAART, IL-2 results in a 
significant rise in CD4 cell count compared with HAART alone, with only transient 
or even no associated bursts of HIV plasma viraemia (Kovacs et al, 1996) (Hengge et 
al, 1998) (David et al, 2001) (Katlama et al, 2002) (Levy et al, 2003). Martinez-
Marino et al (2004) reports that IL-2 therapy in combination with HAART leads to 
significant increases in CD4 numbers that are maintained for six months after 
discontinuation for the IL-2 treatment. This group also report that CD8 cell non-
cytotoxic anti-HIV response was restored among subjects receiving HAART and IL-
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2 whereas it declined among those receiving HAART alone and in untreated infected 
subjects. The percentage of HAART subjects with CD8 cells showing at least 50% 
suppression of HIV replication increased significantly following IL-2 therapy and 
persistence for 6 months. According to Marchetti et al (2005), IL-2 administration 
resulted in a significant increase in CD4 cells, sustained up to one year of follow up, 
whereas HAART patients experienced a much less relevant and slower rise in CD4 
cells. Furthermore Machetti and her group report that clinical recods of the patients 
enrolled suggested that the accelerated IL-2 driven CD4 cell gain might indeed be 
effective in preserving an adequate cellular immunity, as no HIV-related clinical 
eevents were observed among IL-2 treated patients, whereas more than 30% of 
HAART alone patients presented minor opportunistic infections. 
            In DNA vaccination against cancer coexpression of cytokine genes together 
with antigen-encoding genes in DNA vaccination vectors can increase humoral and 
cellular immune responses and may steer them in a TH1 or TH2 direction. In a study 
by He et al (2005), a plasmid expressing the OVA tumour antigen incorporated into 
the signal peptide of human IL-2 was tested as a DNA vaccine in a murine model 
system. Results showed that antigen specific CTL responses were elicited by 
intramuscular injection of these plasmids. Importantly, compared with the minigene 
vector expressing the same OVA epitope, IL-2 expression plasmid vaccination was 
more effective in protection mice from OVA expressing tumour challenge. The 
improved efficacy appears to result from enhanced antigen presentation as well as the 
immunostimulatory activity of IL-2.     
           But IL-2 does get limitation which has been documented. It shows that higher 
doses of IL-2 appear better clinical responses but cause appreciable toxicity named 
capillary leak (Waldmann, 2006) 
6.5 Other cytokines used as adjuvant in vaccine development. 
            IL-2 is the first cytokine administered in a vaccine trial. But there are many 
other cytokine also contributed as the adjuvant to enhance the vaccine response, like 
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IL-7 and IL-21 for the clinic offered the promise of enhancing anti-tumour responses 
but with far less systemic toxicity and no expansion of regulatory T cell. Some 
preclinical studies are also demonstrated that IL-15 could improve T cell and 
particular NK cell responses too (Christian et al, 2009).  
            Il-7 can be produces by a variety cells and tissues but not by lymphocytes 
themselves. It can involved in maintenance and survival of αβ T cells as well as 
development of B cell and γδ T cells, and also may play a role in DC and monocytes’ 
biology except to support NK cells. IL-7 does not appear to support NK cells. Thus, 
IL-7 plays a critical role in lymphocyte homeostasis as indicated by markedly 
diminished lymphocyte counts in IL-7 and IL-7 receptor gene deleted mice and the 
severe combined immunodeficiency associated with IL-7 receptor mutations in 
humans. An extensive review of IL-7 biology and signalling can be found elsewhere, 
but here is focus to point out it as an agent for adjuvant therapy for vaccines (Fry et 
al, 2002) (Capitini et al, 2009) (Christian et al, 2009). Recently, adjuvant IL-7 was 
shown to improve vaccine mediated survival in a spontaneously occurring murine 
tumour model via enhanced Th17 differentiation and reduced T cell-intrinsic 
inhibitory networks. IL-7 is a very promising agent to enhance overall immune 
competence and, potentially, tumour specific immune responses. The absence of 
Treg expansion and the lack of toxicity observed in this clinic would suggest that IL-
7 offers definite advantages over IL-2 as an adjuvant. But IL-7 does play a role in 
either the initiation or maintenance of some leukaemias and lymphomas which 
described as the potential limitations for IL-7 therapy. Therefore it will need to be 
used with extreme caution in immunotherapy regimens involving lymphoid 
malignancies (Korte et al, 1999) (Vudattu et al, 2008) (Christian et al, 2009).   
            IL-15 is constitutively expressed by a variety of cell types and tissues, but in 
contrast to IL-2, is mainly membrane bound. IL-2 and IL-15 have pivotal roles in the 
control of the life and death of lymphocytes. IL-15 and IL-2 exhibit similar immune 
effects and share the IL-2 receptor subunits IL-2 β and γ except α chain (Waldmann 
2006) (Budagian et al, 2006) (Fehniger et al, 2002) (Christian et al, 2009). IL-15 is 
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required for the differentiation of NK cells and plays a role in maintaining and 
expanding CD8
+
 T cells particularly memory subsets, NK cells, NKT cells 
interferon-killer DCs and γδ T cells. And IL-15 may also have function related to B 
cells and APCs. So these features of IL-15 biology will have important implication to 
utilize this cytokine as a therapeutic agent. There have been numerous preclinical 
studies exploring IL-15 as a vaccine adjuvant. Although the majority has been in 
infection models, a number of reports of the adjuvant effect of IL-15 have been 
published. One important observation is that IL-15 can revert tolerant T cells to 
become effectors (Teague et al, 2006). Adjuvant use of IL-15 can enhance vaccine 
responses to both dominant and subdominant, tumour antigens (Melchionda et al, 
2005). Recently, IL-15 administered after a gene-modified vaccine resulted in 
enhanced anti-tumour activity in a murine melanoma mode (Basak et al, 2008). 
Based on the available pre-clinical data, IL-15 would appear to be well suited as an 
adjuvant to cancer vaccines (Christian et al, 2009).   
            IL-21 is homologous to IL-15, but the receptor for IL-21 is comprised of a 
unique subunit designated IL-21Rα and the IL-2Rγ(c). IL-21Rα is expressed on most 
mature lymphocyte populations (Figure 6.5). Production of IL-21is restricted to 
activate CD4
+
 T help cells (Wurster et al, 2002). IL-2 appears to play important roles 
in modulating responses of lymphocytes to other cytokines. IL-21 has also been 
shown to induce IL-10 production in models of lupus, suggesting that like IL-2, it 
can also contribute to immunosuppressive activity (Spolski et al, 2009) (Christian et 
al, 2009).  Besides enhancing IL-2 therapy, IL-21 may also improve the effectiveness 
of other cytokines and immunotherapies. Combining IFNα and IL-21 increases NK 
cell and CD8
+
 T cell mediated cytotoxicity in an experimental model of RCC, 
leading to inhibition of tumour growth and an increased survival (Eriksen et al, 2009). 
IL-21 can also significantly augment IL-7 induced expansion of cytotoxic T cells, 
possibly by preventing the cytokine-induced down-regulation of CD127 on antigen-
stimulated T cells, results which suggest that IL-21 may also play a cooperative role 
with IL-7 in modulating primary CD8
+
 T cell responses (Liu et al, 2007). Lastly, in 
regards to a pediatric tumour, vaccinating with IL-21-gene-modified cells in a 
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syngeneic metastatic neuroblastoma model demonstrated a reduction of microvessels 
in late metastases from therapeutically vaccinated mice. A role of survivin as a 
tumour antigen was suggested since a specific T cell response against this antigen 
was induced (Søndergaard et al, 2007) (Christian et al, 2009).      
 
Figure 6.5 Target lymphocyte population for common cytokine receptor γ-chain family 
cytokines . 
There is considered that the effects of stimulatory or inhibitory on lymphocytes depend on 
the cytokine. IL-21 only increases proliferation of T cells stimulated with anti-CD3 or 
antigen, but can augment responses to other gamma(c) cytokines. IL-7 acts on developing B 
cells but not mature cells of this lineage. IL: Interleukin, NK: Natural Killer, NKT: Natural 
Killer-T cell, Treg: Regulatory T cell (Christian et al, 2009).     
6.6 Dendritic cell-based vaccination approaches 
There is large literature involving vaccination strategies using DCs loaded ex 
vivo with antigens. Different sources of DCs for ex vivo loading have been used. 1) 
Peripheral blood DCs. There are obtained by leukaheresis from blood, followed by 
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positive or negative selection (Hsu et al, 1996) (Small et al, 2000) (Reichardt et al, 
1999). 2) Monocyte-derived DCs. Culture of CD14
+
 monocytes and plastic adherent 
mononuclear cells for 7 days in media containing GM-CSF and IL-4, TNF-a, or IL-
13 is the most popular culture method (Sallusto and Lanzavecchia, 1994) (Cao et al, 
2000) (Morse et al, 1993). 3) CD34
+
 precursor-derived DCs. The generation of these 
DCs requires a more substantial cocktail of cytokines, including stem cell factor 
Flt3L, IL-3, and IL-6, followed by differentiation with IL-4 and GM-CSF (Chen et al, 
2001) (Curti et al, 2001). The second and third methods are the most popular 
methods for in vitro generation of DCs for vaccination.  
There are six type of ex vivo antigen loading to DCs: 
1. Protein-loaded DCs. DCs, being professional antigen presenting cells 
are extremely efficient in taking up proteins. Proteins have the benefit of potentially 
containing multiple antigenic epitopes, including class II epitopes, and thus avoid 
MHC restriction. On the other hand proteins are more difficult to synthesis and are 
less readily available for clinical use. Additionally, proteins are broken down into 
many epitopes, only few of which are immunogenic. Despite these concerns studies 
in multiple myeloma inhibitor of DNA binding (Id) proteins loaded DCs have 
demonstrated that Id- specific T cell responses can be stimulated (Timmerman et al, 
2002) (Titzer et al, 2000) (Li et al, 2000). Another concern has been that even though 
DCs are naturally efficient in taking up proteins, the processing of epitopes derived 
thereof into MHC class I molecules requires high amounts of exogenous antigen and 
therefore appears to be rather inefficient (Lanzavecchia, 1996) (Brossart and Bevan, 
1997) (Norbury et al, 1997) (Raychaudhuri and Rock, 1998). Therefore many 
laboratories are involved with the development of methodologies for effective 
delivery of proteins into the class I processing pathway of DCs. In a report by Laus et 
al (2000) two proteins (ovalbumin and a fragment of the HER-2/neu protein) were 
modified through coupling polylysine stretch is proposed to facilitate cellular uptake 
by neutralising the negative charge of the protein. The fusogenic sequence improves 
access of the antigen form the endosomal route into the cytosol, thereby boosting 
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processing of the antigen into MHC class I. addition of the peptide-conjugated 
antigen to muring APCs resulted in a 10 to 100-fold increase in the efficiency of 
class I restricted antigen presentation (Laus et al, 2000).      
2. DCs loaded with peptides. DCs are known to be able to efficiently take 
up and process protein antigens and present them in the form of peptide: MHC 
complexes. However, it was found that peptides can also be loaded to DCs and such 
peptide-pulsed DCs are potent inducers of immune responses. In fact, direct 
comparison of peptide- and protein- loaded DCs showed that immunisation with 
SIINFEKL- loaded DCs resulted in a much stronger H-2Kb-restricted response 
compare with OVA protein-loading DCs (Met et al, 2003). This could be due to the 
notion that protein processing leads to the production of numerous peptides, not all of 
which are immunogenic, whereas the SIINFEKL peptide is reported to be the most 
immunogenic peptide of the OVA antigen. Advances in peptide- pulsed DC 
vaccination are discussed below. Walden and his group carried out a research on the 
efficiency of peptide presentation by peptide-pulsed DCs compared with other 
peptide-pulsed cell types (Zhen et al, 2006). They found that JY EBV-immortalised 
B cell line for a comparable number of peptide: MHC complexes on their surfaces. 
The higher stability of per-existing peptide: HLA molecules on DCs compared with 
other cell types (Zhen et al, 2004) is the most probable explanation for the less 
efficient peptide loading and the need for higher concentrations of peptide compared 
with JY cells. With the use of sodium azide to inhibit all energy- dependent 
membrane turnover or brefelin A to block export of newly synthesised HLA 
molecules and thereby decouple peptide loading from conventional MHC class I-
specific antigen processing, the efficiency of peptide-loading was reduced. The 
loading of peptides in the presence of those reagents suggests that a fraction of the 
peptide: MHC complexes are formed on the cell surface by exchange against 
peptides already bound to MHC molecules. However the reduces efficiency of 
peptide loading in the presence of the inhibitor reagents suggests that a fraction of 
complexes is formed intracellularly (Zhen et al, 2006). Several laboratories have 
been studying ways it improve peptide loading to DCs. Buschle et al (1997) were 
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able to show that polyarginine treatment enhanced peptide delivery by more than 2- 
fold as compared with cells treated with peptide alone; they also showed that 
polylysine treatment resulted in an approximately 10- fold increase in peptide uptake. 
In a more recent study it was reported that peptide linking with a C- terminal Lys-
Asp-Glu-Leu ER retrieval signal leads in a more efficient and prolonged intracellular 
MHC class I presentation, in a TAP- and proteasome- independent, but brefelin A- 
sensitice manner (Wang et al, 2004). The rapid turnover of the peptide: MHC 
complex also contributes to inefficient peptide presentation. Prolongation of 
synthetic of synthetic peptide presentation has been reported by Waeckerle- Men et 
al (2004) employing the peptides encapsulated in biodegradable microspheres.  
3. DCs transfected with DNA and mRNA. These methods provide 
epitopes from endogenously synthesised antigen. DNA and mRNA have the 
advantage of being easier to manufacture than full-length proteins. Although DCs 
may be loaded with naked DNA, this approach has low efficiency of transfection, 
and thus viral vectors are generally employed. However, there have been studies to 
improve transfection; in a study by Irvine et al, (2000) a cationic peptide (CL22) was 
used to condense plasmid DNA encoding the antigens of choice to improve 
transfection efficiency of human and murine DCs. An alternative is to load DCs with 
mRNA encoding tumour antigens (Boczkwski et al, 1996) (Mitchell and Nair, 2000). 
mRNA is transfected in its naked form with liposomes or via  electroporation. 
VanTendeloo et al (2001) reported that mRNA-electroporated DCs are more potent 
in activation antigen specific CTLs than mRNA-liposome transfected DCs. It has 
been reported that even low levels of transfection are adequate for mRNA-loaded 
DCs to strongly stimulate antigen specific CTLs (Nair et al, 1998). Importantly, 
mRNA can be amplified from small amount of tumour, and thus this method may 
increase applicability of DC based vaccines to patients with minimally available 
tumours (Heiser et al, 2001). A general advantage of nucleotide transfection of DCs 
is that endogenously sythesised antigens have better access to the MHC class I 
pathway. 
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4. DCs transuded with viral vectors. Several classes of viral vectors have 
been developed for the delivery of genetic material to DCs. Retroviral vectors can 
successfully transducer proliferating CD34
+
 progenitors prior to their differentiation 
into DCs. These viral vectors carry the risk of oncogenic transformation and have 
relatively low transduction efficiency (Osada et al, 2006). Lentiviral vectors do not 
encode viral proteins, thereby minimising their potential to interfere with the function 
of transduced DCs via the induction of vector –specific immunity (Osada et al, 2006). 
Lentiviral vectors have been developed with increased safety profiles that prevent the 
generation of replication- competent recombinants (Firat et al, 2002) (Lizee et al, 
2004) (Dull et al, 1998). He et al (2005) directly compared lentiviral vector-
transducer DCs with peptide/protein-pulsed DCs by analysing the kinetics and 
strength of the resultant in vitro and in vivo antigen-specific immune responses, and 
demonstrated that the lentivirus stimulated more potent and persistent in vivo CTL 
activity, resulting in superior therapeutic efficacy. Adenoviruses have also been used 
to transduce DCs and different modifications have been explored to avoid vector 
immunogenicity and increase safety (Amalfitano et al, 1998) (Rea et al, 2001) 
(Worgall et al, 2004). Fowlpox vectors have been studied as well, being interesting 
due to their ability to infect but not replicated within human cells (Brown et al, 2000). 
Kim et al (1998) reported that fowlpox transduced DCs were able to stimulate CD8
+
 
T lymphocytes in vitro from 10 out of 11 patients. Fowlpox vectors with co-
stimulatory molecules and antigen have been used to transducer DCs and led in 
superior antigen presentation capacity (Zhu et al, 2001) (Tasang et al, 2005).  
5. DCs loaded with tumour cells or tumour cell lysates. Tumour cells 
have been explored as a strategy to load DCs, as they contain all the necessary 
material against which the desired immune response should be directed. In murine 
models immunisation with DCs that had phagocytosed apoptotic/ necrotic tumour 
cells resulted in a greater tumour-specific CTL response and successful eradication 
of lung metastases compared with immunisation with tumour peptide pulsed in many 
clinical trials, as the processing of the lysate by DCs allows for the targeting of broad 
variety of unknown proteins (Yu et al, 2004) (Lee et al, 2005) (Chang et al, 2002).  
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6. DC- tumour cell fusions. Another method for delivering the contents of 
tumour to DCs is the construction of DC-tumour cell fusions. These fused cells 
express a large repertoire of TAAs, high levels of MHC class I and II molecules, and 
adhesion/ co-stimulatory molecules, making them strong antigen-presenting 
platforms (Osada et al, 2006). Preclinical data has demonstrated that DCs fused with 
tumour cells are potent inducers of tumour-specific immune responses (Gong et al, 
2000) (Koido et al, 2004). Polyethylene glycol has long been utilised for fusing cell, 
and electrofusion has also emerged as an alternative technique (Parkhurst et al, 2003) 
(Scott-Taylor et al, 2000). Many clinical trials employing DCs fused with autologous 
tumour or allogeneic tumour cell lines have been initiated, with the results suggesting 
that hybrid cell vaccination is a safe and well tolerated procedure capable of inducing 
T cell responses (Martein et al, 2003) (Kikuchi et al, 2001). 
6.6.1 Peptide-pulsed DCs in the clinical setting  
 New methods and technologies allow easier generation and collection of 
large number of either monocyte- or CD34
-
 derived autologous DCs from cancer 
patients (Sallusto and Lanzavecchia, 1994) (Siena et al, 1995). In vitro experiments 
and animal models demonstrated that autologous DCs can effectively present human 
TAA as loaded proteins or peptide to naïve T cells (Fong and Engleman, 2000). 
Several clinical trials, mainly on melanoma patients, have been carried out using 
peptide-pulsed DCs (Figure 6.6).  
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Figure 6.6 Strategy for immunization with autologous peptide-pulsed DCs (Jay et al, 
2001) 
Monocytes or CD34
+
 precursors are isolated from patient blood by cytopheresis. Cells are 
cultured in the presence of various cytokines to differentiate them into immature dendritic 
cells, which are then loaded with the antigen of interest before or following dendritic cell 
maturation. Mature antigen-loaded autologous DCs are then administered to patients. 
            In an early study by Mukherji et al (1995) melanoma patients whose tumour 
cells express the MAGE-1 gene and who are HLA-A1﹢were immunized with a 
vaccine made of culture autologous APCs (peripheral blood-derived plastic-adherent 
mononuclear cells culture in GM-CSF) pulsed with the synthetic MAGE-1 
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nonapeptide EADPTGHSY. Analyses of the nature of the in vivo host immune 
response to the vaccine revealed that the peptide-pulsed APCs are capable of 
inducing autologous melanoma reactive and peptide-specific CTLs in situ at the 
immunization site and at distant metastatic disease sites (Mukherji et al, 1995).  
            In another study (Banchereau et al, 2001) eighteen patients with metastatic 
melanoma received s.c injections with CD34 progenitor-derived autologous DCs 
pulsed with peptides derived from four melanoma antigens. Immune responses 
(expansion of melanoma-specific IFNγ-producing CD8+ T cells in the blood) to one 
or more peptides were observed in sixteen out of eighteen patients (Banchereau et al, 
2001). The overall immunity to melanoma antigens after DC vaccination was 
associated with a clinical response. In a later follow up study the same group further 
analysed twelve of the patients to determine whether vaccination with peptide-pulsed 
CD23-DCs permits expansion of melanoma-specific CD8
+
 T cells that can yield 
functional CTLs able to kill melanoma antigen-expressing cells (Paczesny et al, 
2004). They showed in nine out of twelve analysed patients the expansion of 
cytolytic CD8
+
 T cell precursors specific for melanoma differentiation antigens. 
Larger follow up studies to assess the immunological and clinical response to 
peptide-pulsed CD34-DC vaccines are underway.     
            Peptide-pulsed SC vaccination has also been employed for numerous other 
clinical trials involving several types of malignancies like multiple myeloma (Titzer 
et al, 2000), malignant glioma (Yu et al, 2001), nasopharyngeal carcinoma (Lin et al, 
2002), chronic myelogenous leukaemia (Takahashi et al 2003), gastrointestinal 
malignancies (Matsuda et al, 2004), colorectal cancer (Liu et al, 2004), 
hepatocellular carcinoma (Butterfiled et al, 2006), renal cancer (Wierecky et al, 
2006), and breast cancer (Svane et al, 2007). 
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6.7 Problems of DC based vaccines 
            DC as the most potent APC has been used to elicit protective T cell immune 
response to viral infection and cancer. However, so far, there are very limited clinical 
success (Melief, 2008) (Steinman and Banchereau, 2007) largely due to a lack of 
knowledge of the ideal antigen-loaded DC for optimal therapy and standardization 
(Figdor et al, 2004) (Steinman and Banchereau, 2007). One of the major problems is 
the creation of HLA and peptide complexes on therapeutic DC cells. Although a 
number of reports demonstrated an induction of CD8 T cell responses by peptide 
loaded DC cells in vitro (Smith et al, 2007) (Melief, 2008), it is impossible to control 
the quantity and quality of peptide – HLA class I assembly on therapeutic DCs 
making the therapeutic DCs inconsistent. It is even more difficult to characterise 
peptide – HLA class II complexes on DCs which is important to induce CD4 helper 
function required for long lasting CTL responses (Smith et al, 2007) (Melief, 2008). 
             The second major problem is the immunogenic heterogeneity of the matured 
of DC matured after derived from monocytes isolated from patient blood in vitro. 
The differentiated DCs have heterogenic population with immunologically active or 
suppressive function for induction of T cell responses. It has discovered that mature 
DCs differentiated in vitro can produce soluble suppressive factors like IL-10, 
Transforming growth factor beta (TGF-β) and indoleamine 2,3-dioxigenase (IDO) 
(Munn et al, 2002) (Lan et al, 2006) (Kobie et al, 2003) (Vassiliki et al, 2009).  
             The other major problems for live DC therapies are low stability after 
transfused back into patients, could not be stored for repeated use, therapeutic DC 
reagents have to be individually prepared from autologous blood monocytes 
(Fernandez et al, 1998). 
             In addition to the difficulties to prepare good DC therapeutic reagents, an 
immune suppressive microenvironment in tumour is also one of the major barriers 
for a successful anti-cancer immune therapy (Melief, 2008). Numbers of 
immunosuppressive cytokines, including IL-10 and TGF-b are produced by tumour 
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or tumour stimulated stromal environment (Kortylewski et al, 2005) (Kortylewski 
and Yu, 2008). immunoediting (Dunn et al., 2006) (Koebel et al, 2007), in contrast to 
the activation and maturation factors for DC under infectious condition, the immune 
suppressive environment induced by tumour negatively affect the function of 
therapeutic DC cells and effector T cells (Hamzah et al, 2008a) (Hamzah et al, 
2008b). In conclusion, the therapeutic DCs manipulated in vitro differ functionally 
from DCs induced by pathogens in vivo and the uncontrolled biological functions in 
therapeutic DCs can severely reduce the efficacy. 
             To overcome the low stability of therapeutic DCs, cell-free antigen-
presenting systems have been reported, including membrane vesicles derived from 
APC such as exosomes, which are secreted from endosomal compartments of APC 
and microvesicles derived from plasma membranes of APC after sonication (Kim et 
al, 2004) (Kovar et al, 2006), However, these vesicles have problems  such as 
difficulty to control the quality and the quantity of pMHCs in the preparation, low 
yield and have to be prepared from patient cells. Our group has generated a novel 
vesicle based vaccine by using microsomal vesicles from the ER membranes of 
APCs (Vassiliki et al, 2009). The data demonstrated that these microsomal 
membranes not only can be monitored and controlled quantitatively and qualitatively 
of the level of pMHC with reporter peptides, but also possess a high level of co-
stimulatory molecules (Vassiliki et al, 2009). 
6.8 Liposomes 
            Liposomes are colloidal, vesicular structures based on lipid bilayers. Their 
characteristics depend on the manufacturing protocol and choice of bilayer 
components. They range from 20nm to 10μm in diameter. The liposomes can be 
unilamellar (with only one bilayer surrounding an aqueous core) or multilamellar 
(several bilayers concentrically oriented around an aqueous core). Moreover the 
choice of bilayer components determines the ‘rigdity’ (or ‘fluidity’) and the charge of 
the bilayer. For example saturated phospholipids with long acyl chains, such as 
dipalmitoylphosphatidylcholine, for a rigid, rather impermeable bilayer structure, 
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while unsatureated phosphatidycholine species from natural sources (egg or soybean 
phoshatidylcholine) give much more permeable and less stable bilayers. The 
introduction of positively or negatively charged lipids gives the liposomes a surface 
charge. Liposome surface can be readily modified. The circulation time of liposomes 
in the blood stream is dramatically increased by attaching poluethylene glycol 
(PEG)-units to the bilayer. Alternatively homing molecules can be attached to 
liposome bilayers to make these structures target site specific. Size, lamellarity, 
bilayer rigidity, charge and bilayer surface modifications are all parameters that 
determine the fate of liposomes on the shelf and in vivo. Over the years the behaviour 
of liposomes has been investigated in great detail (Gregoriadis, 1993) (Storm and 
crommelin, 1997). Algorithms can be used to help the pharmaceutical formulation 
scientist to select the proper liposome type (Figure 6.7). 
 
            Figure 6.7 A drawing of a small spherical liposome seen in cross section  
           Liposomes are used as carriers for drugs and antigen because they can serve 
several different purposes. Liposomes can direct a drug to a certain target. Secondly, 
liposomes can prolong the duration of drug exposure, acting as a slow release 
reservoir (Oussoren et al, 1999).  This has been demonstrated in a number of studies, 
for example with the antimalarial drug chloroquine or the radical scavenger 
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superoxide dismutase. Liposomes can protect a drug against degradation (e.g. 
metabolic degradation). Conversely, liposomes can protect the patient against side 
effects of the encapsulated drug. For example liposome encapsulation greatly reduces 
exposure to the heart to doxorubicin and thereby its cardiotoxicity. As liposomes can 
solubilise lipophilic compounds, this solubilising potential can be used to inject 
poorly water soluble compounds intravenously. If a fast pharmacological response is 
desired, then ‘fragile’ liposomes with ‘fluid’ bilayers should be selected.  
            Liposomes can be made tissue or cell specific. Most of the work on liposome 
targeting has been done with antibodies or antibody fragments attached to the 
liposome surface (Mastrobattista et al, 1999). However other homing devices have 
also been considered, e.g. plasminogen-coated liposomes were designed to 
endothelial cells to block angiogenesis (Koning et al, 2006). Saccharide directed 
targeting has also been described to direct liposomes to hepatocytes. Targeted 
liposomes should readily have access to the target site and should not be taken up by 
macrophages before encountering their target tissue or cells. Therefore nowdays 
stealth technology is often combined with the attachment of a homing device to the 
terminal end of the PEG chain that is exposed to the aqueous medium. 
            In cancer immunotherapy, liposomes have been used to deliver antigen and 
immunomodulating agents to DCs. Different startgies are being explored to target 
liposomeal antigens to DCs in vivo. In a study by Kawamura and colleaques (2006) 
IgG conjugated liposomes without attaching PEG were most efficiently endicytosed 
by DCs. Immunisation of mice with DCs that endocytosed ovalbumin containing IgG 
liposomes completely prevented the growth of OVA-expressing lymphoma cells. 
Importantly administration of DCs that endocytosed OVA containing IgG liposomes 
to the mice with established OVA expressing tumours strongly suppressed tumour 
growth (Kawamura et al, 2006). 
            The potential for using cell-deriver liposomal membranes to deliver tumour 
antigens to DCs recently has been explored using tumour cell derived plasma 
membrane vesicles (PMVs). Tumour cell derived PMVs are known to retain tumours 
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antigens from established tumour cell lines. They can be prepared by brief sonication 
of the cells, followed by separation of the membrane fraction by high speed 
centrifugation on sucrose (van Broekhoven et al, 2002) (van Broekhoven et al, 2004). 
The membrane fraction PMVs is then collected and used for vaccine production.  
            Various tumour vaccine combinations have been prepared recently from 
tumour cell derived PMVs that have been modified to contain cytokines and 
engrafted with either T cell co-stimulatory molecules or with ScFv that target the 
surface markers CD11c and DEC-205 on murine DCs. Importantly, immunological 
studies showed that PMV preparations containing the co-stimulatory molecules B7.1 
and CD40 and IL-2 cytokines can exert potent antitumour responses, including the 
inhibition of tumour growth and regression of established tumours (van Broekhoven 
et al, 2002). Later, the same group used an approach where single chain antibody 
fragments to the DC surface molecules CD11c and DEC-205 were attached to 
vesicles containing IFNγ or lipopolysaccharide, to target them to DCs (Altin et al, 
2004) (van Brokhoven et al, 2004). Such membranes induce dramatic antitumour 
responses and immunotherapeutic effects when used as a vaccine in the murine 
tumour model B16-OVA melanoma. Therefore, PMV targeting of antigen and 
maturation signals directly to DCs in vivo represents a much simpler strategy for 
cancer immunotherapy than antigen loading DCs ex vivo (Altin et al, 2004) (van 
Broekhoven et al, 2004).  
            Clinical trials of liposomal vaccines on cancer patients have revealed that 
liposomes are safe and well tolerated and can induce tumour specific T cell responses 
(Neidhart et al, 2004) (Neelapu et al, 2004). In a study by Neelapu et al (2004), ten 
patients with advanced stage follicular lymphoma were vaccinated with liposomal 
idiotype/IL-2 vaccine. 6 out of 10 patients showed complete remission. However, 
only a few clinical trials have been carried out, generally with no significant clinical 
results.  
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6.9 Dendritic cell-based cell-free vaccination approaches 
6.9.1Exosomes 
             Exosomes are saucer shaped vesicles of 30-100nm in diameter, which are 
delimited by a lipid bilayer and which float at a density of 1.13-1.19g/ml in sucrose 
gradients. These vesicles are secreted by various cells in culture (Figure 6.8). 
Analysis of the protein composition of exosomes that are secreted by various cells 
reveals the presence of some common proteins, which define exosomes as a bona 
fide secreted subcellular compartment, as well as the presence of some cell type 
specific proteins, which could mediate the different functions of exosomes that are 
produced by different cell types. All of the proteins that have been identified in 
exosomes are localised in the cell cytosol or endosomal compartments, never in the 
endoplasmic reticulum, Golgi apparatus, mitochondria or nucleus. Exosomes also 
contain some plasma membrane proteins, which have been described also in 
endosomal compartments. These observations are consistent with the proposed origin 
of exosomes as internal vesicles of late multivesicular compartments (Tery et al, 
2002) 
            The biological functions of exosomes remain unclear. The original role of 
exosomes was most probably to eliminate undergraded endosomal or lysosomal 
proteins and mmembranes. Recent results indicate, however, that in different cell 
types, exosomes might have other functions, such as the stimulation or inactivation 
of T cells, or the transfer of antigens to DCs. Scientists at the institute Curie proposed 
a novel mode of functioning of exosomes (Thery et al, 2002); After the uptakge of 
incoming pathogens in the periphery, immature or maturing DCs generate peptide 
MHC complexes. Some of these complexes could be secreted on exosomes, and 
locally sensitize other DCs that have not encountered the pathogen directly, as a 
result of the effects of inflammation, all of these DCs migtate out of the tissue 
towards the draning lymph nodes. Although maturing DC seem to secrete fewer 
exosomes that immature cells, an exchange of exosomes inside the lymph nodes 
between newly arrived and resident DCs could take place too. Therefore, exosomes 
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production would increase the number of DCs that bear the revelant peptide MHC 
complexes, and thereby amplify the magnityde of immune responses. In the absence 
of inflammation, spontaneous migration of exosomes-bearing DCs could contribute 
to tolerance induction. Figure 6.8  
             
 
Figure 6.8 The exosome pathway (Laura et al, 2008) 
              By now results have shown that DC derived exosomes stimulate T cell    
proliferatio in vitro and have a potent capacity to generate antitumour immune 
resposes in vivo. All these reported studies have involved in vitro grown mature DCs 
expanded from precursors with cytokines. However, immature DCs produce higher 
numbers of exosomes than mature DCs and this is thought to be due to a reduction in 
endocytosis as DCs mature, associated with reduced formation of multivesiculatr 
bodies and reduced exosomes formation. In Segura et al (2005) group they found that 
exosomes secreted by mature DCs are enrighed in MHC class II, B7.2 and ICAM-1, 
and up to 100fold more potent than exosomes form immature DCs both in vitro and 
in vivo. Functional analysis using DCderived exosomes from knock out mice showed 
96 
 
that MHC class II and ICAM-1 are required for mature exosomes to prime naïve T 
cells. 
            The feasibility of using DC derived exosomes as a cancer therapeutic 
vaccines has been tested in two Phase I clinical studies in melanoma and lung cancer 
patients (Escudier et al, 2005) (Morse et al, 2005). Both of these studies highlighted 
the feasibility of large scale exosomes production and safety of exosomes 
admistration. However, T cell immunomonitoring did not reveal any significantly 
strong peptide specific CTL expansion nor clinically significant DTH responses.  
6.9.2 Membrane vesicles form APCs 
            A newly described method involving membrane vesicles for vaccination was 
published by Kovar et al (2006). They made the hypothesis that since the 
immunogenicity of DCs presumably reflects their dense expression of MHC/peptide 
plus high levels of costimulatory molecules, one might expect that the direct 
immunogenicity of mature DCs could be mimicked by plasma membrane fragments 
from these cells. In line with this prediction, using a DC line, they shoed that 
ultracentrifuged vesicles derived from sonicatied of mature DCs contain MHC class I 
as well as costimulatroy and adhesion molecules such as ICAM-1, B7.1 and B7.2. 
These vesicels have a round shape and cle=osedly resemble classic exosomes, naïve 
CD8 T cells were able to bind membrane vesicles from DCs in vitro but only in the 
presence of peptide. A key finding was that in the presence of specific peptide, 
sonicated from DCs were strongly stimulatory for CD8 T cells in vitro in the absence 
of APC. Vesicles from immature DCs were poorly immunogenic. Peptide loaded 
vesicles led to efficient cells capable of tumour cell elimination. The vesicels, given 
as a single injection, were immunogenic after either i.v. or s.c. injection. (Figure 6.9). 
            As discussed earlier, DC derived exosomes are proving a very useful tool for 
tumour immunotherapy, but their use is limited by low yields, especially from mature 
DCs. They show that this problem can be overcome simply by degrading DCs into 
small fragments by sonication. Discarding nuclei and larger debris, the yielded 
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materal has the form of small membrane vesicels which have the size and 
morphology of exosomes, and are strongly immunogenic for CD8 T cells when 
pulsed with peptide. 
 
Figure 6.9 EM images of exosomes and sonicates prepared form IFNγ stimulated DCs 
(Boyman et al. 2006)  
            How the vesicles are presented to T cells in vivo is unclear. Also unclear is 
the potential of these vesicles in tumour vaccination in humans; further studies need 
to be carried out. However it is reported by th eauthors that at least in vitro, vesicles 
were more immunogenic than exosomes and obtained in much higher yields (Kovar 
et al, 2006) 
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7 Proposed system and thesis aims. 
             From the studies of therapeutic vaccines during last 20 years, it has now been 
clear that;  
1. Manipulation of antigens in vaccine preparation is not enough, therapeutic 
vaccines have to be able to reverse immune unresponsiveness or enhance antigen 
specific T cells.  
2. Although DCs are most effective antigen presenting cells under infectious 
conditions in vivo, DC vaccines developed from monocytes cannot perform same 
function as naturally differentiated DCs under infection condition in vivo.  
3. The best therapeutic vaccines will be ones that can bypass antigen presentation 
pathways in vivo and directly activate antigen specific T cells.  
            In previous study, we found that the endoplasmic reticular (ER) enriched 
microsomal membranes (microsomes) isolated from APC can directly activate T 
cells and induce immune responds for acute virus infection and cancer in vivo. In 
order to apply this strategy for the development of therapeutic vaccine for chronic 
infectious diseases, we create a nanoAPC able to deliver not only antigen-MHC, but 
also IL-2 to antigen specific T cells to enhance T cell activation leading to overcome 
the immune exhaustion.   
           To develop IL-2-nanoAPC, we constitute a human B cell line 721.221 cells 
with engineered HLA-A2 and IL-2 specifically inserted into the ER membrane. 
721.221 cells express high levels of co-stimulatory molecules, but defect in MHC 
class I (Shimizu et al, 1988). In order to express IL-2 and HLA-A2 into the ER in 
221cells, we fused IL-2 with Tapsin an ER retention protein and HLA-A2 with ER 
retention signal (Turnquist et al, 2002). With an improved procedure, we produced 
homogenous vesicles at a nano-size of ~ 500 nm termed as nanoAPC. Assembled 
with specific antigenic peptides, the IL-2-nanoAPC directly interacted with antigen 
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specific T cells and induced immune synaptic formation of antigen specific T cells. 
The IL-2 on nanoAPC did not affect bystander T cells, but potently enhanced 
activation and effector function of antigen specific T cells. We examined the ability 
of IL-2-nanoAPC in the induction of viral specific T cell responses in peripheral 
blood lymphocytes from chronic HBV patients. Assembled with a pool of five HLA-
A2 peptides, and four DR and DP associated peptides, IL-2-nanoAPC strongly 
induced responses of CD4 and CD8 T cells in patient PBMC, while responses were 
not detected in PBMC following stimulation with peptides or peptide-assembled 
nanoAPC in the absence of IL-2. Our results demonstrated that IL-2-nanoAPC can 
be developed as effective therapeutics for the treatment of chronic infectious diseases.  
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MATERIALS AND METHODS 
1. Experimental tools and conditions. 
1.1 Animals. 
             OTI transgenic mice on the C57BL/6 background were kindly provided by 
Dr. Kioussis D. MRC National Institute for Medical Research, London. C57BL/6 
mice were purchased from Harlan UK, (Oxon, England). All animals were 
maintained in pathogen-free facilities at the Brunel University.  
1.2 Cell lines. 
             The human B-LCL cell line721.221/HLA-A2 cell lines were kindly provided 
by T. Elliott. The murine DC2.4 line was kindly provided by Dr. Mann D. 
Southampton, UK. The murine CTL cell line CTLL4 was kindly provided by Dr 
Gitta Stockinger, NIMR, London. All cell lines were cultured in RPMI 1640 or 
DMEM supplemented with 10% FBS 1% P/S and 1% L-glutamine if not supplied in 
medium. Adherent and cells in suspension were pooled and centrifuged at 1200rpm 
for 5min; the pellet was then resuspended in fresh medium and dispensed into new 
flasks. The growth medium was changed once per week. Briefly, the old medium 
was removed, and then the cells were dislodged and dispensed into new flasks. Cells 
were sub-cultured in a ratio of 1:4, twice a week or as appropriate. All running 
cultures were maintained in a humidified incubator at 37°C in 5% CO2. All cell 
stocks were stored in freezing medium at >10
6
cells/ml in liquid nitrogen vapour 
phase. 
1.3 Reagents and antibodies. 
             All cell culture reagents were from Invitrogen Ltd. (Gibco-BRL, Rockville, 
MD). Ficoll Pacj was from Amersham (Amersham Biosciences UK Limited, Little 
Chalfont). FITC-conjugated mouse anti human antibodies to CD54 (ICAM-1), CD80 
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(EuroBioSciences), and FITC-conjugated Streptavidin; PE-conjugated mouse anti 
human antibodies to pErk, PD1, HLA A2, , Foxp3, W6/32, FITC-conjugated mouse 
anti human CD4, APC-conjugated mouse anti human CD8 and PEcy5-conjugated 
mouse anti human IFNγ were from BD Biosciences. CD8 microbeads (Miltenyi 
Biotec) were used for isolation of CD8 T cells from spleens of OTI mice, according 
to the manufacturer's protocol. Goat anti-human IL-2 and anti-human CD3, and 
W6/32, specific to human MHC class I and MA2.1 specific to HLA A2 were used 
for immune staining of cells and nanoAPC. Texas Red labelled rabbit anti-goat Ig 
and FITC labelled goat anti-mouse Ig were used for secondary antibodies. 
1.4 Peptides. 
             Peptides were synthesized by Invitrogen and purified to more than 95% 
purity. Peptides were reconstituted following the manufacturer's instructions by 
calculating the hydrophobic and hydrophilic amino acids and accordingly dilute in 
recommended medium. Specifically, OVA257–264 SIINFEKL CMV pp65 peptide 
NLVPMVATV HBV HLA-A2 peptide C18-27 FLPSDFFPSV; HBV envelope 183-
191 FLLTRILTI; 335-343 WLSLLVPFV; 338-347 LLVPFVQWFV; 348-357 
GLSPTVWLSV (Das A et al, 2008) and DR/DP binding peptides HBV Env 180-195 
AGFFLLTRILTIPQS; Env 339-354 LVPFVQWFVGLSPTV; and Pol 767-782 
AANWILRGTSFVYVP) (Mizukoshi et al, 2004)  were reconstituted in DMSO 
under sterile conditions. Working concentrations of all peptides were prepared in the 
appropriate cell culture medium. 
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2. IL-2-tapasin construct  
2.1  Construct creation  
             To establish IL-2-A2-721.221 seed cells, IL-2-tapasin and HLA-A2-E3-19K 
fusion constructs were constructed by PCR cloning approaches. For IL-2-tapasin, an 
expression construct of tapasin was modified by substitution of the signal sequence 
(Li et al 1997) with a 2 x GS linker (GGSG) (Casto and Feng 2000) by PCR cloning. 
Then, a PCR product of human IL-2 coding region was cloned to upstream of GS 
linker to create IL-2-GS-tapasin.  The sequence of insert contains tapasin and IL-2 
shows in figure 1.9. The HLA-A2-E3-19K was constructed by insertion of a 16-aa 
(LKYKSRRSFIDEKKMP) from E3-19K proteins (Gabathuler and Kvist 1990) to C-
terminus of HLA-A2 in an HLA-A2 expression construct (Li et al 2000).  
2.1.1 DNA extraction from agarose gel & Restriction enzyme digestion and 
ligation 
             After the PCR sample is run on a 7% agarose gel the gel slice is excised, put 
in an eppendorf tube and its weight is determined. Extraction is carried out using the 
QIAGEN gel extraction kit and protocol which is carried out in the following way: 
three volumes of buffer QG to 1 volume of gel. Incubate at 50
o
C for 10 min while to 
help dissolve the gel vortex the tube every 2-3 min. The sample is then centrifuged at 
maximum speed at room temperature for 1 min in the QIAquick spin column on top 
of a collection tube. After 0.5 ml of buffer QG to column and spin for 1min, the 
sample will be washed under 0.75 ml PE buffer once. Finally the sample has been 
dissolved into 30-50ul of EB buffer and then collected into another clean eppendorf 
tube. 1-2ul of the supernatant is then used test concentration. After same Restriction 
Enzyme Digest both vector and insert, the vector will be processed under 
dephosphorylation stage which is the essential process before ligation maximum to 
avoid vector self ligation. And finally both linearizing vector and insert ligate with 
T4 ligase and the appropriate buffer at 16
o
C overnight. 
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2.1.2 Plasmid extraction  
             The constructions transfamation into E.coil under heating shock flowing by 
clone select on LB argos plat and small cultures.  The Plasmid extractions from small 
cultures which are about 1ml-3ml were carried out as follows. After the bacteria 
cultured overnight, and then are centrifuged for 1min at 13000rpm and the 
supernatant is removed. The pellet is resuspended in 100ul P1 buffer (Tris 2.5M, 
EDTA 0.5M, 500ul RNase) and incubated for 5min at room temperature. 200ul of P2 
buffer (NaOH 10M, SDS 2.5%) is then added to the mixture, and a further incubation 
follows for 5min on ice. 15ul P3 (KOAc 3M pH 4.8) are added to the mixture which 
is then mixed gently and incubated for a further 5min on ice. The mixture is 
centrifuged at 4°C at 13000rpm for 5min and the supernatant is transferred to another 
tube. Add 70% of this volume of isopropanol to the supernatant and after mixing and 
for centrifuging 5min at 13000rpm the supernatant is discarded and the pellet is 
washed with 500ul 70% ethanol. The pellet is finally resuspended in water and 
frozen down at -20°C.  
             The positive clone will be confirmed by restricted enzyme test and sequence. 
Chose one positive construct plasmid extraction from big cultures was carried out the 
QIAGEN plasmid purification kit and protocol.  
2.2 Construct plasmid transfection 
            Construct plasmid were transfected into 721.221 cells using T cell 
nucleofector solution (Lonza). First Spin 5-10 million cells under 1200rpm for 5 min 
the supernatant is removed. The pellet is resuspended in 110ul T cell nucleofector 
solution plus 8ug of DNA and incubated for 2min at room temperature. And then the 
60ul of this mixture is transferred to a cuvette and electroporation with program S-
018. Immediately add 500ul 37°C prewarmed complete medium. Finally, add 
another 8ug of DNA to rest of the mixture and repeat same process as before. The 
transfectants into complete medium and selected with antibiotic or running sorting 
couple of days later.  
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3. Protein analysis. 
3.1 Western blot analysis of protein. 
3.1.1 Cell lysis  
             Harvest cells from 1x 75 cm
2
 flasks and then wash once with PBS. 
Resuspend cells in 100ul 1% NP40 lysis buffer and add 1ul PI and 1ul 10mM PMSF 
following shaking for one hour at 4
o
C. Spin down at 14000rpm for 30min at 4
o
C and 
then transfer the supermatant to new tube. After measure protein content via BioRad 
Dye reagents, the protein sample is ready for western blot analysis.  
3.1.2 Gel preparation  
            Gels were cast and run using the Bio-Rad Western apparatus. The plates were 
cleaned, the spacers were introduced and the plates clamped in place. The resolving 
gel was poured first. A 10ml preparation of 10% consists of 2.4ml purified water, 
3.35ml 30% acrylamide, 3.75ml 1M Tris pH 8.8, 100μl 10% SDS, 100μl 10% APS 
and 4μl TEMED. After pouring the gel was covered with isopropanol (~0.5ml) to 
ensure a level surface to the top of the gel and to aid polymerization. Once set 
isopropanol was removed and the plates were dried. The stacking gel was then 
poured and the comp was fitted. A 2.5ml preparation of 5% stacking gel consists of 
1.7ml of purified water, 415μl 30% acrylamide, 315μl 1M Tris pH 6.8, 25μl 10% 
SDS, 25μl 10% APS and 5μl TEMED.  
3.1.3 Test sample running 
            Transfer 25ug protein for each well which need to take required volume of 
smaple and then mix with smaple buffer and 1ul 1M DTT/10ul sample volume 
fllowing heating at 95
o
C for 5min. The gel is run at 30mA for ~1hour at cool room 
(4
o
C). After running the top plate is removed and the stacking gel is cut away. 
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3.1.4 Transfer-semi-Dry Blot 
             The transfer apparatus is then assembled. The bottom plat is covered with 4 
sheets of Whatman 3MM paper, then the membrane and gel, 4 more sheets of  
Whatman 3MM paper. Using a graduated pipette carefully roll out any air bubbles. 
The sandwich is then placed into the transfer tank with top plate in positive. The 
transfer of protein to the membrane for 1.5 hours at ~175mA and ~10V was then 
performed at RT with continuous circulation of the buffer. 
3.2 Western blot hybridisation. 
             Membranes were blocked with 50ml of Western block buffer consisting of 5% 
w/v non-fat dry milk in TBS, for 1-2 hours at room temperature, before been probed 
with the corresponding antibodies. Primary antibodies were diluted according to 
manufacturer’s instructions in blocking buffer and incubated for overnight at 4oC 
with agitation. After 3 washes for 15min with 5ml of wash buffer (0.05% Tween-20 
in TBS), the secondary antibodies were diluted according to manufacturer’s 
instructions and added in 5ml block solution. After 1 hour at room temperature, 3 
washes for 15min in wash buffer were performed. 
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4. Preparation of nanoAPC from antigen presenting cells. 
4.1 Fractionation of cell contents. 
            The seed cells were expanded to large volume at a viability of > 99% and 
used for preparation of nanoAPC. The nanoAPC was prepared by two steps; 
preparation of the ER enriched microsomes and processing of nano-particles. Human 
nanoAPC from these transfected 221-A2-IL2 and control 221-A2 cell lines were 
prepared and purified according to previously described protocols.  Mouse nanoAPC 
isolated from bone-marrow derived DCs (Wang et al. 1996). Specifically, cell 
cultures were grown to a minimal number of 10
9
cells. All the steps during the 
nanoAPC preparation are performed on ice or at 4°C.  
             Cells were collected, centrifuged at 1500rpm for 5min and washed once with 
cold PBS. Cells were washed and resuspended in homogenization buffer. After 
homogenization, the nuclear, mitochondria and larger cell debris were removed by 
centrifugation at 10 000g. The total microsomes were recovered by centrifugation at 
100 000g and subfractionated by flotation in sucrose gradients. The microsomes were 
layered on top of 5mL of 0.33M sucrose, layered in turn on top of a discontinuous 
sucrose gradient consisting of 2mL of 2M and 1mL of 2.5M sucrose. Centrifugation 
in a TH-641 rotor for 1h at 110000g at 4°C yielded a microsome band on top of the 
2M sucrose cushion, which was collected and resuspended in RM buffer (250mM 
Sucrose, 50mM triethanolamine-HCl, 50mM KOAc, 2mM MgOAc2, 1mM DTT). 
The microsomes were further processed to homogenous nano-particles by 
sequentially homogenized in a fine cell homogenous (isobiotec) with different cut off 
size between 6 and 4 microne. The homogenized particles were recovered by 
centrifugation in a TH-641 rotor for 1 hours at 110 000g at 4
o
C and then resuspended 
in RM buffer. After protein assess the nanoAPC was stored at -80
o
C until use. 
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5. Labelling and detection of antigens in nanoAPC and cells. 
5.1 Flow cytometry. 
             Flow cytometry analysis was used to detect cell surface or markers on cells 
and nanoAPC. Single cell suspensions were obtained from homogenised spleens and 
lymph nodes, or from PBMCs, or from cell cultures. 
             Cells or nanoAPC after washing, cells were first stained with surface 
markers with antibodies (0.5mg/ml) were 1 into 10 diluted with FACS media and 
then incubate for 30min at 4°C in dark, washed in 1ml FACS media and collected by 
centrifugation. The stained cells were washed with PBS and fixed according to 
intracellular staining Kit (BD) after washing step for intracellular staining. 
Antibodies were diluted according to manufacturer’s instructions and added to the 
pellets, mixed gently and incubated at 4°C for 30min in dark. The stained cells were 
washed with PBS, then analysed on a FACS (CantoII). The data were analysed using 
flowjo (Tree Star, Inc). The isotype Ig was used as background controls for all the 
staining of both cells and nanoAPC.  
5.2 Peptide biotinylation. 
            DR/DP binding peptides HBV Env 180-195 AGFFLLTRILTIPQS; Env 339-
354 LVPFVQWFVGLSPTV; and Pol 767-782 AANWILRGTSFVYVP was 
biotinylated using the NHS-LC-Biotin reagent (Pierce Chemical). Dissolve FITC in 
conjugation buffer at a final concentration for 1mg/ml, immediately before use. The 
reaction was initiated by adding 90μl of 1mM peptides diluted in PBS in the biotin 
solution. The mixture was allowed to react for 2 hours at room temperature by 
continuous agitation. Remove excess and hydrolyzed FITC by gel filtration. After 
analysis the fluorescent biotinylated peptides were stored at -80°C until use. 
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5. 3 NanoAPC labelling with chemical fluorescence. 
             For the detection nanoAPC by fluorescence microscopy nanoAPC were 
labelled with chemical fluorescence using the FITC1 fluoroTagtm FITC conjugation 
kit from Sigma FITC1-1KT, according to manufacturer’s instructions. For each 
labelling 1mg of nanoAPC were used. NanoAPC were labelled before or after 
peptide loading. 
             Briefly, the contents of one sodium carbonatebicarbonate capsule were 
dissolved in 50ml of de-ionized water. The pH of the resulting buffer (C0688 at 0.1M) 
was measured and calibrated at pH 9. NanoAPC suspension was centrifuged at 
10000rpm for 5min and the resulting pellet was re-suspended in 200μl of the C0688 
buffer. At this stage one vial of FITC was re-constituted in 2ml of C0688 buffer. 50μl 
of the FITC solution were added drop wise to the nanoAPC suspension on a slow 
shaker. The mixture was covered in foil to reduce exposure to light and the reaction 
was allowed for 30min at room temperature, on a shaker. To stop the reaction 50μl of 
0.2M glycine pH 8 were added and the experimental tube containing the mixture was 
stored on ice. 
             The reaction was centrifuged at 10000rpm for 5min at 4°C and the 
supernatatnt was removed. Labelled nanoAPC were re-suspended in 50μl of RM 
buffer and stored in -80°C and protected from dark until further use. 
5.4 Distribution of nanoAPC in lymph nodes 
             For distribution of nanoAPC in lymph nodes, nanoAPC were prepared from 
CFSE labeled mouse DC2.4 cells. An aliquot of 20μg of peptide-loaded nanoAPC or 
FITC labeled Dextran was injected into C57BL/6 mice i.v. After 48 hours, lymph 
nodes were isolated and processed to single cell suspension. The cellular fraction was 
collected by concentration at 1000g for 5 min, while cell-free particles were 
recovered after removing supernatants through microfilter nanoAPC at cutoff size of 
3000kd (Millipore Amicon Ultra centrifugal filters) which can recover both 
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nanoAPC and dextran. The cellular and cell-free particles were stained with PE-
labeled CD11c as DC marker and analysed by FACS.  
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6. Isolation of primary cells. 
6.1 Isolation of mononuclear cells from mouse secondary lymphoid organs. 
             Mouse spleens and lymph nodes were harvested and single cell suspensions 
were prepared. The cells were pelleted by centrifugation at 1200rpm for 5min at 
room temperature and the supernatant was discarded by aspiration. The pellets were 
re-suspended in 5ml of RBC lysis buffer per spleen and incubated at 37
o
C for 4-5min. 
The cell suspension was centrifuged at 1200rpm for 5min at room temperature, the 
supernatant was discarded by aspiration and the resulting cell pellet was re-
suspended in the complete medium and incubated at 37
o
C for 30min to exclude 
macrophage. The cell suspension was centrifuged at 1200rpm for 5min at room 
temperature. At this stage, the cells were counted. 
6.2 Isolation of mononuclear cells from human peripheral blood. 
             Mononuclear cells were isolated from human peripheral venous blood by 
density gradient centrifugation over Ficoll-Histopaque. 15ml of Ficoll hypaque were 
aliquoted per 50ml test tube in sterile conditions and allowed to equilibrate to room 
temperature. A dilution of 1/1 in serum free medium was slowly layered on top of the 
Ficoll-hypaque and centrifuged for 30min at 400 x g centrifuge force in room 
temperature, with the centrifuge breaks off. After centrifugation the interface of 
PBMCs was collected, further diluted with serum free medium (approximately 1:2) 
and centrifuged at 250 x g centrifuge force for 10min at room temperature. The 
supernatants were then discarded and the remaining cell pellet was resuspended in 
with serum free medium. The cell suspension was washed with serum free medium 
and centrifuged at 250 x g centrifuge force for 10min at room temperature. The 
resulting pellet was resuspended in 10ml of complete medium and the cells were 
counted. 
111 
 
7. Activation assays. 
7.1 Peptide loading of nanoAPC. 
             NanoAPC suspended in RM buffer were first processed by freeze– thaw 
(30sec in liquid nitrogen and 5min at 37
o
C) repeated three times, followed by 
addition of an equal amount of stripping buffer (0.26M citric acid, 132mM Na2HPO4, 
2% BSA, pH 5.5) and incubation for five minutes on ice.  
             For MHC class I loading, 20μg/ml human β2-microglobin and SIINFEKL 
peptide at indicated doses were pulsed onto 1-4μg of nanoAPC membranes the 
mixture was incubated for 5 min on ice followed by neutralization with 1M Tris 
buffer pH11. And then incubate for one hour at 37°C. After loading free peptides and 
reaction buffers were removed by washing through a filter at cut-size of 3000kd 
(Millinpore Amicon Ultra centrifugal filters). The loaded nanoAPC were 
resuspended in serum free medium at 2mg/ml concentration. 
             For MHC class II, after the freeze-thaw process, the nanoAPC in RM buffer 
were mixed with equal volume of acidic buffer and peptide at 1uM or as indicated 
for one hour at 37°C. And then neutralization with 1M Tris buffer pH11 following 
loading excess peptides were removed by washing through a microfilter at cut-size of 
3000kd (Millipore Amicon Ultra centrifugal filters). The assembled nanoAPC were 
resuspended in serum free medium at 2mg/ml.  
7.2 Interaction of nanoAPC and T cells 
             Interaction of SIINFEKL-Kb-nanoAPC or Kb-nanoAPC from CFSE labeled 
DC2.4 cells and OTI cells were measured by incubation of 10ug SIINFEKL-Kb-
nanoAPC or Kb-nanoAPC with 10
6
 OTI cells in normal medium incubate at 37
o
C for 
30 minutes. Free-nanoAPC was removed by low speed centrifugation at 1000g for 5 
min and washing with cold PBS. Cells were then stained with anti-CD3 antibody 
followed by DIP counter staining. The samples were analysed by confocal 
microscopy (ZEISS LSM 510).  
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7.3 Human study 
7.3.1 Experimental subjects 
             6 CMV serum converted health donors and 57 chronic HBV patients 
participated in this study. All subjects are HLA A2 positive. Informed consent was 
obtained, and the study was approved by local ethical committees at the two 
participating clinics (East London and the City Research Ethics Committee for Barts 
and The London NHS Trust and Huashan hospital ethics committee, Shanghai 
China). Out of 26 chronic HBV patients, 47.4% were positive for HBeAg, 18 had 
raised ALT (>50IU/liter) and high HBV DNA (>10
6
 IU/ml) as quantified by real-
time PCR assay. 31 patients were HBeAg negative, and positive for serum anti-HBe 
antibody. All patients were negative for antibodies to hepatitis C virus, HIV-1, and 
HIV-2. 
7.3.2 Isolation of PBMCs and in vitro stimulation  
             PBMCs were isolated from fresh hepatinized blood by Ficoll-Hypaque 
density gradient centrifugation and resuspended in RPMI 1640 and 10% heat-
inactivated FBS (invitrogen) as mentioned. For some experiments, CD8 positive T 
cells were isolated with anti-CD8 coated beads (MACS). 5 x 10
5
/well PBMC or 
CD8
+
 cells in 24-well plates were co-cultured either with antigenic peptide at a 
concentration of 5uM (the same concentration used for assembling MHC class I in 
nanoAPC) or 10ug nanoAPC for five days. Cells were cultured with PBS or anti-
CD3 coated beads served as negative or positive controls. After five days, 20nM of 
PMA and Inomycine (sigma) were added together with Golgi stopper (BD) and 
cultured for 4 hours. Cells are now ready to staining with antibody for FACS analysis. 
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7.4 Proliferation assays. 
             To determine CTLLA4 IL-2 dependent cell proliferation 1μCi/ml [3H] 
Thymidine was added after one days of culture with IL-2-A2-nanoAPC or A2-
nanoAPC, recombinant IL-2 severed as positive control. The cells were harvested 
after 16 hours and tritium incorporation into thymidine was measured. 
             For [3H] labelling the working surfaces in a radiation controlled area were 
swept with a tissue and after sweeping 1cm piece of tissue was used to evaluate 
background radiation. The labelling medium was made at a concentration of 1μCi/ml 
in RPMR1640. Culture plates were transferred to the radiation culture area after one 
days of activation assay. Labelling medium was added at 20μl/well; the micro-plate 
was placed in plastic container and kept in 5% CO2, at 37°C for 16 hours. At this 
stage the working surfaces were tested for radiation levels. Following 16 hours of 
incubation, the labelled cultures were harvested in a cell harvester or stored at -20°C 
until measured. 
             For harvesting, the orientation of the filter was marked, it was placed with 
the plate in the harvester and harvesting was initiated. Following harvesting of 
cultures, the filters were air-dried and melted with scintillation gel. The processed 
filter was placed in a cassette and the amount of [3H] incorporated by thymidine was 
measured. Following measurements the filters were disposed as appropriate for 
disposal of radioactive material. 
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8. Statistics. 
              Statistical comparisons were performed using Student’s t test; survival was 
plotted using Kaplan-Meier curves and statistical relevance was determined using 
log-rank comparison. Unless noted, data were presented as means ± SD of pooled 
data from four to six independent experiments. 
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9. List of Buffers. 
Complete growth medium: -Culture medium, 10% FBS, 1% Penicillin-
Streptomycin–L-glutamine. 
Freeze medium: -90% PBS; 10% DMSO. 
FACS media: -5% BSA in PBS. 
Lysis Buffer: -1% NP40, 5% PMSF, 10ug/ml PI. 
PBS: -80.0g NaCl, 11.6g Na2HPO4, 2.0g KH2PO4, 2.0g KCL, q.s. to 10L; pH to 7.0. 
RM buffer: -250mM sucrose, 50mM triethanolamine-HCl, 50mM KOAc, 2mM 
MgOAc2, 1mM dithiothreitol, pH to 7.2. 
Stripping buffer: -0.26M citric acid, 132mM Na2HPO4, 2% BSA, pH 5.5. 
Neutralization buffer: - 1M Tris buffer pH 11 
LB medium: -10g Bactotrypton, 5g Bactoyeast, 7g NaCl q.s. to 1L                        
LB Argos: -10g Bactotrypton, 5g Bactoyeast, 7g NaCl, 15g Bactoagar q.s. to 1L                        
P1 buffer: -Tris 2.5M, EDTA 0.5M, 500ul RNase q.s. to 50ml                        
P2 buffer: -NaOH 10M, SDS 2.5% q.s. to 50ml                        
P3 buffer: -KOAc 3M pH 4.8 
1X TBS: 50 mM Tris.HCl, pH 7.4 and 150 mM NaCl. 
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 Western blot: 
Stacking gel: -10ml preparation of 10% consists of 2.4ml purified water, 3.35ml 30% 
acrylamide, 3.75ml 1M Tris pH 8.8, 100μl 10% SDS, 100μl 10% APS and 4μl 
TEMED. 
Resolving gel: -2.5ml preparation of 5% stacking gel consists of 1.7ml of purified 
water, 415μl 30% acrylamide, 315μl 1M Tris pH 6.8, 25μl 10% SDS, 25μl 10% APS 
and 5μl TEMED. 
Sample buffer (2x): -125mM Tris pH 6.8, 4% SDS, 20% glycerol, 10% β 
mercaptoethanol, 4mg BPB/10ml. 
Running buffer (10x): -250mM Tris pH 7.5, 192mM glycine, 0.1% SDS. 
Transfer buffer: -25mM Tris base pH 8.3, 192mM glycine, 20% methanol. 
Blocking buffer: -5% w/v non-fat dry milk powder, 2% w/v BSA, 0.1% v/v Tween-
20 in PBS 
Wash buffer: -0.1% non-fat dry milk powder, 0.1% Tween-20 in PBS 
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RESULTS 
1 Generation of Seed Cells 
1.1 Seed cell selection 
            In order to apply nanoAPC as a delivery vehicle to develop a therapeutic 
vaccine for broad patient groups, we selected cell lines that are MHC class I deficient.  
This allowed me to reconstitute popular MHC class I alleles, such as HLA A2, which 
are predominantly expressed in a large population (Komlos et al, 2007). The seed 
cells have to express high levels of co-stimulatory molecules which are essential for 
optimal T cell activation (Jennifer D Stone et al, 2009). Based on our previous 
studies, we choose 721.221 cells to develop seed cells (Li et al, 1997). The 721.221 
cells are derived from parental 721 cells that are human lymphoblastoid cell lines 
(LCL) 721. 721 cells are established from peripheral blood lymphocytes (PBLs) 
which were isolated from heparinised blood of the 721 donor (female age 21-25). To 
investigate the mechanisms of antigen presentation, Dr Robert DeMars’s group 
developed 721 MHC deficient variants selected after mutagenesis treatment with 
gamma-irradiation (Shimizu et al, 1988). Table 1.1 describes MHC phenotypes of 
donor 721 and her parents (Reitnauer et al, 1985).  To avoid HLA-C expression in 
721 mutated cells, 721.221 have been developed via the following sequence: LCL 
721-.45-.144-.184-.184TG3-.221.mutant (Table 1.2). The 721.221 cells were 
developed from 721.184 TG3, one of the 721 variants, by immunoselection 
following γ ray (300 rad) (Shimizu et al, 1987). Thus, the 721.221 cells are absence 
of endogenous HLA-A,-B,-C Ag. The 721.221 cells transfected with MHC class I 
alleles can express MHC class I Ag at normal levels (Shimizu and DeMars 1989), 
which demonstrates that the antigen presenting pathways in 721.221 cells are  intact. 
721.221 cells still retain phenotype of HLA DR, DQ and DP. Since most of the MHC 
class II associated antigenic peptides can be   cross presented by different MHC class 
II alleles with different affinity, the remaining HLA DR and DP can be used to 
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produce antigen-MHC class II complexes to induce CD4 helper responses (Haren et 
al, 2011).  
 
Table 1.1 the HLA types of donor 721 and her parents (Reitnauer et al, 1985) 
 
Table 1.2 Expression of HLA Ag in HLA Ag loss mutants derived from LCL 721  
(Shimizu and DeMars 1989). 
             In addition to antigen recognition activation of T cells, depends on co- 
stimulation for initiating adaptive immune responses. Therefore, the expression of 
co-stimulatory molecules were analysed on 721.221 cells. Both co-stimulatory 
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molecule B7.1 (CD80) and the adhesion molecule ICAM-1(CD54) were highly 
expressed on 721.221 cells (Figure. 1.1).  
 
Figure 1.1 expression of co-stimulation molecule in 721.221 seed cells. 
721.221 cells were analysed for the co-stimulatory molecules CD80 and adhesion molecule 
ICAM-1 by staining with corresponding antibodies and analysed on flow cytometry. Isotype 
Ig was used as background control.  
            The nanoAPC is prepared from the ER membranes of APC seed cells. 
Previously, we have demonstrated that ER enriched microsomal membranes from 
APC have abundant peptide-receptive MHC class I molecules (Sofra et al, 2009). In 
order to maximize ER-expressing MHC class I molecules, I have used a HLA-A2 
transfected 721.221 cell line in which the HLA-A2 is fused with an ER retention 
signal E3-19K (Figure 1.2). Thus, the transfected HLA-A2 can be retained in the ER. 
Due to a high level of expression, part of the expressed HLA-A2 is transported to the 
cell surface which has been detected by HLA-A2 antibody on 721.221-A2 (short for 
221-A2) cells surface (Figure. 1.3). This cell line has been used throughout this study.    
 
Figure 1.2 Schematic representation of the carboxy-terminal portion of the E3/19K 
protein which has KKXX motif at C-terminus. 
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Figure 1.3 Expression of HLA-A2 in 221-A2 cells  
221-A2 cells were analysed for HLA-A2 expression by flow cytometry. The FITC isotype 
Ig was used as background control for the staining. 
1.2 Generation of IL-2-tapasin expression construct   
1.2.1 IL-2-Tapasin fusion constructs 
             The major challenge for effective therapeutic vaccines against chronic 
infectious diseases is the high activation threshold of antigen specific T cells induced 
by persistent viral antigens resulting in T cell exhaustion during chronic viral 
infection (Lopes et al, 2011). In order to overcome the inactivation of antigen 
specific T cells, we designed nanoAPC carrying IL-2 as a bioadjuvant. Previously, in 
an antigen-induced tolerant model, our group demonstrated that IL-2 can effectively 
reverse the tolerance (Anderson et al, 2005). In order to achieve this goal, we 
attempted to create an IL-2 (Figure 1.4) expression construct that can express IL-2 as 
a fusion protein with the ER chaperon tapasin (Li et al 1997), which can keep IL-2 as 
an ER-retention molecule in the 221-A2 cells. The ER retention of tapasin (Figure 
1.4) is mediated by its C terminal double-lysine motif (KKAE) (Momburg and Tan 
2002). Tapasin functions as an ER chaperon specifically for peptide-receptive MHC 
class I in the ER (Li et al, 1997). Based on the published structure of tapasin, the N-
terminus of tapasin is open (Roder et al, 2009). Therefore, we fused C-terminus of 
IL-2 to the N-terminus of tapasin after deletion of a stop code in IL-2 and signal 
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sequence of tapasin (Figure 1.5). To create free space for fused IL-2, trip repeated 
glycine and serine linker (GGSGGS) was introduced between IL-2 and tapasin 
(Figure. 1.5). The designed fusion molecule has IL-2 with C-termini fused with N-
termini of tapasin (the signal sequence of tapasin is deleted) gapped with 2x GS 
linkers. Thus, the expressed IL-2 is retained in the ER and exposes its functional 
structure for receptor interaction (Figure. 1.5).  
A B   
Figure 1.4 the crystal structure of;  
A. human interleukin-2 (Arkin et al, 2003)  
B. Tapasin ERP57 Heterodimer (Dong et al, 2009) 
 
 
N-terminus N-terminus 
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Figure 1.5 Schematic drawing of the backbone of IL-2 fused with Tapasin 
             It has been demonstrated that tapasin is a MHC class I antigen processing 
molecule present in the lumen of the ER, which plays an important role in the 
maturation of MHC class I molecules in the ER lumen (Li et al, 1997). And also it 
has been introduced as one component of the peptide loading complex; therefore IL-
2 fused tapasin may also increase HLA-A2 retention in the ER as peptide receptive 
molecules (Li et al, 1997).  
1.2.2 GFP as a selection mark for transfected seed cells 
            In order to select IL-2-tapasin transfected seed cells, we used expression 
constructs with CMV promoter to drive expression of IL-2-tapasin and green 
fluorescent protein (GFP) as report molecule. GFP has been widely used as selection 
mark in cell biology and other biological disciplines because it is less harmful when 
illuminated in living cells (Yuste 2005) (Figure. 1.6). pEGFP-N3 encodes GFP which 
has been optimised for brighter fluorescence and higher expression in mammalian 
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cells. The insert of IL-2-tapasin was created by sequential PCR-cloning strategies 
(Figure 1.7) with proper restriction enzyme sites corresponding to the sites in the 
vector (Figure 1.8). The final sequence of insert is shown in figure 1.9.  
 
Figure 1.6 (A) schematic drawing of the backbone of GFP produced by the program 
MOLSCRIPT. The chromophore is shown as a ball and stick model. (B) Schematic drawing 
of the overall fold of GFP. Approximate residue numbers mark the beginning and ending of 
the secondary structure elements N, NH2- terminus; C, COOH-terminus (Ormö et al, 1996). 
 
Figure 1.7 Electrophoresis represents the PCR amplified IL-2-Tapasin inserts with 
BamHI site at two ends. 
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Figure 1.8 The construct map of pEGFP-N3 vector ligate with human IL-2 tapasin 
APTSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRNLTFKFYMPKKATEL
KHLOCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCE
YADETATIVESLNRWTTFCQSIIISTLTGGSGGSMKSLSLLLAVALGLATAVS
AGPAVIECWFVEDASGKGLAKRPGALLLRQGPGEPPPRPDLDPELYLSVHDP
AGALQAAFRRYPRGAPAPHCEMSRFVPLPASAKWASGLTPAQNCPRALDGA
WLMVSISSPVLSLSSLLRPQPEPQQEPVLITMATVVLTVLTHTPAPRVRLGQD
ALLDLSFAYMPPTSEAASSLAPGPPPFGLEWRRQHLGKGHLLLAATPGLNGQ
MPAAQEGAVAFAAWDDDEPWGPWTGNGTFWLPRVQPFQEGTYLATIHLPY
LQGQVTLELAVYKPPKVSLMPATLARAAPGEAPPELLCLVSHFYPSGGLEVE
WELRGGPGGRSQKAEGQRWLSALRHHSDGSVSLSGHLQPPPVTTEQHGARY
ACRIHHPSLPASGRSAEVTLEVAGLSGPSLEDSVGLFLSAFLLLGLFKALGWA
AVYLSTCKDSKKKAE 
 
Figure 1.9 Sequence of insert IL-2 (red) and Tapasin (purple) linked with glycine and 
serine linker (blue)  
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1.3 Expression of IL-2 in 221-A2  
            After I transfected IL-2-tapasin construct into 221-A2 seed cells via 
electroporation, 60% of cells expressed green fluorescent protein (Figure. 1.11). The 
transfected cells were isolated by cell sorter (Yuste, 2005) (Figure. 1.10). A high 
level of expression of HLA-A2 and IL-2 in 221-A2-IL-2 cells were revealed by 
FACS, immunoblotting and fluorescent microscopy with antibodies specific to HLA-
A2 and IL-2 (Figure. 1.10, 1.11, 1.12). From the result (Figure. 1.13) also confirm 
the high expression of co-stimulatory molecule could not be altered by the 
engineered HLA-A2 and IL-2.  
 
Figure 1.10 IL-2 GFP positive cells were purified by flow cytometric sorting of an IL-2 
tapasin construct transfected 221-A2 cells.  
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Figure 1.11 Expression of IL-2 in seed cells 
Immunoblotting analyses of 20ug lysates from 221-A2 and 221-A2-IL-2 cells respectively 
with antibody against GFP.  
 
Figure 1.12 Fluorescence microscopy distributes the IL-2 location in IL-2 transfected 
cell.  
Cell nuclei were visualized by DAPI (blue) counter-staining, and Texas Red labelled anti-
human IL-2 (red) stained both 221-A2-IL-2 (upper panel) and 221-A2 cells (lower panel).   
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Figure 1.13 expression of co-stimulate molecule in tranfected cells  
221-A2-IL-2 cells were analysed for the co-stimulatory molecules CD80 and adhesion 
molecule ICAM-1 by staining with corresponding antibodies and analysed on flow 
cytometry. Isotype Ig was used as background control. 
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2. Preparation of IL-2-A2-nanoAPC 
2.1 Growth of large quantity of seed cells 
2.1.1 Culture condition and cell growth rate control 
            In order to obtain high quality and large quantity of seed cells, we started 
with a small scale, to work out the cell density and survival rates. Under conventional 
culture conditions with 10% FBS and RPMI 1640 medium, we found that 10
5
/ml 
seeding density is optimal to meet rapid expansion at large volumes and the survival 
rates will drop when over the density of  1 x 10
6
 cells/ml (Figure. 2.1). Therefore, the 
cells were expanded by seeding 10
5
cells/ml and reseeding after reaching 1 x 10
6
 
cells/ml. Thus, the survival rates maintained at > 98%. 
 
Figure 2.1 S-shaped growth curves of 221-A2-IL-2 cells 
In the beginning the cells stay at an initial LAG phase which is the rate of growth or when 
the cell division is very slow, and then the growth or cell division starts to accelerate into the 
exponential phase which is when  the cells are growing or multiphying  rapidly.  
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Figure 2.2 Flowchart of cell expansion  
             At 10
6
/ml density, one gram of cells could be harvested from 1000ml culture. 
After washing, the cells were snap-frozen in the liquid nitrogen and stored at -80ºC 
until further use. The cell enriched large scale culture did not alter the expression of 
transfected HLA-A2 and IL-2 molecules (Figure. 2.3).     
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Figure 2.3 IL-2 and HLA-A2 expression on 221-A2-IL-2 cell  
Cells were stained with antibodies against IL-2 and HLA-A2 molecule, respectively and 
then analysed on flow cytometry. The isotype Ig was used as background control.  
2.2 IL-2-A2-nanoAPC preparation 
            To ensure the nanoAPC’s quality and function, the temperature was 
maintained at 4ºC throughout the isolation procedure. We developed protocols that 
were used to prepare IL-2-A2-nanoAPC at homogenous size of ~500nm and enriched 
with HLA-A2 and IL-2. Importantly, the prepared nanoAPC have to maintain 
peptide receptive HLA-A2 molecules and bioactivation of IL-2. Based on previously 
developed methods for microsome preparation, we used fine homogenizer, 221-A2-
IL-2 cells to prepare microsomes and final nanoAPC. To homogenize seed cells, a 
cut off size of 12 microtron was used to break cells to a mixture of nuclear, 
mitochondrial and membrane fractions. I used a gradient of sucrose to separate 
particles based on their individual densities. The generated IL-2-A2-nanoAPC layer 
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on top of the 2M sucrose cushion was collected (Figure. 2.4). The collected ER and 
Golgi fractions were finally homogenized at cut off size of 4 microtron to make a 
homogenous membrane fragments at size of ~ 500nm (Figure. 2.5) (Figure. 2.7). 
This size is referred as nano-size and can pass micro-vessels and freely distribute to 
target organs such as peripheral lymph nodes. Our result also confirmed that 
nanoAPC still maintained high levels of co-stimulatory molecules; CD80 and ICMA-
1 (Figure 2.6). The yield of IL-2-A2-nanoAPC is usually about 3-5% of the total 
APC cell weight.  
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Figure 2.4 IL-2-A2-nanoAPC preparations. 
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To prepare IL-2-A2-nanoAPC from IL-2 transfected APCs, a cell suspension in a hypertonic 
solution was placed in a 5ml syringe. Cells were passed though the homogenizer on ice. The 
nuclear, mitochondrial and larger cell debris was removed from the cell homogenate by 
centrifugation at 10,000 x g. The total IL-2 nanoAPC was recovered by centrifugation at 
100,000 x g and further subfractioned by flotation in discontinuous sucrose gradients. 
 
Figure 2.5 IL-2-A2-nanoAPC contained IL-2, HLA-A2 and co-stimulatory molecules 
NanoAPC with reconstituted MHC, IL-2-Tapasin and co-stimulatory molecule, which will 
reactive with T cells working as professional antigen presenting cells.  
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Figure 2.6 expression of co-stimulate molecule in NanoAPC  
NanoAPC isolated from either 221-A2 or 221-A2-IL-2 cells were analysed for the co-
stimulatory molecules CD80 and adhesion molecule ICAM-1 by staining with 
corresponding antibodies and analysed on flow cytometry. Isotype Ig was used as 
background control. 
            To confirm co-expression of IL-2 and HLA-A2 in nanoAPC, nanoAPC were 
stained with anti-IL-2 and HLA-A2 antibodies, respectively and analysed by 
confocal microscopy. Confocal fluorescent micrographs revealed that IL-2 molecule 
(Red) and HLA-A2 molecule (Green) on nanoAPC prepared from 221-A2-IL-2 seed 
cells while nanoAPC from 221-A2 seed cells only showed HLA-A2 (Figure 2.7 
down panel). This result demonstrated that the IL-2-A2-nanoAPC was of a largely 
homogenous size, ~500nm, and contained high levels of HLA-A2 and IL-2.  
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Figure 2.7.  Confocal images of GFP expressing nanoAPC 
 NanoAPC has enriched HLA-A2 and IL-2. NanoAPC was prepared from 221-A2-IL-2 or 
221-A2 cells and then stained with antibodies to IL-2 (Red) or HLA-A2 (Green) indicated. 
2.3 Analysis of IL-2 bioactivity 
            Although the IL-2-A2-nanoAPC expressed fused IL-2, it was unclear whether 
this IL-2 molecule still had their initial biological function. The IL-2-tapasin fusion 
protein retained IL-2 bioactivity as demonstrated by the proliferation of the IL-2-
dependent CTLL4 cell line in response to IL-2-A2-nanoAPC (Figure 2.8A). The 
pharmacological activity of IL-2 on nanoAPC was ~2 International Unit (IU)/ug 
nanoAPC (Figure 2.8A). The activity of IL-2 on IL-2-A2-nanoAPC was effectively 
neutralized by IL-2 neutralizing antibody (Figure 2.8B). Although the activity is 
about fifty times lower than the ~100 IU per 1ug of recombinant IL-2, the IL-2 on 
nanoAPC is immobilized which may create an enriched microenvironment for T 
cells that are specifically interacting with the nanoAPC. This strategy can be applied 
to other cytokines or bio-active proteins depending on the therapeutic aim. 
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Figure 2.8 IL-2 activity of IL-2-A2-nanoAPC.  
Proliferation of CTLL4 was measured and converted to international units after comparing 
with recombinant IL-2.  
(A) A2-nanoAPC engineered with or without IL-2 at different doses was incubated with 
CTLL4 cells for 24 hours. Proliferation of CTLL4 was measured and converted to 
international units after comparing with recombinant IL-2. 
(B) IL-2 activity was neutralized by anti-IL-2 antibodies. The data presented as mean of 
triplicate cultures ±SD and are representative of four experiments 
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3 NanoAPC-associated MHC can bind to antigenic peptides. 
3.1 conditions for peptide loading 
            To explore whether the MHC molecules in ER-enriched nanoAPC from APC 
can present antigens to T cells, we first examined the ability of MHC molecules in 
isolated nanoAPC membranes to assemble with peptides.  
3.1.1 Inverted nanoAPC’s membrane via freeze-thaw to expose the luminal side 
of nanoAPC 
            Since assembly of MHC molecules occurs on the luminal side of the ER 
membrane, the assembly of the MHC molecules present in nanoAPC would occur on 
the interior surface of the nanoAPC vesicle, which represents the ER lumen (Kvist 
and Hamann 1990). Thus, in order to achieve maximum access to MHC molecules 
for peptide-loading we attempted to ‘break-open’ the nanoAPC membrane, so as to 
expose the luminal side of nanoAPC, by a repeated freeze-thawing procedure. Based 
on our findings and previous studies, the repeated freeze-thaw process is applied in 
order to disrupt the nanoAPC, such that the luminal side of the membrane is exposed. 
MHC and co-stimulatory molecules are glycoprotein transmembrane proteins 
naturally exposed to the luminal side of the ER (Kreibich et al, 1978) (Sabatini et al, 
1978), which is equivalent to the lumen of the nanoAPC (Kvist and Hamann 1990) 
(Vassiliki et al, 2009). Therefore, after ‘inversion’ of nanoAPC by repeated freeze 
thawing to expose the luminal nanoAPC surface, the MHC glycoproteins should also 
be exposed, allowing better access of soluble peptides to the peptide-binding site of 
the MHC molecule (Figure 3.1).  
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Figure 3.1 Experimental designs for loading of antigenic peptides on MHC class I and 
MHC class II.    
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Both MHC molecules are synthesised and matured in the lumen of the ER. Newly 
synthesized and properly folded MHC class I molecules are retained in the ER until they 
form stable peptide-MHC class I complexes, while MHC class II molecules associate with 
an invariant chain and are transported from the ER to the endosome. The invariant chain 
protects the peptide binding site until it encounters peptide competition (mediated by HLA-
DM in human) in the endosomal acidic environment. Peptide loading in an acidic buffer of 
pH 5 dramatically increased the peptide receptiveness of MHC class II molecules. In 
addition to generating peptide receptive MHC class II molecules, the acid stripping process 
also led to a significant increase in peptide-receptive MHC class I molecules, which may be 
due to dissociation of pre-processed peptides on MHC class I molecules.  
3.1.2 Acidic treatment for class I and II peptide loading  
            Detection of peptide/MHC class I complexes were achieved with the use of 
specific antibodies. In this experiment we used the H2-K
b
 molecules in the processed 
nanoAPC could be loaded with the K
b
-specific peptide SIINFEKL, as shown by 
staining with the SIINFEKL-K
b
 specific antibody 25-D1.16 (Figure 3.2). It has been 
shown by our group that the acid-stripping process also led to a significant increase 
in peptide-receptive MHC class I molecules, which may be due to the dissociation of 
pre-processed peptides on MHC class I molecules (Vassiliki et al, 2009). The whole 
process has been clearly presented by the flowchart above (Figure 3.1). As we see 
that the MHC class I assembly with antigenic peptides takes places in the ER, and 
from the result it shows that the nanoAPC load with SIINFEKL-K
b
 specific peptide 
can be detected and monitored by 25-D1.16 antibody with double mount of the  
fluorescene means.  
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A.  
B.   C.  
Figure 3.2 Flow cytometric analysis of peptide loading onto MHC molecules in 
nanoAPC membranes. 
NanoAPC from Jaws-II cells were pulsed with either SIINFEKL peptide or PBS. Excess 
peptides were washed and peptide-loaded nanoAPC were analyzed in comparison to 
nanoAPC that had been loaded without peptides.  : 
A. Panel displays the mean fluorescence intensity of PE-labelled 25-D1.16 antibody specific 
to SIINFEKL-K
b
 complexes.  
B. NanoAPC with or without pretreatment with acid-stripping and   
C. NanoAPC with or without freeze-thaw process treatment before peptide loading. 
NanoAPC without peptide serves as a background control.     
            We have also developed a method for loading MHC class II antigens onto 
purified ER vesicles to assemble pMHC class II (Sofra et al, 2009). In this 
experiment we used three HBV peptides reported to bind to DR and/or DP, and then 
use FITC biotin to label them by flow cytometry. Analysis of the assembly of HLA 
DR molecules with peptide showed that HLA DR binding peptides could effectively 
assemble with DR under acidic conditions (Figure 3.3). 221 cells are deficient in 
MHC class I, but still express HLA DR and DP molecules. Since MHC class II 
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molecules are much more promiscuous than MHC class I molecules in terms of 
selection of their antigenic peptides, as most of the DR associated peptides can also 
bind to DP to certain degrees (Sadegh-Nasseri et al, 2010), we used the endogenous 
HLA DR and DP molecules from seed cells to assemble antigenic peptide-MHC 
class II complexes for activation of effector CD4 helper T cells. Although it shows 
that the peptide can be loaded on the nanoAPC, however if comparing to naturally 
processed pMHC in live DCs, the assembled pMHC is still limited. The optimal 
approach to generate pMHC in nanoAPC is to introduce native antigen protein into 
seed cells to pMHC processing naturally.  
 
Figure 3.3.   Acidic treatment induces peptide-receptive MHC class II 
Peptide loaded A2-nanoAPC from 221-A2 cells under pH 7.0 or pH 5.0 conditions. The 
same nanoAPC with PBS or with 5 times unlabeled peptide serve as a background control. 
# Fluorescence peptide plus five times unlabelled peptide with A2-nanoAPC under acide 
condition.  
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4 Activation of T cells 
            NanoAPC are designed to directly deliver antigen, co-stimulatory and 
cytokine signals to antigen specific T cells. Therefore, a sustained interaction 
between nanoAPC and antigen specific T cells is essential for the T cells to engage 
IL-2, or other engineered cytokines, effectively.  
4.1 Interaction of nanoAPC to OT1 cell 
            Previously, we have shown that ER vesicles containing pMHC molecules, 
generated by assembly of the MHC on the vesicles with peptide, can directly activate 
antigen specific T cells in vitro (Sofra et al, 2009). To further investigate whether the 
interaction of nanoAPC and antigen specific T cells can induce membrane clustering 
to form stable immune synapses (Fooksman et al, 2010), we examined the interaction 
of nanoAPC, prepared from the murine DC cell line DC2.4 were processed by 
repeated freeze-thaw to facilitate inversion of the luminal side, before loading either 
with SIINFEKL peptides or without. Excess peptides were washed and peptide-
loaded nanoAPC were incubated with splenic T cells isolated from OT-I TCR 
transgenic mice (Jameson et al. 1994), which express TCR specific to SIINFEKL-K
b
. 
T cells without peptide-loaded nanoAPC, were used as a negative control (Figure 
4.1). 
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Figure 4.1 Experimental designs for the analysis of T cell responses induced by 
inverted nanoAPC. 
NanoAPC is processed by repeated freeze-thaw so as the luminal side of the membrane is 
exposed. Endogenous peptides are dissociated from MHC class I, by acid stripping, and 
peptides of interest are loaded on the nanoAPC.  
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4.2 Synapse formation  
            The interaction of nanoAPC and T cells was carried out on an experimental 
system with nanoAPC derived from mouse DC cell line H-2 Kb positive DC2.4 and 
Kb binding peptide SIINFEKL. The SIINFEKL loaded nanoAPC were incubated 
with OTI T cells carrying TCR specific to SIINFEKL-Kb for different periods of 
time at 30ºC. We found that a stable interaction of nanoAPC and T cells formed 
rapidly after just 30 min incubation, while after less than an hour, nanoAPC induced 
synapse formation on T cells (Figure. 4.2). The nanoAPC were completely emerged 
into synapse. The process resembles the membrane processing observed at the 
contactpoint between live DC and T cells (Fooksman et al, 2010). The nanoAPC 
associated synapses can facilitate the recruitment of IL-2R into complexes with the T 
cellbound IL-2-nanoAPC, thus bringing the IL-2R into lipid rafts which can sustain 
IL-2 activation in effector T cells (Cho et al, 2010). Thus, nanoAPC can fully 
substitute for live DC, inducing T cell activation and the formation of immune 
synapses. This creates a stimulatory microenvironment allowing engagement of 
pMHC, co-stimulatory molecules and engineered bio-adjuvants with their respective 
receptors on antigen specific T cells. After 6-hours incubation, nanoAPC were 
infused into T cells a phenomenon observed after interaction of APC and T cells 
previously. Such interactive process will lead to sustained antigen presentation and 
bioactivation of engineered bioadjuvants such as IL-2 or IL-7 (Marc et al, 2011).  
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Figure 4.2 NanoAPC interact and activate antigen specific T cells.                                         
NanoAPC labelled with FITC at 10ug/ml was loaded without (upper panel) or with 
antigenic peptides (low panel) and incubated with antigen specific T cells for 60 min. Free 
nanoAPC were washed off. The cells were stained with anti-CD3. The nanoAPC interacted 
with T cells and formed synapse with CD3.  
146 
 
5 Endocytosis of nanoAPC in vivo 
5.1 NanoAPC do not be endocytozed by DCs in peripheral lymphoid 
organs 
            Most reported nano-delivery systems for therapeutic vaccines rely on 
endogenous DC in patients to process and present antigens to T cells (Nandedkar et 
al, 2009). However, the nanoAPC, functionally equivalent to live DC, act directly on 
antigen specific T cells in vivo (Sofra et al, 2009). Accumulation of a 
pharmacokinetic dose of free-nanoAPC in DC rich organs such as lymph nodes and 
liver will be important to effectively induce activation of antigen specific T cells. 
Previously, we found that ER membrane vesicles prepared from DC accumulated in 
the peripheral lymphoid organs and were not endocytosed by DC in vitro (Sofra et al, 
2009). However, whether the nanoAPC are endocytosed by DC in lymphoid organs 
is not known.  
5.2 Test phagocytic function of DCs for the ER membrance vesicles 
            To investigate whether nanoAPC remain in lymphoid organs as free nano-
particles, nanoAPC prepared from murine DC2.4 cells were labelled with 
fluorescence and injected i.v. into B6 mice. After 48 hours, the lymph nodes were 
isolated and separated into cellular and cell-free fractions. The cell-free fragments 
and DC from the lymph nodes were examined for the presence of free and 
endocytosed nanoAPC. In contrast to the efficient endocytosis of dextran by DC in 
lymph nodes, the nanoAPC that accumulated in the lymph nodes remained as free 
particles (Figure 5.1A). To exclude the possibility that DC activation is required for 
phagocytosis of the ER membrane vesicles, we infected mice with a vaccinia virus to 
induce DC activation five days before injection of nanoAPC. Similar levels of free-
nanoAPC were detected in lymph node samples from mice pretreated with vaccinia 
and mice that had not received pretreatment (Figure 5.1B), indicating that the 
intracellular membrane vesicles from APC were not effectively endocytosed by DC 
even with a concomitant viral infection. The lack of endocytosis of nanoAPC may be 
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due to failure of pattern recognition receptors, which enable the DC to discriminate 
between normal physiological components and pathological particles in vivo 
(Geijtenbeek et al, 2004), to recognise the nanoAPC.  
 
Figure 5.1 NanoAPC are accumulated in lymph nodes as free nano-particles.  
A. FTIC labelled Dextran or DC2.4 nanoAPC were injected i.v. at 1mg/kg to C57BL mice. 
48-hour post-injection, lymph nodes were suspended as cellular fraction and cell-free 
fraction. Both were stained with anti-CD11c and analysed by FACS. B. C57BL mice were 
infected with vaccinia virus at dose of 2 x 10
5
 PFU. Five days after infection, FTIC labelled 
Dextran or DC2.4 nanoAPC were injected i.v. at 1mg/kg. 48-hour post-injection, lymph 
nodes were suspended and cell-free fraction was stained with anti-CD11c as described in 
materials and methods. 
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6. IL-2-A2-nanoAPC present peptides to human T cells in vitro. 
6.1 Induction of antigen specific CD8+ T cell responses by IL-2-A2-
nanoAPC  
            The design of IL-2-nanoAPC aims to target IL-2 to antigen specific T cells 
leading to increased T cell activation. To investigate this, IL-2-A2-nanoAPC was 
assembled with human CMVnlv peptides and used to examine the efficacy for 
stimulating CMV specific CD8 T cell responses, in peripheral mononuclear cells 
(PBMC). PBMC isolated from CMV sero-positive and HLA-A2 positive health 
donors and activation of T cells in the absence of assembled CMVnlv peptides. T cell 
responses were evaluated by IFNγ production via FACS analysis (Figure 6.1).   
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Figure 6.1 Experimental designs for detection of induced memory T cell responses in 
vitro in PBMCs from latently infected individuals by a nanoAPC based vaccine.  
IL-2-A2-nanoAPC prepared from IL-2 transfected 221-A2 cells were inverted, stripped and 
loaded with an HLA-A2-specific CMV peptide that has amino acid sequence 
‘NLVPMVATV’. CMV peptide-loaded IL-2-A2-nanoAPC was cocultured with PBMC of 
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CMV serum converted and HLA-A2 positive healthy donors. The presence of reactivated 
CMV-specific CD8
+
 T cells was analyzed by IFNγ antibody detection via FACS analysis. 
            Here we investigate whether IL-2-A2-nanoAPC can induce CMV-specific T 
cell responses in vitro (Figure 6.2). IL-2-A2-nanoAPC are isolated from 221-A2-IL-2 
cells, while A2-nanoAPC isolated form 221-A2 cells as control for IL-2 effect 
though the whole experiment. Human PBMC obtained from HLA-A2 healthy 
individuals, who were serologically positive for CMV, were co-cultured with IL-2-
A2-nanoAPC or A2-nanoAPC loaded with a CMV peptide (amino acid sequence 
“NLVPMVATV”). Co-cultures with IL-2-A2-nanoAPC without peptide or with 1uM 
soluble CMV peptide, served as controls. The presence of reactivated CMV-specific 
CD8
+
 T cells was indirectly detected by CD8 and IFNγ antibody following analysed 
analysis by flow cytometry. There is a weak amount of IFNγ in stimulation of 
PBMC’s with soluble CMV peptides which is possibly due to uptake and 
presentation of the peptide by APC’s naturally present in the PBMC’s. This result 
shows (Figure 6.3) that CMV-specific IFNγ-secreting cells can be detected in the 
samples after stimulation with CMV peptide loaded either IL-2-A2-nanoAPC or A2-
nanoAPC. However IL-2-CMVnlvA2-nanoAPC induces significant more strong CD8 
T cell responses which can effectively neutralized by human IL-2 antibody (Figure 
6.4). To further confirm the antigen-dependent effect of IL-2, the IFNγ producing 
cells were quantified in CMVnlvpentamer
+
CD8
+
 cells in PBMC after stimulation 
(Figure 6.5). The antigenic peptide dependent T cell response between IL-2-A2-
nanoAPC and T cells demonstrating that this IL-2 in IL-2-A2-nanoAPC only 
enhances the response of antigen specific T cells but not bystander T cells. 
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Figure 6.2 Induction of CMVnlv specific CD8 T cell responses.  
Six CMV seropositive PBMC’s were stimulated with CMVnlvA2-nanoAPC or IL-2- 
CMVnlvA2-nanoAPC for five days. After re-stimulation with PMA and Inomycine, IFNγ 
producing CD8 T cells were quantified. Six HLA-A2 negative PBMC’s served as controls. 
Statistical comparisons were performed using Student’s t test.  
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Figure 6.3. IL-2 on nanoAPC enhances responses of antigen specific CD8 T cells.                
PBMC from three HLA-A2 positive and CMV serum converted donors (A, B C) were 
incubated with 1uM CMVnlv peptide or 10ug/ml of IL-2-CMVnlvA2-nanoAPC or 10ug/ml 
CMVnlvA2-nanoAPC or 10ug/ml IL-2-A2-nanoAPC for five days. After restimulation with 
PMA and Inomycin for three hours, cells were stained with anti-CD8 and anti-IFNγ. The 
IFNγ producing cells were measured on CD8 gated cells.  
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Figure 6.4. IL-2 increases efficacy of nanoAPC on induction of IFNγ producing T cells 
can be neutralized by IL-2 antibody.  
CD8 T cells From CMV serum converted and HLA-A2 positive PBMC were stimulated for 
5-days. Cells were stained with anti-IL-2 and IFNγ. 
 
Figure 6.5 IL-2 on nanoAPC enhances the responses of CMV specific CD8 T cells 
PBMC’s from donor A and C were incubated with 10ug/ml CMVnlvA2-nanoAPC or IL-2-
CMVnlvA2-nanoAPC or IL-2-A2-nanoAPC for five days. After restimulation with PMA and 
Inomycin for three hours, cells were stained with anti-CD8, anti-IFNγ, CD19 and 
CMVnlvPentamer. IFNγ producing cells were measured after gating on 
CMVnlvPentamer
+
CD8
+
CD19
-
 cells. 
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6.2 IL-2-CMVnlvA2-nanoAPC can increase CD25 expression on CD8 T 
cells without influence of Treg cells 
            It has been  mentioned that the IL-2 does have the function to upregulate the 
expression of CD25 and IL-2Rα chain, which can assemble with IL-2 low affinity 
receptor, formed by IL-2Rβ and γ chain, switch it to high affinity receptor which is 
required for IL-2 to induce T cell activation (Malek et al, 2010). The result shows 
that IL-2 on the IL-2-CMVnlvA2-nanoAPC can increase CD25 expression on 
CMVnlvtetramer
+
CD8
+
 T cells (Figure 6.6). IL-2 is also important for the 
maintenance and expansion of CD4
+
CD25
+
Foxp3
+
 Treg cells, but the result shows 
that there is no increase of the Treg cells detected in IL-2-CMVnlvA2-nanoAPC 
stimulated PBMC sample (Figure 6.7)    
 
Figure 6.6. IL-2-CMVnlvA2-nanoAPC induced CD25 expression on CD8 T cells  
PBMC from HLA-A2 positive and CMV serum converted donor were incubated with 
10ug/ml CMVnlvA2-nanoAPC or IL-2-CMVnlvA2-nanoAPC for three days. CD25
+
 cells 
were quantified after gating on CMVnlvPentamer 
+
CD8
+
CD19
-
 cells via FACS analysis. 
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Figure 6.7. Foxp3
+
CD4
+
 T cells measurement  
Foxp3
+
CD4
+
 T cells were measured in two PBMC’s from CMV serum converted donor 
after stimulation with indicated stimuli for five days. 
            Overall, IL-2-A2-nanoAPC induced better immune responses in terms of 
IFNγ secretion compared to the responses induced by the others (Figure 6.3) even 
better than A2-nanoAPC loaded with same peptide which cannot reach to the similar 
level. These data indicate that IL-2-A2-nanoAPC can present peptides in vitro to 
induce stronger antigen specific T cell response without affecting any bystander T 
cells like Treg cells. 
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7 Examine the efficacy of IL-2-A2-nanoAPC to induce HBV 
specific responses in PBMC from chronic HBV patients.  
            The aim is to use IL-2-A2-nanoAPC to reactivate immune responses in 
chronic infectious patients such as chronic HBV. In chronic HBV infection, the 
function of HBV specific T cells is impaired and activation threshold is high due to 
disregulation of TCR signalling (Anderson et al, 2005). Previously studies have 
shown that the additions of IL-2 can effectively overcomes the tolerance and the 
activation of T cells towards antigen stimulation.    
7.1 Selection of HLA-A2 associated HBV peptides.  
              We also investigated HBV peptide binding. We chose peptides that have 
been studied for their ability to induce specific CD8 T cell responses (Das et al, 
2008). In order to maximize the response, we selected five HLA-A2 peptides to 
establish as HLA-A2-HBV peptide pool. The five peptides are HBV core 18-27 
FLPSDFFPSV; HBV envelope 183-191 FLLTRILTI; 335-343 WLSLLVPFV; 338-
347 LLVPFVQWFV; 348-357 GLSPTVWLSV (Das et al, 2008). To validate 
whether these five peptides can bind HLA-A2, we did binding assay by using these 
peptide to compete a known report HLA-A2-binding peptide MP58-66 
(YILGKVFTL). The report peptide has been modified by labelling 125I and a 
crosslinker (Li et al, 2000). According to our previous study, we used 2nm report 
peptide to bind to HLA-A2 molecules in 10ug nanoAPC while using different 
concentrations of HBV peptides to complete the binding (Li et al, 2000). Results 
show that the binding affinity of five peptides was similar (Figure 7.1.). However, 
none of the five peptides is as good as report peptide (Figure 7.1.). We therefore 
pooled five peptides to collectively load HLA-A2 molecules in nanoAPC.  
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Figure 7.1. Five HBV peptides reported for induction of HLA-A2 restricted CD8 T cell 
responses in HBV patients were analysed for their binding to HLA-A2 on IL-2-A2-
nanoAPC by a competition assay.  
Different concentration of peptides were used to compete 125I-labeled HLA-A2-reporter 
NP peptide and percentage of reporter peptide competed for binding to HLA-A2 were 
measured. With a similar binding affinity, these five peptides were mixed and pooled at 
concentration of 1uM each used to assemble HBVA2-nanoAPC or IL-2-HBVA2-nanoAPC. 
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7.2 Selection of DR/DP binding peptides from HBV.  
            In order to induce both CD4 and CD8 T cells, we selected peptides (HBV 
Env 180-195 AGFFLLTRILTIPQS; Env 339-354 LVPFVQWFVGLSPTV; and Pol 
767-782 AANWILRGTSFVYVP) (Mizukoshi et al, 2004) that have been tested to 
interact DR and DP molecules that expressed in IL-2-nanoAPC. To examine the 
binding affinity, we labelled peptides with fluorescent marker and incubated labelled 
peptides to nanoAPC. After removal of free peptides, the peptide binding was 
detected by FACS analysis. The results showed that all these three peptides all can 
associate with DR and DP molecules under acidic conditions (Figure 7.2). Similar to 
HLA-A2 peptides, we pooled three peptides and loaded all three onto DR and/or DP 
molecules in nanoAPC. 
 
Figure 7.2.   Acidic treatment induces peptide-receptive MHC class II 
Peptide loaded A2-nanoAPC from 221-A2 cells under pH 7.0 or pH 5.0 conditions. The 
same nanoAPC with PBS or with 5 times unlabeled peptide serve as a background control. 
# Fluorescence peptide plus five times unlabelled peptide with A2-nanoAPC under acide 
condition.  
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7.3 IL-2-A2-nanoAPCs induce strong CD8 T cell responses in peripheral 
lymphocytes from chronic HBV patients 
            We previously found that IL-2 can effectively reverse tolerance induced by 
antigen persistence (Anderson et al, 2005). T cells from chronic HBV patients show 
reduced production of IL-2 in response to TCR ligation (Frebel et al, 2010), which is 
consistent with the defective induction of IL-2 in T cells rendered tolerant by 
persistent antigen stimulation (Anderson et al, 2005).  To investigate whether IL-2-
A2-nanoAPC can enhance responses of virus specific CD8 T cells from chronic 
HBV patients, we developed HBV specific IL-2-HBVA2-nanoAPC by assembling a 
pool of five HBV peptides, which have been found to induce HBV specific CD8 T 
cell responses in HLA-A2 positive HBV patients (Das et al, 2008), with the HLA-A2 
molecules on the IL-2-A2-nanoAPC. Therefore a pool containing equal amounts 
(5uM) of each peptide was used for assembly of IL-2-HBVA2-nanoAPC and 
HBVA2-nanoAPC. Peripheral lymphocytes from 57 HLA-A2 positive chronic HBV 
patients, with viral loads ranging from 3 x 10
3
 to 10
13
 IU/ml (Table 7.1), were used to 
investigate CD8 T cell responses. We detected minimal CD8 T cell responses, as 
measured by the proportion of IFNγ producing CD8 T cells, after incubation with the 
pool of the five HBV peptides (Figure 7.4.). The HBVA2-nanoAPC induced better 
responses in about 20% of patients (Figure 7.4. table 7.1 and 2). However, IL-2-
HBVA2-nanoAPC induced the strongest responses, with lymphocytes from most 
patients showing a strong CD8 T cell response (Figure 7.4. table 7.1 and 2). 
Consistently, IL-2-A2-nanoAPC, in the absence of antigenic peptide, did not induce 
IFNγ production by CD8 T cells in any of the patient samples (Figure 7.4). 
Furthermore, we could not detect an increase in the proportion of Foxp3
+
CD4
+
 cells 
after stimulation with IL-2-HBVA2-nanoAPC or IL-2-A2-nanoAPC (Figure 7.5.). 
 
 
 
160 
 
CD8 Overall HBV QMUL† Shanghai 
Number 57 20 37 
Median age 
(range) 
36 
(17-69) 
40 
(17-69) 
33 
(18-52) 
Sex (M:F ratio) 
%male 
(42:15) 
73.7% 
(13:7) 
65% 
(29:8) 
78.4% 
Viral load 
(Log; range) 
6.35 
(3.27-9.96) 
5.94 
(3.27- 9.96) 
6.57 
(4.31-9.13) 
Median ALT 
(IU/liter; range) 
120.2 
(20-430) 
81.7 
(30-211) 
141 
(20-430) 
HBeAg status  (% 
positive) 
47.4% 25% 59.5% 
 
Table 7.1. Clinical characteristics of chronic HBV patients investigated with IL-2-A2-
nanoAPC  
HBV patients stimulate with HBV class I peptide pool load on IL-2-A2-nanoAPC or A2-
nanoAPC 
†Queen Mary University of London 
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CD4 Overall HBV QMUL† Shanghai 
Number 28 6 22 
Median age 
(range) 
35.4 
(19-69) 
45.8 
(28-69) 
32.5 
(19-52) 
Sex (M:F ratio) 
%male 
(18:10) 
64.3% 
(4:2) 
66.7% 
(14:8) 
63.6% 
Viral load 
(Log; range) 
6.57 
(3.27-9.96) 
5.00 
(3.27- 9.96) 
7.00 
(5.29-9.13) 
Median ALT 
(IU/liter; range) 
110.4 
(20-430) 
42 
(31-97) 
129 
(20-206) 
HBeAg status 
(% positive) 
46.4% 33.3% 50.5% 
 
Table 7.2. Clinical characteristics of chronic HBV patients investigated with IL-2-
DR/DP-nanoAPC  
HBV patients stimulate with HBV class II peptide pool load on IL-2-DR/DP-nanoAPC or 
DR/DP-nanoAPC 
†Queen Mary University of London 
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 HBVA2-nanoAPC IL-2-HBVA2-nanoAPC 
No respond 77.2% 35% 
Respond >0.5% 
CD8 
13/57=22.8% 
(0.6-6.2) 
37/57=65% 
(0.7-16.4) 
Respond >0.5% CD4 9/28=32% 
(0.6-4) 
18/28=64.3% 
(0.6-5.6) 
IL-2/A2>2‡ 
CD8 
- 70.3% 
IL-2/A2>2‡ 
CD4 
- 46.4% 
 
Table 7.3. Antigen specific T cell response ratio comparison between HBVA2-
nanoAPC and IL-2-HBVA2-nanoAPC 
The data in the bracket shows the range 
‡ IL-2-HBVA2-nanoAPC induce more than twice response compare to HBVA2-
nanoAPC 
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Figure 7.3. Percentages of IFNγ producing CD8 T cells induced in  
A. Total 57 HLA-A2 positive chronic HBV patients 
B. 20 HLA-A2 positive chronic HBV patients from Barts and the London hospital care ethics 
review board and  
C. 37 HLA-A2 positive chronic HBV patients from Huashan hospital ethics committee, 
Shanghai China 
Statistical comparisons were performed using Student’s t test. 
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Figure 7.4. IL-2-HBVA2-nanoAPC enhance HBV specific CD8 T cell responses 
PBMCs from chronic HBV patients were incubated with the pool of five HBV peptides at 
concentration of 1uM each or 10ug/ml IL-2-HBVA2-nanoAPC or 10ug/ml HBVA2-
nanoAPC or IL-2-A2-nanoAPC for five days. After restimulation with PMA and Inomycin 
for three hours, IFNγ producing CD8 T cells were quantified after gating on CD8 cells 
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Figure 7.5. Foxp3
+
CD4
+
 T cells measurement  
Foxp3
+
CD4
+
 T cells were measured in two PBMCs from chronic HBV patients after 
stimulation with indicated stimuli for five days. 
7.4 IL-2-HBVA2-nanoAPC improve TCR signalling and suppress 
expression of inhibit receptor in HBV specific CD8 T cells from chronic 
HBV patients 
             In addition, expression of PD1, an inhibitory co-stimulatory molecule, was 
increased in CD8 T cells from chronic HBV, HCV and HIV patients (Keir et al, 
2007). To investigate whether the enhanced CD8 T cell responses induced by IL-2-
HBVA2-nanoAPC resulted from improved TCR signalling and/or reduced 
expression of PD1, we test the expression of PD1 on IFNγ producing CD8 T cells 
induced by either HBVA2-nanoAPC or IL-2-HBVA2-nanoAPC. To further prove 
that IL-2 on IL-2-A2-nanoAPC can reverse tolerance which was induced by 
persistent antigenic stimulation, effectively increases the threshold for T cell receptor 
activation in response to antigen stimulation by suppressing TCR proximal signalling 
pathways (O’meill et al, 2004) (Anderson et al, 2005) we examined activation of 
extracellular signal-regulated protein kinase (Erk), which is repressed in tolerant T 
cells (Anderson et al, 2005). The results demonstrated that the levels of Erk 
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activation were enhanced in responding CD8 T cells from chronic HBV patients 
stimulated with IL-2-HBVA2-nanoAPC compared to those stimulated by HBVA2-
nanoAPC (Figure 7.6.), suggesting that IL-2 can antagonize T cell tolerance by 
enhancing TCR proximal signals. In addition to increased TCR signalling, the 
expression of PD1 was reduced on IFNγ producing CD8 T cells induced by IL-2-
HBVA2-nanoAPC compared to those stimulated by HBVA2-nanoAPC (Figure 7.6.). 
Thus, we have provided direct evidence to demonstrate that IL-2 on nanoAPC 
effectively reduces the TCR activation threshold and the expression of negative 
regulators in virus specific CD8 T cells; the two important factors needed to 
overcome T cell tolerance.   
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Figure 7.6. IL-2 can enhance T cell activation and suppress expression of PD1 on HBV 
specific CD8 T cells.  
PBMCs from three chronic HBV patients, which showed weak responses to HBVA2-
nanoAPC, but strong responses to IL-2-HBVA2-nanoAPC, were incubated with 10ug/ml of 
IL-2-HBVA2-nanoAPC or HBVA2-nanoAPC for five days. After restimulation with PMA 
and Inomycine for three hours, cells were stained with anti-CD8, anti-IFNγ, anti-PD1 and 
anti-phospho-Erk. IFNγ positive or IFNγ negative CD8 T cells were gated for analysis of 
PD1 expression or Erk phosphorylation.  
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7.5 IL-2-nanoAPC increase CD4 T cell responses to viral antigens 
             It has been proved that CD4 T cell tolerance is similar to CD8 cells, and also 
it has been reported that CD4 helper function is essential for the development and 
maintenance of CD8 T cell effector function. I have shown that MHC class II 
molecules in isolated ER vesicles can assemble with antigenic peptides under acidic 
conditions. 221 cells are deficient in MHC class I, but still express HLA DR and DP 
molecules (Shimizu et al, 1989). Three HBV peptides reported to bind to DR and/or 
DP (Mizukoshi et al, 2004) were analysed for their ability to assemble with nanoAPC 
from 221-A2 and 221-A2-IL-2 cells. Consistent with previous findings (Mizukoshi et 
al, 2004), specific binding of all three peptides to nanoAPC were detected under 
acidic conditions (Figure 7.7.). Pools of the three peptides were assembled with DR 
and/or DP molecules on either nanoAPC or IL-2-nanoAPC to create HBVDR/DP-
nanoAPC or IL-2-HBVDR/DP-nanoAPC, respectively. Peptide alone did not induce 
IFNγ producing CD4 T cells in peripheral lymphocyte populations isolated from 
chronic HBV patients (Figure 7.7.).  HBVDR/DP-nanoAPC induced a weak response 
in 8% patient samples (Figure 7.7.), while significant CD4 T cell responses were 
induced in more than 50% of patient samples treated with IL-2-HBVDR/DP-
nanoAPC (Table 7.3.) (Figure 7.7.). Again, we did not find an increased proportion 
of Foxp3
+
CD4 T cells in peripheral lymphocytes from chronic HBV patients after 
culture with IL-2-HBVDR/DP-nanoAPC (Figure 7.8.).  
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Figure 7.7. IL-2-HBVDR/DP-nanoAPC induce CD4 T cell responses in PBMCs from 
chronic HBV patients 
Induction of IFNγ producing CD4 T cells in PBMCs from chronic HBV patients. PBMCs 
were incubated with 10ug/ml of IL-2-HBVDR/DP-nanoAPC or HBVDR/DP-nanoAPC or 
IL-2-A2-nanoAPC for five days. After restimulation with PMA and Inomycin for three 
hours, IFNγ producing CD4 T cells were quantified after gating CD4 cells. 
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Figure 7.8 Foxp3
+
CD4
+
 T cells were measured in PBMCs from chronic HBV patients 
after stimulation with indicated stimuli for five days.  
The presented data were from patients’ number Q6 and Q16, who were among the patients 
shown CD4 T cell responses towards IL-2-HBVDR/DP-nanoAPC stimulation 
7.6 IL-2-nanoAPC induced CD4 T cell responses leading to stronger viral 
antigens CD8 T cell responses 
            To investigate whether the induced Th1 CD4 responses can enhance viral 
antigen specific CD8 T cell responses, patient lymphocytes were stimulated with 
both IL-2-HBVDR/DP-nanoAPC and IL-2-HBVA2-nanoAPC. The results showed 
that the induction of Th1 CD4 T cells increased the proportion of IFNγ producing 
CD8 T cells in response to IL-2-HBVA2-nanoAPC (Figure 7.9.), suggesting that 
CD4 responses are indeed important for the expansion of effector CD8 T cells. 
Therefore, the presence of IL-2 on nanoAPC is important to drive optimal CD4 and 
CD8 T cell responses against HBV in lymphocytes from chronic HBV patients. 
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Figure 7.9. IL-2-HBVDR/DP-nanoAPC induces CD4 T cell responses in PBMCs from 
chronic HBV patients leading to the enhanced responses of HBV-specific CD8 T cells. 
PBMCs from chronic HBV patients were incubated with 20ug/ml IL-2-HBVA2-nanoAPC 
or 10ug/ml IL-2-HBVA2-nanoAPC and 10ug/ml IL-2-HBVDR/DP-nanoAPC for five days. 
After restimulation with PMA and Inomycin, IFNγ producing CD4 or CD8 cells were 
quantified after gating on CD4 or CD8 cells.  
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DISCUSSION 
             The study of the immune system has provided insight in the mechanism of 
protection induced by vaccination; primarily that most clinically protective vaccines 
are potent in generating neutralizing antibody responses. Nonetheless, vaccination 
fails to protect against a wide range of acquired chronic infections caused by viruses, 
such as HIV, HBV and HCV, intracellular pathogens, and cancer. Attempts to 
combat these diseases are thought to also require the induction of the cellular arm of 
the immune response, in which dendritic cells (DCs) play a key role. Thus, DCs are 
considered a promising target/tool when designing new-generation vaccines (Farkas 
et al. 2005) (Clay et al. 2006). But these are associated with several difficulties. For 
example, there are limitations involved in the loading of antigen, and in the 
appropriate maturation of DC in vitro. Furthermore, the complexity of DC subsets in 
relation to the induction versus suppression of T cell activation in vivo severely limits 
DC- based vaccine applications (Hawiger et al. 2003). To overcome the difficulties 
of DC therapies, we have developed a microsome based DC vaccine by using ER-
enriched microsomes isolated from professional antigen presenting cells, such as 
DCs (Sofra et al, 2009). This approach not only preserves antigen presenting function 
of DC, but also avoids unrelated function of DC such as inhibitory function and 
soluble factors such as IL10, TGF-β and IDO (Sofra et al, 2009). However, it has 
been clear that poor immune response against viral infection is one of major courses 
of chronic infectious diseases. It is therefore ineffective if the therapeutic vaccine 
delivers only conventional antigen and co-stimulatory signal. Based on our 
microsomal vaccine, here, we have explored the hypothesis by selectively delivering 
IL-2 with HLA-antigen complexes to antigen specific T cells in patients with chronic 
infectious diseases.    
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1. Defective immunoresponses in chronic infectious diseases 
             Our approach is based on the recent understanding of immunological defects 
in chronic infectious diseases. The studies of chronic HBV infection demonstrate that 
the persistent high load of virus can lead to severe immune tolerance (Frebel et al, 
2010). The T cells from chronic HBV are tolerant to viral antigens and fail to 
produce effective cytokines such as IL-2, TNFα and IFNγ in response to viral 
stimulation. The viral persistence in chronic HBV patients leads to reduction of T 
cell population and the proliferation potential of effector T cells (Frebel et al 2010). 
It has been suggested that the deficiency is due to both cellular intrinsic and extrinsic 
mechanisms. The expression of inhibitory receptors such as CTLA4 and PD1 on 
antigen specific T cells, and regulatory cytokines such as IL-10, and the possible 
increases of Treg cells are found in chronic HBV, HCV and HIV patients (Frebel et 
al 2010) (Keir et al 2007) (Racanelli et al 2007). Recently, the downregulation of 
TCR proximal signalling pathways has been found in T cells from chronic HBV 
patients (Maini and Schurich 2010) (Das et al, 2008); compelling support for the 
notion that persistent antigen engagement is at least one of the mechanisms for the 
induction of virus specific T cell tolerance. The unresponsiveness of viral specific T 
cells has been found as a generic mechanism partly responsible for the chronic 
infections of HIV, HBV and HCV (Keir et al 2007), suggesting that the induction of 
T cell tolerance is due to persistent engagement of T cells with viral antigens, rather 
than the function of specific viral molecules. 
             Together with the findings from chronic infectious diseases and animal 
models, it indicates that viral induced tolerance is not due to loss of antigen specific 
T cells, but rather downregulation of proximal TCR signalling pathways following 
antigen stimulation (Anderson et al, 2005) (Frebel et al, 2010). Such tolerance cannot 
be reversed by an increase in the amount of antigen presented by activated dendritic 
cells and this cannot reverse tolerance (Anderson et al, 2005). Thus the priority to 
develop a therapeutic vaccine for chronic infectious diseases is its capability to 
reverse the function of antigen specific T cells.  
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2. Immunotherapeutics for increasing immunogenicity in chronic 
infectious diseases 
             To overcome the tolerance of viral specific T cells, approaches to increase 
the function of APC have been investigated such as increase of co-stimulatory 
signalling by treating DCs with α‑galactosylceramide which binds to CD1, CD40-
specific antibody and TLR ligands such TLR9 ligand (Paulsson et al, 2007). 
Although some of these modifications have increased efficacy in induction of HBV  
HCV specific T cells in vivo in mouse models, the use of autologous DC and 
dysfunction of DCs in chronic infectious condition (Encke et al, 2005) (Farag et al, 
2010) have limited their clinical applications. The nanoAPC with reconstitute IL-2 
and HLA-A2 not only deliver the bio-adjuvant and antigen directly to T cells, but 
also can be broadly applied to patient groups sharing HLA alleles. Using cytokines as 
bio-adjvenat to immunetherapy the chronic infections have found that IL-7, IL-15 
and IL-2 can effectively improve the anti-viral immune response (Ha et al, 2008). IL-
7 and IL-15 are required for survival and homeostatic proliferation of memory T 
cells (Meldhionda et al, 2005). IL-7 has been found to suppress Socs3 (suppressor of 
cytokine signalling 3) expressions in effector T cells (Marc et al, 2011). Socs3 is 
suppressor of cytokine signalling (Yoshimura et al, 2007). Thus, the inhibition of 
Socs3 results in induction of IL-22 and IL-6 that is required for anti-viral responses 
and protection of liver pathology (Marc et al, 2011). Although unlike IL-2, IL-7 
induces less organ pathology, the function of IL-7 is not limited to viral specific T 
cells. Therefore, it may be less effective under the chronic infectious condition which 
the immune system is largely deregulated with high levels of Treg cells and 
inflammatory cytokine production (Frebel et al 2010).  
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3. IL-2 as adjuvant for immunotherapy 
             IL-2 is the most potent stimulatory cytokine for T cells and is required for 
memory T cell function (Malek 2008). It has been used as a bio-adjuvant to 
overcome low immunogenicity of therapeutic vaccine in the treatment of chronic 
infectious diseases (Ha et al 2008) (Fearon 2007). Previously, our group discovered 
that IL-2 can effectively reverse T cell tolerance induced by antigen persistence 
(Anderson et al, 2005). Therefore, among cytokines used for immune therapy, IL-2 is 
the best choice for a promising strategy to augment the efficacy of therapeutic 
vaccination against chronic viral infections. However, application of IL-2 as a bio-
adjuvant for immunotherapy is hampered by organ pathology induced by therapeutic 
doses and the expansion of Treg cells leading to the suppression of effector T cells 
(Malek and Castro 2010). IL-2 is required for expansion of Treg cells and IL-2 
treatment for HIV induces immune suppressive effect due to the overexpansion of 
Treg cells (Weiss et al, 2010).  
             Our approach to use immobilized IL-2 incorporated into the nanoAPC 
effectively delivers the IL-2 to antigen specific T cells that are engaging pMHC on 
APC. By this, the therapeutic dose of IL-2 to enhance activation of antigen specific T 
cells is much less than the therapeutic dose of soluble IL-2 used for systemic 
administration (Bernsen et al, 1999). IL-2 activation depends on the formation of its 
receptor. In resting T cells, only IL-2 receptor β and γ chains are expressed while IL-
2 receptor α chain is effectively induced by pMHC stimulation (Malek and Castro 
2010). We have shown that nanoAPC can induce synapse formation that can induce 
strong TCR signalling and subsequently the expression of IL-2 receptor α chain 
(Malek and Castro 2010). Thus, the IL-2 on nanoAPC can effectively interact with 
high affinity receptor on antigen specific T cells. Moreover, it has been shown that 
IL-2 can autocrinely induce expression of high affinity receptor on antigen 
stimulated T cells (Ascherman et al, 1997). Consistently, the stimulation of CMV 
specific T cells by IL-2-CMV-A2nanoAPC effectively induces CD25 expression on 
CMV tetramer positive T cells. Thus, the IL-2-nanoAPC creates a microenvironment 
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for antigen specific T cells to effectively engage high doses of IL-2 locally. IL-2 
forms four helical proteins that dock on the trimetric receptor surface. Since the IL-2 
on nanoAPC is preferentially targeting antigen specific T cells, therefore, it does not 
significantly affect bystander T cells and Treg as shown in both systems of CMV and 
HBV.  
             In order to maintain the function of structure of IL-2, We optimized the IL-2-
tapasin structure to remain IL-2 exposed by addition of due GGS linker sequence. 
The amount of the IL-2 expressed in nanoAPC expresses a similar activity to that of 
recombinant IL-2 (~ 100IU/ng) suggesting that the engineered IL-2 maintains its 
activity on nanoAPC. We found that the IL-2 on nanoAPC is much more stable than 
soluble recombinant IL-2 (data not shown). It may be due to the stable structure after 
being immobilized on nanoAPC membranes. IL-2 can sustain its function after 
internalization by T cells following interaction with its high affinity receptor (Malek 
and Castro 2010). We found that nanoAPC engraphed into the synapse can be 
internalized by T cells. Thus, the IL-2 can remain active in complex with its receptor 
after internalization. This approach can be applied with other cytokines or even 
combination of different cytokines if they are beneficial for optimizing viral specific 
T cell activation.  
4. Nano-sized antigen presenting cells (nanoAPC) 
             Nano-particles have been used to develop therapeutic vaccines for chronic 
infectious diseases (Nandedkar, 2009) (Ansari et al, 2011). Most of the nano-
particles are developed by synthesis of chemical reagents or viral particles or 
microbial after engineered with antigens (Nandedkar, 2009). So far, the reported 
nano-vaccine aim to introduce antigen to DC in vivo and activate DC to stimulate T 
cells (Cruz et al, 2011). However, the high level of viral load in chronic infectious 
diseases indicates that the immune unresponsiveness to virus is not resulted from 
lack of antigens, but the defects in both innate and adaptive immune systems 
including function of DC (Frebel et al, 2010). It is therefore the induction of 
exogenous antigen to DC may not be effective for reactivation of defected immune 
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system. Some of the nano-vaccine aim to deliver pMHC to T cells by coupling 
folded recombinant pMHC to surface of particles (Cruz et al, 2011). Due to the 
nature of MHC-peptide folding process, only limited number of antigen peptides can 
effectively induce MHC class I folding and the conformation of folded pMHC on 
particles may differ from physiologically processed pMHC in APC. The nanoAPC 
are derived from APC with abundant peptide receptive MHC class I molecules that 
semi-folded under physiological condition. It is therefore effectively assembled with 
peptides. We have shown that all the HLA-A2 peptides used in this study can 
effectively bind to HLA-A2 molecules in the nanoAPC. In addition, the engineered 
IL-2 is also processed naturally in APC seed cells. It is therefore nanoAPC present 
physiological pMHC and IL-2 to T cells. In addition, nanoAPC have perfect 
biocompatibility with nature components including co-stimulatory molecules 
synthesised in APC cells. At a nanosize, we demonstrate that nanoAPC can 
effectively distribute to peripheral lymphoid organs. Importantly, unlike nano-
particles, nanoAPC are not effectively endocytosed by DCs in lymph nodes. This is 
also largely due to the physiological pattern of nanoAPC that are not recognized by 
pattern reorganization receptors on DC (Namswskar, 2009).  
             In previous report, HBV antigenic peptides can induce viral specific T cells 
in PBMC (Das et al, 2008). However, these reports were using IL-2 in stimulatory 
cultures (Das et al, 2008). We have discovered that even a minimal dose of IL-2 
(20IU) can globally activate T cell activation and proliferation. It is therefore in the 
absence of IL-2 we could not detect significant T cell responses by antigen peptides 
alone. The induced responses are only observed in some cases with peptide 
assembled nanoAPC. The significant responses are only detected in IL-2-nanoAPC 
which is consistent with our previous observation that IL-2 can effectively reverse 
responses of tolerant T cells to antigen stimulation (Anderson et al, 2005).  
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5. TH1 helper cells are important for the induction of effective 
responses of viral specific CD8 T cells  
             We however confirmed that an induced TH1 response is important for a 
maximum response of CD8 T cells to viral antigens. We tried two different 
approaches to induce both CD4 and CD8 responses by either separately assembling 
MHC class I and MHC class II on nanoAPC then mixed together for stimulation of 
PBMC and also assembling sequentially the pMHC class I and class II on same 
nanoAPC. Results showed that the pMHC class II can induce strong CD4 T cell 
response when stimulated by IL-2-nanoAPC and the induced CD4 T cell response 
can enhance the response of HBV specific CD8 T cells. This finding indicate; 1. IL-2 
is important for the induction of viral specific CD4 T cells and 2. TH responses are 
important for the development and maintenance of CD8 T cell function (Yang et al, 
2010). However, in all the cases analysed, the proportion of CD4 cells that responded 
was lower than the proportion of responding CD8 cells. This may be due to the fact 
that CD8 T cells are more sensitive to IL-2 than CD4 T cells (Li et al, 2000). Another 
possibility, is that the level of MHC class II molecules expressed on nanoAPC 
prepared from 721.221 seed cells is lower than the level of HLA-A2 (Gabathuler and 
Kvist 1990) or that the pMHC class II complexes, generated by assembly with the 
selected HBV peptides, are not optimal for induction of CD4 T cell responses. It is 
therefore important for further development to detail screen the MHC class II binding 
peptides from HBV viral peptide databases. We have tried different parameters to 
assemble pMHC class I in order to obtain maximum loading. We found a pre-acidic 
treatment reported for increasing peptide receptive MHC class I by striping bound 
peptides is not effective. This suggests that the MHC class I in nanoAPC derived 
from the ER membranes are effectively peptide receptive. However, when we 
compared SIINFEKL-Kb complexes on nanoAPC prepared from OVA transfected 
APC and SIINFEKL loaded nanoAPC, the level of pMHC is much higher in 
nanoAPC if the pMHC is processed naturally. I therefore propose that instead of 
loading antigenic peptide in vitro onto nanoAPC, the antigen has to be engineered 
into the seed cells and let the seed cells to process pMHC complexes.  
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             The effect cytokines induced by antigen peptides in CD8 T cells from 
chronic HBV patients have been investigated and a differential expression of IL-2 
and IFNγ was discovered with defective IL-2 expression, but induction of IFNγ 
(Frebel et al 2010). We however did not detect significant increase of IL-2 producing 
CD8 T cells after five day stimulation. This may be due to the addition of IL-2 into 
the culture in reported studies and also to the time for detection of IL-2 as the 
reported results are from peptide stimulated T cells in short time (less than 48 hours) 
( Schurich et al, 2011).  
6. IL-2 enhances T cell responses by reciprocally regulating 
expression of PD1 and TCR signalling 
             One of the major disorders of viral specific immune response in chronic 
infectious diseases such as HIV, HCV and HBV is the elevated expression of PD-1 
on viral specific T cells (Das et al, 2008). Although it remains unknown by which 
mechanism the PD-1 has reported that the expression of PD-1 can effectively induce 
Batf expression, an AP1 repressor and the expressed Batf can subsequently inhibit 
TCR mediated AP1 activation (Quiqley et al, 2010). PD1 expression has been found 
in T cells from chronic HBV patients (Keir et al, 2008). We have now demonstrated 
that stimulation of viral specific T cells from chronic HBV patients with IL-2 and 
pMHC delivered by nano-APC can effectively reduce expression of PD1. Our data 
not only supports previous findings of induced expression of PD1 on T cells by viral 
persistence (Keir et al, 2008) and also demonstrates a possible mechanism for IL-2 to 
repress PD1 expression on effector T cells. In addition, we could also engineer 
membrane bound single chain antibodies to PD1 and/or CTLA4 to further reduce 
negative co-stimulatory signals on viral specific T cells. 
             One of the major mechanisms for viral specific T cell to be tolerant is the 
impairment of TCR signalling in chronic infectious diseases (Das et al, 2008). We 
have previously demonstrated that persistent stimulation with high affinity viral 
antigens can effectively induce T cell tolerance with severe impaired TCR signalling 
which resemble the findings from chronic infections (Anderson et al, 2005). In 
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chronic HBV conditions, a defective expression of CD3ζ downregulate was 
discovered on CD8 T cells (Das et al, 2008). The reduced expression of CD3 ζ 
associates with defective function of CD8 induced by anti-CD3 (Das et al, 2008). It 
has been found that the reduced expression of CD3 ζ is due to persistent infections. 
In another investigation, Bim has been found to be induced in T cells from chronic 
HBV, but not acute infected patients (Schurich et al, 2011). Bim is a pro-apoptotic 
protein and expression can repress TCR signalling (Hale et al, 2011). A generous 
defect in TCR signalling is a common disorder of T cells in chronic infections largely 
due to the viral persistence (Maini and Schurich 2010) (Das et al, 2008). In a tolerant 
model induced by persistant antigen stimulation, we have demonstrated that IL-2 can 
effectively reverse the tolerance and restore full responses to tolerogenic antigens 
(Anderson et al, 2005). Consistently, we have now demonstrated that IL-2 together 
with pMHC on IL-2 nanoAPC can enhance TCR signalling, a therapeutic mechanism 
to reverse T cell tolerance.  
7. NanoAPC are biocompatible as live APC and accumulate in 
peripheral lymphoid organs 
             Unlike reported nano-vaccine, nanoAPC affects directly on antigen specific 
T cells in vivo (Nandedkar, 2009). It is therefore important that nanoAPC remain as 
free particles in peripheral lymphoid organs. Previously, we demonstrated that 
nanoAPC are not effectively endocytosed by DCs in vitro (Sofra et al, 2009). Here, 
we further confirmed that the nanoAPC largely remain as free particles in the lymph 
nodes and accumulated for more than 48 hours. This is important not only for 
induction of memory T cells in lymphoid organs and also for activation of viral 
specific T cells in pathological organs such as liver in chronic HBV with a high level 
of lymphatic infiltration. Although we do not know why the nanoAPC are resistant to 
endocytosis, the lack of pattern recognition molecules those are recognized by 
pattern recognition receptors on DC may be the reason (Geijtenbeek et al, 2004). In 
addition to the tolerance to endocytosis, nanoAPC are also highly accumulated in 
peripheral lymphoid organs (Sofra et al, 2009). This may result from high levels of 
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homing receptors inherited from seed APC cells (Sachstein, 2005). Nevertheless, the 
nanoAPC have great advantages in lymphoid distribution and sustained free particles 
comparing to synthesised nano-vaccines.  
8. NanoAPC induce immune synapse on antigen specific T cells  
             Synpatic formation on the interactive parts between DC and antigen specific 
T cells is the functional architectures of effective antigen recognition (Fooksman et al, 
2010). The clustering of multi surface molecules including pMHC-TCR, co-
stimulatory molecules are required for the initiation of potent TCR signalling. The 
nanoAPC can effectively induce synapthesis formation on antigen specific T cells. 
Importantly, the membrane clustering leads to the engrapher of whole nanoAPC into 
T cells, a phenotype observed in the process of synapthses after interaction between 
DC and antigen specific T cells (Fooksman et al, 2010). The endocytosis of 
synapesis is important to sustain the interaction of pMHC-TCR and co-stimulatory 
molecules in the T cells (Fooksman et al, 2010). It has been reported that an 
interaction of IL-2 with high affinity IL-2 receptor on T cells can also induce 
endocytosis of IL-2-IL-2R complex which is also important for a sustained IL-2 
stimulation. Thus, the endocytosis of nanoAPC can result in the sustained stimulation 
of both TCR and IL-2 receptor, a maximum induction of viral specific T cells which 
is critical for the reversed immune responses in chronic infectious conditions.  
9 NanoAPC can be applied as vaccine delivery system. 
             In addition to the flexible reconstitution of selected bio-active molecules and 
physiolocially processed therapeutic molecules, the nanoAPC created from MHC 
class I negative seed APC cells (721.221) gives advantages to freely reconstitute 
MHC class I alleles. As statistics reviewed, there are a few of most common MHC 
class I alleles that are distributed in a large population (Janeway et al, 2001). It is 
therefore, reconstitution of these most common MHC class I alleles that can make 
nanoAPC broadly used by large population of patients. Another major advantage of 
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nanoAPC is the sustained activity after storing at -80
o
C, which is not only possible 
for pharmaceutics production but also maintains consistent between benches easier.  
10 Future considerations/ work 
             The ultimate aim of nanoAPC is to deliver engineered bio-adjuvant to 
antigen specific T cells, but not to bystander T cells and Treg cells. It is therefore 
important that reconstituted pMHC on nanoAPC can effectively engage antigen 
specific T cells in vivo. To achieve this, high affinity and broad spectrum pMHC on 
nanoAPC can effectively induce comprehensive responses against viral antigens and 
subsequently deliver engineered adjuvant to antigen specific T cells. We 
demonstrated in this study that pMHC assembled by the loading of exogenous  
peptides to MHC class I in vitro on nanoAPC or live DC is much lower than that 
processed physiologically in APC after forced expression of antigen into the APC. It 
is therefore important in future development that viral antigen has to be transfected 
into seed cells and allow the pMHC to be assembled before isolation of nanoAPC. 
The efficacy of nanoAPC with engineered bio-adjuvant has to be tested in clinical 
trials and the induction of viral specific CD4 and CD8 T cells and viral clearance 
have to be examined in vivo. 
11 Conclusions: 
             To overcome the unresponsiveness of viral specific T cells induced by viral 
persistence in chronic infectious patients, in this study, we merged advantages from 
nano-technology, bio-adjuvant, antigen presenting cells and selected viral antigenic 
peptides in the development of therapeutic vaccines for chronic infectious diseases 
(Nandedkar, 2009) (Ha et al, 2008) to develop a novel form of nano-vaccine, 
nanoAPC, to pMHC, co-stimulatory signals and IL-2 or other engineered bio-
adjuvant to viral specific T cells, but not bystander T cells and Treg cells. The 
selection of MHC class I defective human B cell line as seed cells allows us to 
reconstitute the most popular MHC class I alleles into nanoAPC. Thus, the 
therapeutic vaccines can apply to large population sharing same MHC class I alleles. 
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Derived from natural APC, the nanoAPC serve native APC function and effectively 
induce functional synapses on antigen specific T cells. Therefore, I conclude that 
nanoAPC serve as a most effective delivery platform for the development of 
therapeutic vaccines for chronic infectious diseases or cancer in which the T cells are 
tolerant to antigens. 
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Table 1. Administration of stimulatory cytokines to boost exhausted T cells during chronic infection 
(Ha et al, 2008) 
Cytokine General effect on T cells Treatment Infection Effect References 
IL-2 
• Expansion of recently activated T cells 
• Expansion and maintenance of Tregs 
IL-2 LCMV 
• ↑Virus-specific T cells 
• ↓Viral load 
•Blattman et 
al, 2003 
 
• Induction of AICD 
• Upregulation of Bcl-2 
IL-2+ 
Anti-retroviral 
drugs HIV* 
• ↑CD4 T cells Virus-
specific T cells (ND) 
• Viral load (no effect) 
•Aladdin et al, 
2001  
• Levy et al, 
1999 
• Kovacs et al, 
1996 
  
IL-2+ 
Therapeutic 
vaccine + HIV* 
• ↑Virus-specific T cells  
• ↓Lower viral load† 
•Levy et al, 
2005 
  
Anti-retroviral 
drugs HIV‡ 
• Virus-specific T cells (no 
effect)  
• Viral load (no effect) 
• Hardy et al, 
2007 
• Kilby et al, 
2006 
• Smith et al, 
2007  
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SIV‡ 
• ↑Virus-specific T cells 
• ↓Lower viral load † 
•Tryniszewska  
et al, 2002  
IL-7 
• Maintenance of memory 
• T cells Survival of IL-7RαHi effector T 
cells 
• Upregulation of Bcl-2 IL-7 SIV 
• ↑CD4 and CD8 T cells 
Virus-specific T cells (ND)  
• Viral load (no effect) 
• Beq et al, 
2006 
•Nugeyte et al, 
2003 
•Fry et al, 2003 
  
IL-7 + 
Therapeutic 
vaccine + 
Anti-retroviral 
drugs SIV‡ 
• Virus-specific T cells (no 
effect)  
• Viral load (no effect) 
•Hryniewicz et 
al, 2007 
IL-15 
• Maintenance of memory T cells 
• Survival of IL-7RαLow effector T cells  
• Upregulation of Bcl-2 
IL-15+ Anti-
retroviral 
drugs SIV* • ↑Virus-specific T cells 
•Picker et al, 
2006 
  
IL-15+ 
Therapeutic 
vaccine + 
Anti-retroviral 
drugs SIV‡ 
• Virus-specific T cells (no 
effect) 
• ↑Viral load† 
•Hryniewicz et 
al, 2007 
*Compared with anti-retroviral therapy alone. 
†After cessation of anti-retroviral therapy. 
‡Compared with therapeutic vaccine 1 anti-retroviral therapy. 
ND not determined. 
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Table 2 Different types of immunotherapy 
Type of 
vaccine 
Origin/generation Antigen 
loading 
Characteristics/ 
advantages 
Disadvantages Reference 
Free 
peptides 
 Synthetic 
immunogenic 
peptides from TAAs 
  Administered with 
or without 
adjuvants. 
 Induction of CTL 
responses in vivo 
and in clinical 
trials. 
 No induction of 
immunity with free 
peptides in the 
absence of adjuvant 
in clinical models. 
 Therapeutic 
vaccination with 
IFA is effective in a 
few animal models. 
 Some clinical trials 
showed some 
clinical responses 
against melanoma. 
 Easy and 
inexpensive 
production of 
 Can induce 
tolerant. 
 Inconclusive 
clinical results, 
limited clinical 
responses. 
 Ineffective 
prophylactic 
vaccination 
against non-
virally induced 
cancers in vivo 
models. 
 Some clinical 
trials showed no 
clinical response. 
 Require uptake by 
patients DCs, 
which can be 
compromised. 
 Schulz et al, 1991 
 Mandelboim et al, 
1995 
 Wang et al, 1999 
 Jager et al, 1996 
 Jager et al, 2000 
 Gjertsen et al, 
1997 
 Gjertsen et al, 
2001 
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peptides. 
 Simple peptides 
administration in a 
clinical setting. 
Dendritic  
Cells 
 Monocyte-derived 
DCs. 
 CD34+ precursor-
derived DCs. 
 Peripheral blood 
DCs. (Maturation is 
induced by culturing 
with cytokines.) 
 DCs pulsed 
with 
peptides. 
 DCs pulsed 
with 
proteins. 
 DCs loaded 
with DNA 
and mRNA 
 DCs loaded 
with viral 
vectors. 
 DCs loaded 
with tumour 
cell lysates. 
 DC-tumour 
cell fusions. 
 Professional APCs 
for potent T cell 
induction. 
 Superior than other 
methods in tumour 
models. 
 Strong CTL 
induction in animal 
models. 
 Effective 
prophylactic and 
therapeutic 
vaccination in 
mouse models (eg, 
melanoma, HPV). 
 Expansion of 
tumour specific 
CTLs and 
regressions in 
cancer patients. 
 Can also induce Th 
cell responses. 
 In i.v. 
administration DCs 
 Problematic long-
term storage. 
 Time consuming 
and labour 
intensive. 
 Expensive. 
 On a large scale 
this approach will 
be problematic. 
 DCs generated ex 
vivo home poorly 
in the lymph 
nodes after s.c. 
injection 
(although the few 
cells that reach the 
draining lymph 
nodes generate T 
cell responses). 
 Even though they 
can stimulate T 
cell responses, 
these are often not 
accompanied with 
significant clinical 
 Mayordomo et al, 
1995 
 Zitvogel et al, 
1996 
 Bellone et al, 2000 
 Soares et al, 2001 
 Eggert et al, 1999 
 Mullins et al, 2003 
 Saha et al, 2007 
 Nestle et al, 1998 
 Thurner et al, 1999 
 Banchereau et al, 
2001 
 Schuler-Thurner et 
al, 2002 
 Mandic et al, 2005 
 Londge et al, 2000 
 Thomas-Kaskel et 
al, 2006 
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home to the spleen 
and do not reach 
the lymph nodes 
(effective in lung 
cancer model but 
not for 
subcutaneous 
tumour). 
 S.C. injection leads 
to mixed homing to 
spleen and lymph 
nodes. 
 Safe and well 
tolerated for 
clinical use. 
 Have shown 
clinical responses 
to melanoma, 
prostate cancer, and 
metastatic renal cell 
carcinoma... 
 
responses. In 
general clinical 
results are 
unsatisfactory. 
Liposomes  Manufactured in the 
lab from 
phospholipids. 
 Tumour cell-derived 
liposomes. 
 
 TAA or 
TAA-derived 
peptide 
incorporation 
during 
preparation. 
 Can be modified 
for site-specific 
delivery, can be 
targeted to DCs. 
 Efficiently 
endocytosed by 
 Very few clinical 
trials with cellular 
but no significant 
clinical response. 
 Require uptake by 
patients DCs, 
 Kawamura et al, 
2006 
 Van Broekhoven 
et al, 2004 
 Van Broekhoven 
et al, 2002 
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 Tumour cell-
derived 
liposomes 
retain 
antigenic 
properties 
from original 
tumour cells. 
DCs, 
 Can be prepared to 
contain cytokines 
and DC maturation 
signals. 
 Offer antigen 
protection against 
degradation. 
 Cell free vaccine 
(simpler). 
 Can be rapidly 
available and in 
large quantities. 
 Induce strong CTL 
responses in 
animals. 
 Provide 
prophylactic 
immunity in animal 
models against 
tumour challenge. 
 Therapeutic effects 
in animal models 
inducing regression 
of established 
tumours. 
 Better than free 
peptides. 
 Clinical response to 
which can be 
compromised. 
 Altin et al, 2004 
 Neelapu et al, 
2004 
 Neidhart et al, 
2004 
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B cell lymphoma. 
ISCOMs 
 
 Manufactured in the 
lab from cholesterol, 
saponin and 
phospholipids. 
 Proteins and 
peptides 
incorporate 
into iscomes 
during 
preparation. 
 Cationic 
antigens 
naturally 
associate to 
ISCOMATR
IX when 
admixed. 
 Cell-free. 
 Fuse with DCs 
unloading their 
contents. 
 Available in large 
quantities. 
 Protect antigen 
from degradation. 
 Contain saponin 
which is highly 
immunogenic. 
 Promote high 
antibody levels and 
strong CTL and Th 
cell responses in 
animal models. 
 Induced antibody 
and CD8
+
 T cell 
response against 
HPV16 protein in a 
clinical trial. 
 Better than free 
peptides. 
 Safe for clinical 
use. 
 One clinical trial 
reported against 
cancer with no 
significant clinical 
response. 
 Require uptake by 
patients DCs, 
which can be 
compromised. 
 Barr and Mitchell, 
1996 
 Claasen and 
Osterhaus, 1992 
 Maloy et al, 1995 
 Lenarczyk et al, 
2004 
 Stewart et al, 2004 
 Frazer et al, 2004 
Exosomes  Secreted from DCs or 
tumour cells and 
obtained from culture 
 Exosomes 
pulsed with 
peptides. 
 Naturally secreted 
and endocytosed by 
DCs, so efficient 
 Low yields from 
mature DCs, 
which limits their 
 Zitvogel et al, 
1998 
 Andre et al, 2004 
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supernatants.  Pulsing 
peptides to 
DCs before 
exosome 
production 
and 
purification. 
uptake for 
vaccination 
purposes. 
 Contain MHC class 
I and II. 
 Contain co-
stimulatory/adhesio
n molecules. 
 Require mDCs 
from antigen 
presentation. 
 Induce potent CTL 
responses in animal 
models. 
 Only exosomes 
from mDCs are 
efficiently 
immunogenic. 
 Both prophylactic 
and therapeutic 
immunity in animal 
models. 
 As efficient as DCs 
and more efficient 
than peptides in 
animal models. 
 Cell-free. 
 Can be stored for 
prolonged periods 
clinical use. 
compromised 
 Require uptake by 
patients DCs, 
which can be 
compromised. 
 Only a couple of 
phase I trials at 
the moment, with 
no clinical and 
limited cellular 
response. 
 Chaput et al, 2004 
 Segura et al, 2005 
 Escudier et al, 
2005 
 Morse et al, 2005 
 Andre et al, 2002 
 Dai et al, 2006 
 Chen et al, 2006 
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in vitro. 
 Safe and well 
tolerated.  
Membrane 
Vesicles 
from DCs 
 Membrane vesicles 
obtained by 
ultracentrifugation of 
sonication-disrupted 
DCs. 
 Administered 
together with 
peptides. 
 Cell-free therefore 
simple. 
 Can be obtained in 
high yields. 
 Contain MHC class 
I and co-
stimulatory/adhesio
n molecules. 
 Can stimulate T 
cells in the absence 
of APCs in vitro. 
 Prime CD8+ T cells 
in vivo. 
 Induce a 
prophylactic 
response against 
tumour challenge in 
vivo. 
 No clinical results 
available. 
 System not well 
characterized. 
 Kovar et al, 2006 
Microsomes  ER membrane 
obtained from lysed 
APCs by rounds of 
ultracentrifugation. 
 Pulsed with 
peptides. 
 Cell-free, therefore 
simpler. 
 Can be obtained in 
high yields. 
 Microsomes 
efficiently bind 
peptides. 
 Directly stimulate 
 No clinical results 
available. 
 Sofra et al, 2009 
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T cell in vitro, 
without the 
presence of APCs. 
 Contain MHC class 
I and II. 
 Contain co-
stimulatory/adhesio
n molecules. 
 Induce peptide-
specific CD8
+
 
responses in vivo. 
IL-2-
nanoAPC 
 ER membrane 
obtained from lysed 
IL-2 and HLA-A2 
transfected 721.221 
cell line by rounds of 
ultracentrifugation. 
 Pulsed with 
peptides. 
 Continue each 
advantage from 
microsome 
 Delivery  both 
antigen peptide and 
bio-adjuvant IL-2 
to antigen T cell  
 Broad application 
to HLA shared 
patient groups 
 IL-2 direct active 
on antigen T cell no 
effect to the rest T 
cells or Treg cells 
 Nano-size free pass 
and accumulate 
 Limitation of high 
affinity and broad 
spectrum pMHC 
 Manuscript send to 
Journal of 
Immunology  
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into peripheral 
lymph nodes 
 Formed in a part of 
immune synapse to 
induce T cell 
responds 
 More than 50% 
patient samples 
shown positive 
responds for the IL-
2-nanoAPC with 
peptide in the HBV 
clinical trail  
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Table 3 Strategles Applies to Vaccine Development and Their Featurres 
     Production   Immunity     
Vaccine 
Type 
Structure Replication Mark Cell 
Culture 
Chemical 
Synthesis 
Recombinant 
DNA 
Administration Humoral Cell 
Mediated 
 Safety Notes 
Classic 
Killed 
Particles 
Microorganisms 
N N *   ** * * +- Uncomplete 
inactivation 
Yes, if 
pathogens 
can be easily 
cultured 
Classic 
Live 
attenuated 
Microorganisms Y N *   * * * +- Rescue of 
Viulence 
In vivo 
recombination 
Yes, if 
pathogens 
can be easily 
cultured 
Subunit Single proteins N Y * * * *** * ? + Yes, if 
properly 
purified 
New 
adjuvants and 
formulations 
Peptides Carrier-
conjugated 
peptide 
N Y  *  *** * ? + Yes, highly 
purified 
Long R&D 
study Also 
polyvalent 
Recombinant 
antigens 
Single proteins 
Carrier-
conjugated 
N Y   * *** * ? ++ Yes, highly 
purified 
 
Micelles 
Liposomes 
Antigens 
embedded 
In lipid Bilayer 
N Y * * * ** * ? ++ Yes, highly 
purified 
Long R&D 
development 
Coexpression 
of antigens 
and/or 
cytokines 
ISCOMs Particles N Y * * * ** * * ++ Yes, highly 
purified 
 
VLPs Particles N Y   * ** * * ++ Yes, no toxic  
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effects 
Recombinant 
Live vectors 
Particles 
Microorganisms 
Y Y   * * * * +- Rescue of 
virulence 
Recombination 
with WT virus 
Long R&D 
development 
Coexpression 
of antigens 
and/or 
cytokines 
Naked DNA Plasmid DNA, 
RNA, Lipsomes 
Gold 
Microbullets 
N Y   * ** * * ++ Applicable to 
gene therapy 
Easy to 
prepare 
Thermostable 
Avirulent 
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Table 4 Patient characterization and CD8 T cell response 
induced by nanoAPC for each patient 
Subject  ALT  HBeAg  Viral load  Sex  Age  IL-2M-I  M-I  Control  
 (IU/liter)   (log)     CD8
+
 IFNγ+ (%)   
1  39  N  5.28  F  36  5.9  3.1  0  
2  37  N  3.27  M  44  0.8  0.3  0.1  
3  24  N  4.58  M  69  0.8  0.1  0  
4  53  N  5.98  M  23  10.1  0.7  0.2  
5  32  P  7.99  F  35  0.1  0  0  
6  24  N  5.84  M  42  0.5  0.4  0  
7  36  N  4.67  F  44  3.7  0.3  0.3  
8  127  N  4.63  M  26  1.5  0.3  0.4  
9  65  N  7.14  F  58  7.3  0.2  0.2  
10  30  P  7.45  M  17  0.1  0  0.1  
11  211  N  5.22  M  33  4.2  2.3  0.1  
12  97  P  4.05  F  56  0.3  0.1  0  
13  206  N  5.27  M  51  16.1  5.4  0.2  
14  45  P  7.31  M  18  12.3  3  0.3  
15  202  N  8.37  F  27  0.1  0.1  0  
16  31  P  9.96  M  28  4.5  0.5  0.1  
17  79  N  5.58  M  52  0.5  0.3  0  
18  44  N  5.11  M  42  0.7  0.3  0  
19  169  N  6.65  F  36  14.2  6.2  0.2  
20  83  N  4.49  M  57  0  0  0  
21  27  P  5.36  M  27  1.4  1.4  0.1  
22  135  p  7.23  F  52  0.5  0.3  0  
23  430  p  4.68  M  33  11.4  4.5  0.3  
24  110  P  7.54  M  22  4  2.5  0.1  
25  143  N  7.03  F  32  3.5  2  0.1  
26  188  N  6.13  M  19  1.8  1.6  0  
27  194  P  7.05  F  41  3.5  1.5  0.1  
28  121  N  5.79  M  37  1.7  1.4  0.1  
29  267  N  9.13  M  22  1  1  0  
30  126  P  6.23  M  19  1  0.3  0  
31  20  P  7.04  F  40  1.4  0.5  0  
32  313  N  6.32  M  38  1  0.9  0.1  
33  212  P  9.12  M  47  1.5  0.2  0  
34  122  P  7.15  M  32  1.7  1.2  0.1  
35  42  N  5.21  M  44  1.3  1.3  0.3  
248 
 
36  35  N  7.24  M  20  4.2  1.3  0.3  
37  23  N  7.24  F  37  1.1  0.8  0.2  
38  73  N  5.58  M  23  1.4  1.2  0.3  
39  46  N  6.09  F  38  0.8  0.3  0.8  
40  310  N  7.61  M  34  4  0.4  0.1  
41  76  N  7.14  M  46  0.6  0  0.1  
42  362  P  4.31  M  32  2.6  0.7  0  
43  211  N  7.54  M  33  1  0.6  0.1  
44  79  N  6.23  F  52  3.7  0.2  0  
45  140  N  5.38  M  40  12.4  1.1  0  
46  170  P  5.42  M  27  7.8  0.5  0  
47  35  P  6.34  M  26  4  2  0  
48  120  P  5.49  M  29  3.6  3.3  0  
49  278  P  5.83  M  40  4.9  2.3  0.3  
50  40  P  5.87  M  25  0.9  1.5  0  
51  46  P  7.38  M  18  2.1  1.1  0.3  
52  80  P  7.24  F  27  5.6  0.9  0  
53  423  P  5.63  M  33  2.5  0.8  0.2  
54  43  P  7.23  M  18  4.7  3.9  0.2  
55  86  P  7.42  M  30  2.8  0.9  0.3  
56  47  P  7.86  M  41  0.9  0.9  0.1  
57  42  P  6.1  M  28  0.7  0.6  0  
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The Journal of Immunology
IL-2–Engineered nano-APC Effectively Activates Viral
Antigen-Mediated T Cell Responses from Chronic Hepatitis B
Virus-Infected Patients
Mengya Liu,*,†,1 Tizong Miao,†,1 Haoxiang Zhu,‡ Alistair L. J. Symonds,† Li Li,†
Anna Schurich,x Mala K. Maini,x Jiming Zhang,‡ Patrick T. F. Kennedy,† Suling Li,* and
Ping Wang†
Impaired function of virus-specific T cells resulting from virus persistence is one of the major mechanisms underlying the devel-
opment of chronic hepatitis B viral infection. Previously, we found that IL-2 can restore the effector function of T cells rendered
tolerant by Ag persistence. However, systemic administration of IL-2 induces organ pathology and expansion of T regulatory cells.
In this study, we show that nano-APC with engineered HLA alleles and IL-2 deliver peptide–MHC complexes, costimulatory
molecules, and IL-2 to Ag-responding T cells, resulting in enhanced expression of CD25 and activation of TCR signaling pathways,
while suppressing PD-1 expression on viral-responding CD8 T cells from chronic hepatitis B virus patients. The enhanced
activation of CD4 and CD8 T cells induced by IL-2–nano-APC was Ag dependent and IL-2–nano-APC did not affect T regulatory
cells. At a size of 500 nm, the nano-APC effectively induce immune synapse formation on Ag-specific T cells and accumulate as
free particles in the lymphoid organs. These attributes of IL-2–nano-APC or other bioadjuvant-engineered nano-APC have
profound implications for their use as a therapeutic strategy in the treatment of chronic hepatitis B virus infection or other
chronic viral diseases. The Journal of Immunology, 2012, 188: 1534–1543.
H
epatitis B virus (HBV) is a noncytopathic hepadnavirus
that can cause acute and chronic hepatitis (1). Approx-
imately 350 million people worldwide are chronically
infected with HBV, which greatly increases the risk of hepato-
cellular carcinoma and causes .1 million deaths annually (1).
Despite recent advances in the development of immunotherapies
for chronic HBV infection, effective induction of virus-specific
T cell activation in persistent HBV infections remains a chal-
lenge (2). One of the major problems for the development of
therapeutic vaccines for chronic HBV infection is the functional
defects in T cells resulting from continual stimulation of these
T cells by persistent viral Ags (3, 4). The functional properties lost
by the antiviral T cells can range from the failure to produce ef-
fector cytokines, such as IL-2, TNF-a and IFN-g, to complete
deficiency in cytokine production and proliferation ability, in ad-
dition to a reduction in virus-specific T cell populations (4). These
deficiencies are due to both cell intrinsic and extrinsic mecha-
nisms, including the expression of inhibitory receptors, such as
CTLA4 and PD-1; regulatory cytokines, such as IL-10; and pos-
sibly increased numbers of T regulatory (Treg) cells (4–6). The
unresponsiveness of virus-specific T cells has been found to be
a generic mechanism partly responsible for chronic HIV, HBV,
and hepatitis C virus (HCV) infections (5), suggesting that the
induction of T cell tolerance is due to persistent engagement of
T cells with viral Ags, rather than the function of specific viral
molecules. Therapeutic interventions to counter the effects of
T cell tolerance, and overcome the immunosuppressive environ-
ment resulting from high viral Ag load, have aimed to boost T cell
responses via administration of defined Ags in combination with
blocking Abs to IL-10 or PD-1 or with cytokines enhancing T cell
activation, such as IL-2 and IL-7 (7–9). Recently, downregulation
of TCR-proximal signaling pathways was found in T cells from
chronic HBV patients (3, 10), compelling support for the notion
that persistent Ag engagement is at least one of the mechanisms
for the induction of virus-specific T cell tolerance. Ag-induced
immune tolerance has been well studied in many animal models
(11). After repeated Ag stimulation, effector T cells become tol-
erant (12). We found that tolerance is not due to loss of Ag-specific
T cells, but rather downregulation of proximal TCR signaling
pathways following Ag stimulation (13, 14), which resembles the
findings from chronic viral infections (4). We found that an in-
crease in the amount of Ag presented by activated dendritic cells
(DC) cannot reverse tolerance (13). However, addition of IL-2 can
effectively overcome tolerance and restore the full activation of
T cells in response to Ag stimulation (13). It has been found that
liver sinusoidal endothelial cells can induce tolerance of HBV-
specific CD8 T cells through interaction between B7-H1 on liver
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sinusoidal endothelial cells and programmed cell death-1 on CD8
T cells, and such tolerance can be effectively overcome by IL-2
(15). IL-2 has been used as a bioadjuvant to overcome the low
immunogenicity of therapeutic vaccines for the treatment of can-
cer and chronic infectious diseases (16, 17). Although IL-2 is
a potent activator of memory and effector T cells, systemic ad-
ministration of high doses of IL-2 not only induces severe side
effects, but may also promote Treg function, which can further
increase the activation threshold of Ag-specific T cells (16).
To use IL-2 to overcome the T cell exhaustion induced in chronic
HBV infection while avoiding the side effects of systemic ad-
ministration, we have now developed a novel therapeutic vaccine
(nano-APC) that delivers Ag and IL-2 to Ag-responding T cells, but
has little effect on bystander T cells. The nano-APC are prepared
from the endoplasmic reticulum (ER) membranes of a MHC-
deficient human B cell line, 721.221 (18), which expresses high
levels of costimulatory molecules and genetically engineered ER-
retained MHC I alleles and IL-2 constructs. After assembly with
antigenic peptide in vitro, the nano-APC directly interact with Ag-
specific T cells and induce formation of immune synapses and
expression of the high-affinity IL-2R on T cells. The IL-2 delivered
by nano-APC enhanced T cell responses and effector function, but
did not affect bystander T cells or Treg cells. When assembled with
a pool of HLA-A2–associated HBV peptides and HBV peptides
associated with HLA-DR and DP, IL-2–nano-APC induced strong
CD4 and CD8 T cell responses in peripheral lymphocytes from
chronic HBV patients. Our results demonstrate that IL-2–nano-
APC, which deliver both Ag and IL-2 to Ag-responding T cells,
can significantly increase functional antiviral responses, thereby
overcoming the immune tolerance induced by persistent viral load.
Materials and Methods
Mice and cell lines
OTI transgenic mice on the C57BL/6 background were provided by
D. Kioussis (Medical Research Council, National Institute for Medical
Research, London, U.K.). All CD8 T cells in OTI mice carry same TCR
recognizing OVA residues 257–264 in the context of H2Kb (19). C57BL/6
mice were purchased from Harlan UK (Oxon, U.K.). All animals were
maintained in pathogen-free facilities at the Brunel University. The DC2.4
DC line was provided by D. Mann (Southampton, U.K.). The 721.221 cells
have been described in our previous reports (20). CTLL4 was provided by
G. Stockinger (National Institute of Medical Research, London, U.K.). All
lines were cultured in RPMI 1640 with 10% FBS (Invitrogen).
Abs, flow cytometry, and confocal microscopy
FITC-conjugated Abs to CD54 and CD80 were from EuroBioSciences,
and FITC-conjugated streptavidin, and PE-conjugated Abs to pERK, PD-1,
HLA A2, W6/32, Foxp3, FITC-conjugated CD4, FITC-conjugated CD19,
allophycocyanin-conjugated CD8, and PEcy5-conjugated IFN-g were from
BD Biosciences. PE-conjugated A2-CMVnlvpentamer was from ProIm-
mune (Oxford, U.K.). Abs against tapasin and E3-19K retention signal
were described previously (21, 22). For all flow cytometry data, the median
fluorescence intensity from three experiments was presented. Isotype Abs
were used as background controls for all experiments. The side-scatter and
forward-scatter settings were the same for cells and microsomes. CD8
microbeads (Miltenyi Biotec) were used for isolation of CD8 T cells from
total splenocytes from OTI TCR transgenic mice, according to the manu-
facturer’s protocol. Goat anti-human IL-2; anti-human CD3; W6/32, spe-
cific to human MHC I; and MA2.1, specific to HLA A2, Abs were used for
immune staining of cells and nano-APC. Texas Red-labeled rabbit anti-
goat Ig and FITC-labeled goat anti-mouse Ig secondary Abs were used, and
samples were analyzed by confocal microscopy (ZEISS LSM 510).
Peptides, peptide modification, and binding assay
Peptides were synthesized by Invitrogen and purified to .95% purity. The
ε-amino group of the lysine in the influenza-A matrix protein (MP), M58–
64G58YF62K (YILGKVFTL) peptide was synthesized by Invitrogen and
was covalently modified by a photoreactive cross-linker and labeled with
iodination (125I), as described previously (23). The N termini of the
HBV peptides, HBV Env 180–195 AGFFLLTRILTIPQS, Env 339–354
LVPFVQWFVGLSPTV, and Pol 767–782 AANWILRGTSFVYVP (24),
were synthesized by Invitrogen, and labeled and purified with a FITC-
labeling kit (Pierce). For the HLA-A2–binding assay, 2 nM modified
MP peptides was incubated with IL-2–A2–nano-APC in the absence or
presence of unlabeled competing peptides, HBV C18-27 FLPSDFFPSV,
HBV envelope 183–191 FLLTRILTI, 335–343 WLSLLVPFV, 338–347
LLVPFVQWFV, 348–357 GLSPTVWLSV, CMV pp65 matrix protein epi-
tope NLVPMVATV, and MP, at various concentrations, as described previ-
ously. HBV peptides were described in previous publication (10). CMV
NLVPMVATV and OVA SIINFEKL peptides were synthesized by Invi-
trogen. After the removal of free peptides, HLA-A2was precipitated with the
W6/32 Ab, and the binding was measured by detection of radioactivity using
a gamma counter (Beckman). For the DR/DP-binding peptides (synthesized
by Invitrogen), HBV Env 180–195 AGFFLLTRILTIPQS, Env 339–354
LVPFVQWFVGLSPTV, and Pol 767–782 AANWILRGTSFVYVP (24), 20
nM FITC-labeled peptides were incubated with IL-2–A2–nano-APC in
acidic condition (23). After removal of free peptides, samples were ana-
lyzed by flow cytometry. The binding specificity was confirmed by com-
petition assays using unlabeled peptides.
Preparation of nano-APC
To establish IL-2-A2-721.221 seed cells, IL-2-tapasin and HLA-A2-E3-19K
fusion constructs were constructed by PCR-cloning approaches. For IL-2-
tapasin, atapasin expression construct was modified by substitution of the
signal sequence (22) by a 23 GS linker (GGSG) (25) using PCR cloning.
Then, a PCR product containing the human IL-2 coding region was cloned
upstream of the GS linker to create IL-2-GS-tapasin. HLA-A2-E3-19K was
constructed by insertion of a 16-aa (LKYKSRRSFIDEKKMP) sequence
from the E3-19K protein (21) downstream of the C terminus of HLA-A2 in
a HLA-A2 expression construct (26). The constructs were transfected into
721.221 cells, as described in our previous publications (26). The seed cells
were expanded to yield a large volume of cells with .99% viability and
then used for preparation of nano-APC. The preparation of nano-APC was
a two-step process, consisting of preparation of ER-enriched microsomes
and processing of nano-particles. Microsomes from cells were prepared
and purified, as described in our previous publication (23). Briefly, cells
were washed and resuspended in homogenization buffer. After homoge-
nization, tonicity was restored to 0.15 M NaCl. The nuclei, mitochondria,
and larger cell debris were removed by centrifugation at 10,000 3 g. Total
microsomes were recovered by centrifugation at 100,000 3 g and sub-
fractionated by flotation in sucrose gradients. The microsomes were lay-
ered on top of 5 ml 0.33 M sucrose, which was, in turn, layered on top of
a discontinuous sucrose gradient consisting of 2 ml 2 M and 1 ml 2.5 M
sucrose. Centrifugation in a TH-641 rotor for 16 h at 110,000 3 g at 4˚C
yielded a microsome band on top of the 2 M sucrose cushion, which was
collected and resuspended in rough microsomes (RM) buffer (250 mM
sucrose, 50 mM triethanolamine-HCl, 50 mM KOAc, 2 mM MgOAc2, and
1 mM DTT). The microsomes were further processed to homogenous
nano-particles by sequential homogenization using an Isobiotec cell ho-
mogenizer (Heidelberg) with a cutoff size between 6 and 4 mm. The ho-
mogenized particles were recovered by centrifugation in a TH-641 rotor for
24 h at 110,000 3 g at 4˚C and then resuspended in RM buffer at a con-
centration of ∼4 mg/ul. The nano-APC were stored at 280˚C until use.
Assembly of peptides with MHC molecules on nano-APC
The nano-APC in RMbuffer were first processed by a freeze-thaw procedure
(three cycles of 30 s in liquid nitrogen, followed by 5 min at 37˚C) three
times. For assembly of MHC I, the nano-APC were mixed with peptides at
1 mM concentration and human b2-microglobulin (5 mg/ml; M4890; Sigma-
Aldrich) under acidic conditions (0.26 M citric acid, 132 mM Na2HPO4,
2% BSA [pH 3]). The mixture was incubated for 5 min on ice, followed by
neutralization with 1 M Tris buffer (pH 7.5). The neutralized mixtures were
incubated for 30 min at 37˚C. Free peptides and reaction buffers were then
removed by washing through Amicon Ultra centrifugal filters with a cutoff
size of 3000 kDa (Millipore Amicon Ultra centrifugal filters). The loaded
nano-APC were resuspended in RM buffer at a 2 mg/ml concentration. For
MHC II loading, after the freeze-thaw process, the microsomes in RM
buffer were mixed with an equal volume of acidic buffer (0.26 M citric
acid, 132 mM Na2HPO4, 2% BSA [pH 3]) containing peptide at 1 mM
concentration or as indicated for 30 min at 37˚C. After loading, free
peptides were removed by washing through Amicon Ultra centrifugal fil-
ters. The assembled nano-APC were resuspended in RM buffer at 2 mg/ml.
Human study
Experimental subjects. Five CMV serum-converted healthy donors and 57
chronic HBV patients participated in this study. All subjects were HLA-A2
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positive. Informed consent was obtained, and the study was approved by the
local ethics committees at the twoparticipating clinics (EastLondon andCity
Research Ethics Committee for Barts and The London National Health
Service Trust, and Huashan Hospital Ethics Committee, Shanghai, China).
Of 57 chronic HBV patients, 47.4% were positive for hepatitis B e Ag
(HBeAg), whereas 18 had raised alanine aminotransferase (.50 IU/l) and
high HBVDNA (.106 IU/ml), as quantified by real-time PCR assay. Thirty-
one patients were HBeAg negative and positive for serum anti-hepatitis B e
Ab. All patients were negative for Abs to HCV, HIV-1, and HIV-2.
Isolation of PBMCs and in vitro stimulation. PBMCs were isolated from
fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation
and resuspended in RPMI 1640 containing 10% heat-inactivated FBS
(Invitrogen). For some experiments, CD8-positive T cells were isolated with
anti-CD8–coated beads (Miltenyi Biotec). A total of 5 3 105/well PBMC
or CD8+ cells in 24-well plates was cocultured either with antigenic
peptide at a concentration of 5 mM (the same concentration used for as-
sembling MHC I on nano-APC) or 10 mg nano-APC for 5 d. Cells were
cultured with PBS, or anti-CD3–coated beads served as negative or posi-
tive controls. After 5 d, 20 nM PMA and ionomycin (Sigma-Aldrich) were
added together with GolgiStop (BD Biosciences) and cultured for 3 h.
Cells were then harvested and washed with cold PBS. After washing, cells
were first stained with surface markers, and then washed with PBS and
fixed for intracellular staining with selected Abs or isotype controls using
an intracellular staining kit (BD Biosciences), according to the manu-
facturer’s instructions. The stained cells were washed with PBS, and then
analyzed on a Canto II flow cytometry. The data were analyzed using
FlowJo (Tree Star).
Interaction of nano-APC and T cells, and in vivo distribution of
nano-APC in lymph nodes
The interaction between nano-APC and OTI cells was visualized by in-
cubation of 10 mg SIINFEKL–Kb–nano-APC or Kb–nano-APC, prepared
from CFSE-labeled DC2.4 cells, with 106 OTI cells in normal medium for
15 min. Free nano-APC were removed by low-speed centrifugation at 1000
3 g for 5 min and washing with cold PBC. Cells were then stained with
anti-CD3 Ab, followed by DAPI counterstaining. The samples were ana-
lyzed by confocal microscopy (ZEISS LSM 510).
For analysis of the distribution of nano-APC in lymph nodes, nano-APC
were prepared from CFSE-labeled mouse DC2.4 cells. An aliquot of 20 mg
peptide-loaded nano-APC or FITC-labeled dextran was injected into
C57BL/6 mice i.v. After 48 h, lymph nodes were isolated and processed to
single-cell suspensions. The samples were centrifuged at 1000 3 g for 5
min, and the pellet containing the cellular fraction was collected. Cell-free
particles were recovered from the supernatant by centrifugation through
a microfilter with a cutoff size of 3000 kDa (Millipore Amicon Ultra
centrifugal filters), which can recover both nano-APC and dextran. The
cellular and cell-free particles were stained with PE-labeled CD11c as
a DC marker and analyzed by FACS.
Statistics
Statistical comparisons were performed using the Student t test; unless
otherwise noted, data were presented as the means 6 SD of pooled data
from four to six independent experiments.
Results
IL-2–nano-APC
To reverse the impairment in viral-specific T cell function induced
by virus persistence (4), we developed IL-2–nano-APC with the
aim to deliver high doses of peptide MHC (pMHC), IL-2, and
costimulatory molecules directly to Ag-specific T cells. We se-
lected the HLA-I–deficient human B cell line 721.221 (18) as seed
cells for the nano-APC. The 721.221 cells express high levels of
costimulatory molecules (Fig. 1A) and HLA-DR and DP mole-
cules (18). We engineered ER-retained HLA-I alleles (in this
study, HLA-A2 was used) and IL-2 by transfecting HLA-A2–ER
retention signal, a 16-aa–long fragment from the C-terminal end
of E19 3K protein (21), and IL-2-tapasin, an ER-retained mem-
brane protein (20, 22), fusion constructs into the 721.221 cells.
The 16-aa ER-retention signal from E19 3K and tapasin effec-
tively retained the HLA-A2 and IL-2 fusion proteins in the ER
membranes, as shown by the ER-staining pattern with anti-A2 and
anti–IL-2 Abs (Fig. 1B). The engineered HLA-A2 and IL-2 did
not alter the expression of costimulatory molecules (data not
shown). The HLA-A2– and IL-2–expressing 721.221 cells were
used for preparation of nano-APC (IL-2–A2–nano-APC), as de-
scribed in Materials and Methods. The IL-2–A2–nano-APC were
of a largely homogenous size, ∼500 nm, and contained high levels
of HLA-A2, IL-2, and costimulatory molecules (Fig. 1B, 1C). The
IL-2–tapasin fusion protein retained IL-2 bioactivity, as demon-
strated by the proliferation of the IL-2–dependent CTLL4 cell line
in response to IL-2–A2–nano-APC (Fig. 2A). The pharmacologi-
cal activity of IL-2 on nano-APC was ∼2 IU/mg nano-APC (Fig.
2A). The activity of IL-2 on IL-2–A2–nano-APC was effectively
neutralized by IL-2–neutralizing Ab (Fig. 2B). Although the ac-
tivity is about 50 times lower than the ∼100 IU/1 mg rIL-2, the
IL-2 on nano-APC is immobilized, which may create an enriched
microenvironment for T cells that are specifically interacting
with nano-APC. This strategy can be applied to other cytokines or
bioactive proteins depending on the therapeutic aim. Previously,
we have demonstrated that ER membranes derived from APC
contain peptide-receptive MHC I and abundant costimulatory mol-
ecules, which can assemble with antigenic peptides and induce
protective immune responses (23). Consistent with this, the A2
molecules on IL-2–A2–nano-APC effectively assembled with A2-
binding peptides (Fig. 1D), as shown by reduced binding of known
A2 peptide MP58–64 to IL-2–A2–nano-APC after incubation to-
gether with CMVnlv peptide in a competition assay. We have also
developed a method for loading MHC II Ags onto purified ER
vesicles to assemble pMHC II (24). Analysis of the assembly of
HLA-DR molecules with peptide showed that HLA-DR–binding
peptides could effectively assemble with DR under acidic con-
ditions (Fig. 1E). Because MHC II molecules are much more
promiscuous than MHC I molecules in terms of selection of their
antigenic peptides, as most of the DR-associated peptides can also
bind to DP to certain degrees (27), we used the endogenous HLA-
DR and DP molecules from seed cells to assemble antigenic
pMHC class II complexes for activation of effector CD4 Th cells.
Thus, at a size of ∼500 nm, the IL-2–nano-APC are designed to
deliver pMHC, IL-2, and costimulatory molecules to T cells.
The IL-2 on IL-2–nano-APC enhances activation of
Ag-responding T cells, but does not affect bystander T cells
The IL-2–nano-APC are designed to deliver IL-2, Ag, and co-
stimulatory molecules to Ag-specific T cells. To investigate
whether the IL-2 on nano-APC can affect both Ag-specific and
bystander T cells, A2–nano-APC and IL-2–A2–nano-APC were
assembled with CMVnlv peptide to generate CMVnlvA2–nano-
APC and IL-2–CMVnlvA2–nano-APC, which were used to stim-
ulate CD8 T cells isolated from peripheral lymphocytes of CMV-
seropositive and HLA-A2–positive healthy donors. In contrast
to treatment with free 1 mM CMVnlv peptide, which induced low
CD8 T cell response, CMVnlvA2–nano-APC could induce de-
tectable Ag-specific CD8 responses (Fig. 3A). However, IL-2–
CMVnlvA2–nano-APC induced far stronger CD8 T cell responses
(Fig. 3A). These enhanced CD8 responses induced by IL-2–
CMVnlvA2–nano-APC could be effectively neutralized by anti–
IL-2 Ab (Fig. 3B). Although we analyzed IFN-g–producing
T cells after a 3-h restimulation with PMA and ionomycin, in the
absence of antigenic peptide, IL-2–A2–nano-APC did not induce
a T cell response, suggesting that the IFN-g–producing cells were
Ag-responding T cells (Fig. 3A). To further confirm the Ag-
dependent effect of IL-2, the IFN-g–producing cells were quan-
tified in CMVnlvtetramer
+CD8+ cells in PBMC after stimulation.
Consistently, an enhanced response of Ag-specific CD8 T cells
was detected specifically after stimulation with IL-2–CMVnlvA2–
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nano-APC (Fig. 3C). We compared Ag-specific responses of CD8
T cells induced by IL-2–CMVnlvA2–nano-APC and CMVnlvA2–
nano-APC plus 20 IU/ml soluble IL-2. Although soluble IL-2 did
increase IFN-g–producing CD8 T cells, most of the IFN-g–pro-
ducing CD8 T cells in PBMC stimulated by CMVnlvA2–nano-
APC and soluble IL-2 were CMVnlvA2-tetramer negative (Fig.
3D). In contrast, IL-2–CMVnlvA2–nano-APC effectively induced
responses of CMVnlv-specific CD8 T cells (Fig. 3D). These results
demonstrate that the overall dose of IL-2 delivered by IL-2–
CMVnlvA2–nano-APC is not sufficient for a pharmacological ef-
fect on bystander T cells. We found that in the absence of Ag,
a minimum of 50 IU/ml IL-2 is required to induce any detectable
T cell response (data not shown), whereas the IL-2 dose equiva-
lent of 10 mg/ml IL-2–CMVnlvA2–nano-APC is ∼10 IU/ml. It is
known that IL-2 upregulates expression of CD25, the IL-2Ra
chain that is required for assembly of the high-affinity IL-2R
needed for IL-2 to induce T cell activation (28) on preactivated
T cells (28). Indeed, in addition to induction of high levels of CD8
T cell responses, IL-2–CMVnlvA2–nano-APC also induced CD25
expression on CMVnlvtetramer
+CD8+ T cells (Fig. 3E). IL-2 is
also important for the maintenance and expansion of CD4+CD25+
Foxp3+Treg cells (28). However, we did not observe an increase in
the proportion of Foxp3+CD4+Treg cells in PBMCs after stimu-
lation with IL-2–A2–nano-APC (data not shown). These findings
suggest that nano-APC can selectively deliver IL-2, together with
pMHC and costimulatory molecules, to Ag-specific T cells.
IL-2–A2–nano-APC induce strong CD8 T cell responses in
peripheral lymphocytes from chronic HBV patients
Functional impairment of virus-specific T cells due to persistent
viral Ags is one of the important mechanisms leading to, and
maintaining, chronic HBV infection (3, 10). We previously found
that IL-2 can effectively reverse tolerance induced by Ag per-
sistence (13). T cells from chronic HBV patients show reduced
production of IL-2 in response to TCR ligation (4, 10), which is
consistent with the defective induction of IL-2 in T cells ren-
dered tolerant by persistent Ag stimulation (13). To investigate
whether IL-2–A2–nano-APC can enhance responses of virus-
specific CD8 T cells from chronic HBV patients, we developed
HBV-specific IL-2–HBVA2–nano-APC by assembling a pool
of five HBV peptides, which have been found to induce HBV-
specific CD8 T cell responses in A2-positive HBV patients
(10), with the A2 molecules on the IL-2–A2–nano-APC. We
found that the five HBV peptides had similar binding affinities
for A2, as measured by competition assays with a known A2-
binding peptide: a modified influenza MP peptide YILGKVFTL
(26) (Fig. 4A). Therefore, a pool containing equal amounts (5
mM) of each peptide was used for assembly of IL-2–HBVA2–
nano-APC and HBVA2–nano-APC. Peripheral lymphocytes from
57 HLA-A2–positive chronic HBV patients, with viral loads rang-
ing from 3 3 103 to 1013 IU/ml (Table I), were used to investi-
gate CD8 T cell responses. We detected low CD8 T cell responses,
FIGURE 2. Bioactivity of IL-2 on IL-2–A2–
nano-APC. The bioactivity of IL-2 was measured
by stimulation of the IL-2–dependent CTLL4 cell
line. A2–nano-APC and human rIL-2 served as
negative and positive control, respectively. A,
Dose-dependent induction of CTLL4 proliferation
by IL-2–A2–nano-APC. B, The activity of IL-2 on
IL-2–A2–nano-APC can be neutralized by anti–
IL-2 Ab.
FIGURE 1. Characterization of IL-2–A2–nano-APC assembled with MHC I and II peptides. A, 721.221 seed cells express the costimulatory molecules
CD80 and ICMA1. B, IL-2-A2-721.221 cells and IL-2–A2–nano-APC were stained with anti–IL-2 (red) and A2 (green). Nuclei were visualized by DAPI
counterstaining. C, Costimulatory molecules CD80 and ICMA-1 on IL-2–A2–nano-APC. D, Binding of A2-associated peptides. Binding of MP58–64 and
CMVnlv peptides to A2 in IL-2–A2–nano-APC was measured by competing with
125I-labeled MP58–64 peptides at the same 20 nM concentration. HBV Env
180–195 AGFFLLTRILTIPQS peptide served as control. E, Assembly of HLA-DR with HBV Env 180–195 AGFFLLTRILTIPQS on IL-2–A2–nano-APC.
Binding of HBV Env 180–195 to IL-2–A2–nano-APC was measured under different pH. Binding was measured by detection of FITC-labeled HBV Env 180–
195 on IL-2–A2–nano-APC after removal of excess peptides at the end of the binding reaction. PBS and addition of unlabeled peptide as controllers.
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as measured by the proportion of IFN-g–producing CD8 T cells,
after incubation with the pool of the five HBV peptides (Fig. 4B).
The HBVA2–nano-APC induced better responses in ∼50% of
patients (Fig. 4B, 4C, Supplemental Fig. 1, Supplemental Tables
1, 2). However, IL-2–HBVA2–nano-APC induced the strongest
responses, with lymphocytes from most patients showing a strong
CD8 T cell response (Fig. 4B, 4C, Supplemental Tables 1, 2).
The increased responses by IL-2–HBVA2–nano-APC were not
significantly related to viral load, HBVeAg, age, and sex (Sup-
plemental Tables 1, 2), suggesting that IL-2–HBVA2–nano-APC
improved effector function of viral-specific T cells rather than
induced immune responses of naive T cells. Consistently, IL-2–
A2–nano-APC, in the absence of antigenic peptide, did not in-
duce IFN-g production by CD8 T cells in any of the patient
samples (Fig. 4B). Furthermore, we could not detect an increase
in the proportion of Foxp3+CD4+ cells after stimulation with IL-
2–HBVA2–nano-APC or IL-2–A2–nano-APC (data not shown).
Thus, taken together with the induction of CMVnlv-specific CD8
T cell responses, we have demonstrated that the addition of IL-2
into nano-APC effectively enhanced the response of Ag-
responding T cells, which may be essential to overcome virus-
induced T cell tolerance and the tolerogenic environment in
chronic HBV patients.
IL-2–HBVA2–nano-APC improve TCR signaling and suppress
the expression of PD-1 on HBV-responding CD8 T cells from
chronic HBV patients
Evidence of T cell exhaustion has been found in both virus-specific
and nonspecific CD8 T cells in chronic HBV patients (3, 10).
Exhaustion induced by persistent antigenic stimulation effec-
tively increases the threshold for TCR activation in response to
Ag stimulation by suppressing TCR-proximal signaling pathways
(12, 13). In addition, expression of PD-1, an inhibitory costim-
ulatory molecule, was increased in CD8 T cells from chronic
HBV, HCV, and HIV patients (5, 29). To investigate whether
the enhanced CD8 T cell responses induced by IL-2–HBVA2–
nano-APC resulted from improved TCR signaling and/or reduced
expression of PD-1, we examined activation of ERK, which is
repressed in tolerant T cells (13), and the expression of PD-1
on IFN-g–producing CD8 T cells induced by either HBVA2–
nano-APC or IL-2–HBVA2–nano-APC. The results demonstrated
that the levels of ERK activation were enhanced in responding
CD8 T cells from chronic HBV patients stimulated with IL-2–
HBVA2–nano-APC compared with those stimulated by HBVA2–
nano-APC (Fig. 5), suggesting that IL-2 can antagonize T cell
tolerance by enhancing TCR-proximal signals. In addition to
increased TCR signaling, the expression of PD-1 was reduced on
IFN-g–producing CD8 T cells induced by IL-2–HBVA2–nano-
APC compared with those stimulated by HBVA2–nano-APC (Fig.
5). Although the cells were restimulated with PMA and iono-
mycin for 3 h before analysis, a similar level of pERK and PD-1
in IFN-g–negative T cells suggests that IL-2–HBVA2–nano-APC
improves TCR signaling and represses PD-1 expression on Ag-
responding T cells compared with HBVA2–nano-APC. These re-
sults suggest that IL-2 on nano-APC reduces the TCR activation
threshold and the expression of negative regulators in viral-
responding CD8 T cells, two important factors needed to over-
come T cell tolerance.
FIGURE 3. IL-2–nano-APC enhances the responses of Ag-responding CD8 T cells. A, PBMCs from three A2-positive and CMV-seropositive donors (A–
C) were incubated with 1 mM CMVnlv peptide, 10 mg/ml IL-2–CMVnlvA2–nano-APC, 10 mg/ml CMVnlvA2–nano-APC, or 10 mg/ml IL-2–A2–nano-APC
for 5 d. After restimulation with PMA and ionomycin for 3 h, cells were stained with anti-CD8 and anti–IFN-g. IFN-g–producing cells were measured after
gating on CD8 cells. B, Part of PBMC from donor C was incubated with 10 mg/ml IL-2–CMVnlvA2–nano-APC in the presence of IL-2 neutralization Ab. C,
PBMCs from donors A and C were incubated with 10 mg/ml CMVnlvA2–nano-APC, IL-2–CMVnlvA2–nano-APC, or IL-2–A2–nano-APC for 5 d. After
restimulation with PMA and ionomycin for 3 h, cells were stained with anti-CD8, anti–IFN-g, CD19, and CMVnlvpentamer. IFN-g–producing cells were
measured after gating on CMVnlvpentamer
+CD8+CD192 cells. D, PBMCs of donor A were stimulated either with 10 mg/ml IL-2–CMVnlvA2–nano-APC
for 5 d or with 20 IU/ml IL-2 and 10 mg/ml CMVnlvA2–nano-APC for 3 d, and then restimulated with same doses of IL-2 for another 2 d. IFN-g–producing
and CMVnlvpentamer-positive cells were quantified on gated CD8 cells. E, PBMCs of donors A and C were stimulated with 10 mg/ml CMVnlvA2–nano-
APC, IL-2–CMVnlvA2–nano-APC, or IL-2–A2–nano-APC for 3 d. CD25
+ cells were quantified after gating on CMVnlvpentamer
+CD8+CD192 cells.
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IL-2–nano-APC increase CD4 T cell responses to viral Ags,
leading to stronger CD8 T cell responses
Like CD8 T cells, virus-specific CD4 T cells are functionally
defective in chronic HBV patients (4), consistent with our finding
that persistent antigenic stimulation can effectively induce CD4
T cell tolerance. It has been reported that CD4 helper function is
essential for the development and maintenance of CD8 T cell
effector function (30). Previously, we have demonstrated that
MHC II molecules in isolated ER vesicles can assemble with
antigenic peptides under acidic conditions (23). The 721.221 cells
are deficient in MHC I, but still express HLA-DR and DP mole-
cules (18). Three HBV peptides reported to bind to DR and/or DP
(24) were analyzed for their ability to assemble with nano-APC
from A2-721.221 and IL-2-A2-721.221 cells. Consistent with
previous findings (24), specific binding of all three peptides to
nano-APC was detected under acidic conditions (Fig. 6A). A pool
of the three peptides was assembled with DR and/or DP mole-
cules on either nano-APC or IL-2–nano-APC to create HBVDR/
DP–nano-APC or IL-2–HBVDR/DP–nano-APC, respectively.
Peptide alone did not induce IFN-g–producing CD4 T cells in
peripheral lymphocyte populations isolated from chronic HBV
patients (Fig. 6B, Supplemental Table 3). HBVDR/DP–nano-APC
induced a weak response in a few patient samples (Fig. 6B),
whereas significant CD4 T cell responses were induced in .50%
of patient samples treated with IL-2–HBVDR/DP–nano-APC (Fig.
6B, Supplemental Table 3). Again, we did not find an increased
proportion of Foxp3+CD4+ T cells in peripheral lymphocytes
from chronic HBV patients after culture with IL-2–HBVDR/
DP–nano-APC (data not shown). To investigate whether the in-
duced Th1 CD4 responses can enhance viral Ag-responding CD8
T cell responses, patient lymphocytes were stimulated with both
IL-2–HBVDR/DP–nano-APC and IL-2–HBVA2–nano-APC. The
results showed that the induction of Th1 CD4 T cells increased the
proportion of IFN-g–producing CD8 T cells in response to IL-2–
HBVA2–nano-APC (Fig. 6C), suggesting that CD4 responses are
indeed important for the expansion of effector CD8 T cells.
Therefore, the presence of IL-2 on nano-APC is important to drive
optimal CD4 and CD8 T cell responses against HBV in lympho-
cytes from chronic HBV patients.
nano-APC form stable interactions with Ag-specific T cells as
part of immune synapses
nano-APC are designed to directly deliver Ag, costimulatory, and
cytokine signals to Ag-specific T cells. Therefore, a sustained in-
teraction between nano-APC and Ag-specific T cells is essential for
the T cells to engage IL-2, or other engineered cytokines, effectively.
Previously, we have shown that ER vesicles containing pMHC
molecules, generated by assembly of the MHC on the vesicles with
FIGURE 4. HBV-specific CD8 T cell responses were induced by delivering IL-2 to viral-specific T cells. A, Five HBV peptides reported to induce HLA-
A2–restricted CD8 T cell responses in HBV patients (7) were analyzed for their ability to bind to HLA-A2 on IL-2–A2–nano-APC by a competition assay.
Different concentration of these peptides was used in a competition assay with a 125I-labeled A2-reporter MP peptide, and the percentage of reporter peptide
that failed to bind to A2 was measured. Due to their similar binding affinities, these five peptides were pooled at a concentration of 1 mM each, and used to
assemble HBVA2–nano-APC or IL-2–HBVA2–nano-APC. B, PBMCs from chronic HBV patients were incubated with the pool of five HBV peptides at
concentration of 1 mM each or 10 mg/ml IL-2–HBVA2–nano-APC, 10 mg/ml HBVA2–nano-APC, or IL-2–A2–nano-APC for 5 d. After restimulation with
PMA and ionomycin for 3 h, IFN-g–producing CD8 T cells were quantified after gating on CD8 cells. C, Percentages of IFN-g–producing CD8 T cells
induced in 57 A2-positive chronic HBV patients. The CD8 T cell responses induced by IL-2–HBVA2–nano-APC or HBVA2–nano-APC for each patient
were summarized in Supplemental Table 1.
Table I. Clinical characteristics of chronic HBV patients
Overall HBV
Queen Mary University
of London Shanghai
Number 57 20 37
Median age (range) 36 (17–69) 40 (17–69) 33 (18–52)
Sex (M:F ratio) % male (42:15) 73.7 (13:7) 65 (29:8) 78.4
Viral load (log; range) 6.35 (3.27–9.96) 5.94 (3.27–9.96) 6.57 (4.31–9.13)
Median alanine aminotransferase
(IU/l; range)
120.2 (20–430) 81.7 (30–211) 141 (20–430)
HBeAg status (% positive) 47.4 25 59.5
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peptide, can directly activate Ag-specific T cells in vitro (23). To
further investigate whether the interaction of nano-APC and Ag-
specific T cells can induce membrane clustering to form stable
immune synapses (31), we examined the interaction of nano-APC,
prepared from the murine DC cell line DC2.4 and assembled with
peptide to form SIINFEKL–Kb complexes, with SIINFEKL-Kb–
specific OTI T cells (23). An Ag-dependent interaction between
nano-APC and T cells induced changes in the TCR distribution on
the T cell membrane, leading to clustering of TCR complexes with
nano-APC to form synapses (Fig. 7A). The process resembles the
membrane processing observed at the contact point between live
DC and T cells (31). The nano-APC–associated synapses can
facilitate the recruitment of IL-2R into complexes with the T cell-
bound IL-2–nano-APC, thus bringing the IL-2R into lipid rafts,
which can sustain IL-2 activation in effector T cells (32). Thus,
nano-APC can fully substitute for live DC, inducing T cell acti-
vation and the formation of immune synapses; this creates a
stimulatory microenvironment allowing engagement of pMHC,
costimulatory molecules, and engineered bioadjuvants with their
respective receptors on Ag-specific T cells.
nano-APC are not endocytosed by DC in peripheral lymphoid
organs
Most reported nano-delivery systems for therapeutic vaccines rely
on endogenous DC in patients to process and present Ags to T cells
(33). However, the nano-APC, functionally equivalent to live DC,
act directly on Ag-specific T cells in vivo (23). Accumulation of
a pharmacokinetic dose of free nano-APC in DC-rich organs such
as lymph nodes and liver will be important to effectively induce
activation of Ag-specific T cells. Previously, we found that ER
membrane vesicles prepared from DC accumulated in the pe-
ripheral lymphoid organs and were not endocytosed by DC in vitro
(23). However, whether the nano-APC are endocytosed by DC in
lymphoid organs is not known. To investigate whether nano-APC
remain in lymphoid organs as free nano-particles, nano-APC pre-
pared from murine DC2.4 cells were labeled with fluorescence
FIGURE 5. Enhanced TCR signaling and reduced
expression of PD-1 on HBV-specific CD8 T cells.
PBMCs from three chronic HBV patients, which
showed weak responses to HBVA2–nano-APC, but
strong responses to IL-2–HBVA2–nano-APC, were
incubated with 10mg/ml IL-2–HBVA2–nano-APC or
HBVA2–nano-APC for 5 d. After restimulation with
PMA and ionomycin for 3 h, cells were stained with
anti-CD8, anti–IFN-g, anti–PD-1, and anti–phospho-
ERK. IFN-g–positive or IFN-g–negative CD8 T cells
were gated for analysis of PD-1 expression or ERK
phosphorylation.
FIGURE 6. CD4 Th function is important for the responses of HBV-specific CD8 T cells. A, Three HBV peptides reported to bind to DR and/or DP and
induce CD4 T cell responses in HBV patients (25) were examined for their ability to interact with DR and/or DP on nano-APC. A total of 100 nM of these
FITC-labeled peptides was incubated with 10 mg IL-2–A2–nano-APC under different pH. After removal of unbound peptides, binding to nano-APC was
assessed by flow cytometry. The specificity of binding was measured by addition of unlabeled peptide at a concentration of 500 nm. These three peptides
were pooled at 1 mM each used to assemble with DR and/or DP on nano-APC. B, Induction of IFN-g–producing CD4 T cells in PBMCs from chronic HBV
patients. PBMCs from indicated patients were incubated with 10 mg/ml IL-2–HBVDR/DP–nano-APC, HBVDR/DP–nano-APC, or IL-2–A2–nano-APC for
5 d. After restimulation with PMA and ionomycin for 3 h, IFN-g–producing CD4 T cells were quantified after gating CD4 cells. C, PBMCs from chronic
HBV patient were incubated with 20 mg/ml IL-2–HBVA2–nano-APC or 10 mg/ml IL-2–HBVA2–nano-APC and 10 mg/ml IL-2–HBVDR/DP–nano-APC
for 5 d. After restimulation with PMA and ionomycin, IFN-g–producing CD4 or CD8 cells were quantified after gating on CD4 or CD8 cells. The presented
data are from patient Q1 (Supplemental Table 1).
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and injected i.v. into B6 mice. After 48 h, the lymph nodes were
isolated and separated into cellular and cell-free fractions. The
cell-free fragments and DC from the lymph nodes were examined
for the presence of free and endocytosed nano-APC. In contrast to
the efficient endocytosis of dextran by DC in lymph nodes, the
nano-APC that accumulated in the lymph nodes remained as free
particles (Fig. 7B). To exclude the possibility that DC activation
is required for phagocytosis of the ER membrane vesicles, we
infected mice with a vaccinia virus to induce DC activation
5 d before injection of nano-APC. Similar levels of free nano-APC
were detected in lymph node samples from mice pretreated with
vaccinia and mice that had not received pretreatment (Fig. 7C),
indicating that the intracellular membrane vesicles from APC
were not effectively endocytosed by DC even with a concomitant
viral infection. The lack of endocytosis of nano-APC may be due
to failure of pattern recognition receptors, which enable the DC
to discriminate between normal physiological components and
pathological particles in vivo (34), to recognize the nano-APC.
Discussion
T cells are essential for the clearance of HBV postinfection (30).
Like most chronic viral infections, persistent HBV infection re-
sults in functional defects in virus-specific T cells largely due to
immune tolerance (unresponsiveness) induced by continual stim-
ulation by viral Ags and the tolerogenic environment induced by
HBV (4). The unresponsiveness of virus-specific T cells results
from downregulation of TCR signaling pathways and upregulation
of suppressive molecules such as PD-1 (5), tolerogenic mecha-
nisms common to many tolerance models induced by persistent
antigenic stimulation (12, 13). Although IL-2 is an important
cytokine in modulation for effective function of T cells and it is
required for the expansion of effector T cells and effector function
of memory T cells (28), application of IL-2 as a bioadjuvant
for immunotherapy is hampered by organ pathology induced by
therapeutic doses and the expansion of Treg cells, leading to the
suppression of effector T cells (28). By immobilizing IL-2 on
membrane nano-particles prepared from bioengineered APC, we
have shown that IL-2–nano-APC can potently induce effector
functions in virus-responding T cells, by providing an immuno-
stimulatory microenvironment to Ag-specific T cells and delivering
IL-2 to Ag-responding T cells, without the activation of bystander
T cells or organ pathology. The impaired T cell function in chronic
HBV infection resembles, in many respects, T cell tolerance in-
duced by Ag persistence (4, 12, 13). Indeed, studies have shown
that the proximal TCR signaling molecule CD3z is downregulated,
whereas the expression of the inhibitory molecule PD-1 is up-
regulated in CD8 T cells from chronic HBV patients (10). IL-2
on nano-APC is able to enhance TCR-proximal signaling and
downregulates PD-1 expression on virus-responding CD8 T cells
from chronic HBV patients, which could effectively reverse tol-
erance, as demonstrated by induction of IFN-g–producing CD8
T cells in lymphocytes from chronic HBV patients. In addition to
TCR signaling, MAPK activation can directly result from IL-2R
signaling (28). It has been found that the activation of MAPK and
PI3K through Shc recruited by the IL-2R is independent on STAT5
signaling in effector T cells, which differs from that in Treg cells,
and is important for the expansion of activated CD8 T cells (35).
We have demonstrated that nano-APC can induce CD25 expres-
sion and immune synapse formation, which not only execute the
function to induce T cell activation, but also bring engineered
bioadjuvant such as IL-2 stably into signalsomes of effector T cells
(36). The increased expression of CD25 on CMVAg-specific CD8
T cells by IL-2–CMVnlvA2–nano-APC is consistent with the well-
known observation that IL-2 can induce CD25 expression on
preactivated CD8 T cells. Thus, together with pMHC and co-
stimulatory molecules, the selective delivery of IL-2 is important
to induce activation of HBV-responding T cells from chronic HBV
patients. As the overall pharmacological dose remains low, the
IL-2–nano-APC do not activate Treg cells, indicating that this
approach can be adapted for use with other bioadjuvants.
Expression of PD-1 is low in memory CD8 T cells, but it is
upregulated in chronic viral infections; this leads to defects in
proliferation and production of effector cytokines, which facilitate
viral persistence (37). The enhancement of HBV-Ag–dependent
CD8 T cell effector function by IL-2–HBVA2–nano-APC was
associated with downregulation of PD-1, suggesting that the ex-
pression of PD-1 on T cells may be associated with impaired
function of those T cells. Indeed, PD-1 expression correlates with
FIGURE 7. Nano-APC induce immune synapse formation on Ag-specific T cells and remain as free particles in lymphoid organs in vivo. A, Kb–nano-
APC, prepared from murine DC2.4 cells, were labeled with FITC and assembled with or without SIINFEKL peptides. SIINFEKL-Kb–specific OTI CD8
T cells were incubated with SIINFEKL–Kb–nano-APC or Kb–nano-APC for 30 min. After removal of unbound nano-APC, cells were stained with anti-
CD3 Ab, counterstained with DAPI, and assessed for immune synapse formation by confocal microscopy. B, FITC-labeled dextran or DC2.4-derived nano-
APC was injected i.v. at 1 mg/kg to C57BL/6 mice. Forty-eight hours postinjection, lymph nodes were isolated and separated into cellular and cell-free
fractions. Both fractions were stained with anti-CD11c and then analyzed by flow cytometry. C, C57BL/6 mice were infected with vaccinia virus at dose of
2 3 105 PFU. Five days postinfection, FITC-labeled dextran or DC2.4-derived nano-APC were injected i.v. at 1 mg/kg. Forty-eight hours postinjection,
lymph nodes were isolated and the cell-free fraction was stained with anti-CD11c and analyzed by flow cytometry.
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viral load, declining CD4 count, and impaired function of CD8
T cells in HIV infection, and with CD8 T cell exhaustion in
chronic HCV infection (37).
The function of CD4 T cells is essential for an effective and long
lasting antiviral CD8 response and viral clearance (30). Persistent
viral infection can also induce CD4T cell tolerance viamechanisms
similar to those that induce CD8T cell tolerance (13).We found that
IL-2–HBVDR/DP–nano-APC induced strong CD4 T cell respon-
ses, which further enhanced the response of HBV-responding CD8
T cells to IL-2–HBVA2–nano-APC, in lymphocytes from chronic
HBV patients. However, in all the cases analyzed, the proportion
of CD4 cells that responded was lower than the proportion of
responding CD8 cells. This may be due to the fact that CD8 T cells
are more sensitive to IL-2 than CD4 T cells (28). Other possible
reasons are that the level of MHC II molecules expressed on nano-
APC prepared from 721.221 seed cells is lower than the level of
HLA-A2 (18) or that the pMHC II complexes, generated by as-
sembly with the selected HBV peptides, are not optimal for induc-
tion ofCD4T cell responses.We have developed effective screening
methods to define the binding affinity of peptides to MHC I or II
on nano-APC, which can be used to select optimal viral antigenic
peptides from viral peptide databases (23).
Nano-particles prepared from synthetic materials or genetically
engineered microbes have been used to deliver Ags to DC for in-
duction of antiviral or anticancer immune responses (33). In contrast
to these particles, nano-APC are prepared from the ER membranes
of bioengineered APC. Therefore, they are not only more biocom-
patible than synthetic nano-particles or microbars, but also deliver
therapeutic molecules that are physiologically synthesized by APC
seed cells. Thus, the IL-2 on IL-2–nano-APC is more stable than
free IL-2 in vivo, and maintains its physiological conformation,
allowing optimal interaction with the IL-2R (data not shown). Un-
like other nano-particle–based vaccines, nano-APC directly acti-
vate T cells. The nano-APC mimic live DC to induce lipid raft
clustering on T cells and formation of an immunological synapse,
which is essential for T cell activation. Furthermore, using HLA-
I–negative 721.221 cells as seed cells allows us to specifically
express selected HLA alleles, allowing construction of HLA allele-
matched nano-APC for individual patient populations.
Previously, we observed nano-APC homing to T cell areas of
peripheral lymphoid organs, largely due to the expression of
homing receptors by the cells from which the nano-APC are de-
rived (23). We have now further demonstrated that nano-APC are
not effectively endocytosed by DC in vivo, which is important, as
it allows the nano-APC to remain as free particles in peripheral
lymphoid organs. The absence of endocytosis may be due to the
lack of molecules on nano-APC recognized by DC pattern rec-
ognition molecules (34).
In chronic HBV infection, T cells are continuously confronted
with moderate to high levels of viral Ags (4), which, in combi-
nation with the induced immunosuppressive microenvironment
resulting from high viral load and dysregulated immune responses,
lead to the downregulation of T cell activation and, subsequently,
reduction of effector function (4). Therefore, one of the major
challenges for immunotherapy against chronic infectious diseases,
such as HBV, is the development of delivery vehicles targeting
Ag-specific T cells that provide not only Ag, but also designed
bioadjuvant(s) that can restore effector function. Our results
demonstrate that the ability to deliver bioadjuvant, as well as
pMHC, to virus-specific T cells, to generate specific nano-APC for
each individual HLA-shared patient group, and to directly activate
Ag-specific T cells are advantages of nano-APC over current nano-
particles used for immunotherapy of chronic HBV and other
chronic viral infections.
Acknowledgments
We thank Steven Pash (Biological Science, Brunel University) for excellent
technical support.
Disclosures
The authors have no financial conflicts of interest.
References
1. Villa, E., G. Fattovich, A. Mauro, and M. Pasino. 2011. Natural history of chronic
HBV infection: special emphasis on the prognostic implications of the inactive
carrier state versus chronic hepatitis. Dig. Liver Dis. 43(Suppl. 1): S8–S14.
2. Guidotti, L. G., and F. V. Chisari. 2006. Immunobiology and pathogenesis of
viral hepatitis. Annu. Rev. Pathol. 1: 23–61.
3. Maini, M. K., and A. Schurich. 2010. The molecular basis of the failed immune
response in chronic HBV: therapeutic implications. J. Hepatol. 52: 616–619.
4. Frebel, H., K. Richter, and A. Oxenius. 2010. How chronic viral infections
impact on antigen-specific T-cell responses. Eur. J. Immunol. 40: 654–663.
5. Keir, M. E., L. M. Francisco, and A. H. Sharpe. 2007. PD-1 and its ligands in
T-cell immunity. Curr. Opin. Immunol. 19: 309–314.
6. Manigold, T., and V. Racanelli. 2007. T-cell regulation by CD4 regulatory T cells
during hepatitis B and C virus infections: facts and controversies. Lancet Infect.
Dis. 7: 804–813.
7. Wilson, E. B., and D. G. Brooks. 2011. The role of IL-10 in regulating immunity
to persistent viral infections. Curr. Top. Microbiol. Immunol. 350: 39–65.
8. Kim, P. S., and R. Ahmed. 2010. Features of responding T cells in cancer and
chronic infection. Curr. Opin. Immunol. 22: 223–230.
9. Gougeon, M. L., and F. Chiodi. 2010. Impact of gamma-chain cytokines on
T cell homeostasis in HIV-1 infection: therapeutic implications. J. Intern. Med.
267: 502–514.
10. Das, A., M. Hoare, N. Davies, A. R. Lopes, C. Dunn, P. T. Kennedy,
G. Alexander, H. Finney, A. Lawson, F. J. Plunkett, et al. 2008. Functional
skewing of the global CD8 T cell population in chronic hepatitis B virus in-
fection. J. Exp. Med. 205: 2111–2124.
11. Schwartz, R. H. 2003. T cell anergy. Annu. Rev. Immunol. 21: 305–334.
12. O’Neill, E. J., A. Sundstedt, G. Mazza, K. S. Nicolson, M. Ponsford, L. Saurer,
H. Streeter, S. Anderton, and D. C. Wraith. 2004. Natural and induced regulatory
T cells. Ann. N. Y. Acad. Sci. 1029: 180–192.
13. Anderson, P. O., A. Sundstedt, Z. Yazici, S. Minaee, E. J. O’Neill, R. Woolf,
K. Nicolson, N. Whitley, L. Li, S. Li, et al. 2005. IL-2 overcomes the unre-
sponsiveness but fails to reverse the regulatory function of antigen-induced T
regulatory cells. J. Immunol. 174: 310–319.
14. Anderson, P. O., B. A. Manzo, A. Sundstedt, S. Minaee, A. Symonds, S. Khalid,
M. E. Rodriguez-Cabezas, K. Nicolson, S. Li, D. C. Wraith, and P. Wang. 2006.
Persistent antigenic stimulation alters the transcription program in T cells,
resulting in antigen-specific tolerance. Eur. J. Immunol. 36: 1374–1385.
15. Schurich, A., M. Berg, D. Stabenow, J. Bo¨ttcher, M. Kern, H. J. Schild, C. Kurts,
V. Schuette, S. Burgdorf, L. Diehl, et al. 2010. Dynamic regulation of CD8 T cell
tolerance induction by liver sinusoidal endothelial cells. J. Immunol. 184: 4107–
4114.
16. Ha, S. J., E. E. West, K. Araki, K. A. Smith, and R. Ahmed. 2008. Manipulating
both the inhibitory and stimulatory immune system towards the success of
therapeutic vaccination against chronic viral infections. Immunol. Rev. 223: 317–
333.
17. Fearon, D. T. 2007. The expansion and maintenance of antigen-selected CD8(+)
T cell clones. Adv. Immunol. 96: 103–139.
18. Shimizu, Y., and R. Demars. 1989. Production of human cells expressing indi-
vidual transferred HLA-A, -B, -C genes using an HLA-A, -B, -C null human cell
line. J. Immunol. 142: 3320–3328.
19. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and
F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selec-
tion. Cell 76: 17–27.
20. Paulsson, K. M., M. J. Kleijmeer, J. Griffith, M. Jevon, S. Chen, P. O. Anderson,
H. O. Sjogren, S. Li, and P. Wang. 2002. Association of tapasin and COPI
provides a mechanism for the retrograde transport of major histocompatibility
complex (MHC) class I molecules from the Golgi complex to the endoplasmic
reticulum. J. Biol. Chem. 277: 18266–18271.
21. Gabathuler, R., and S. Kvist. 1990. The endoplasmic reticulum retention signal
of the E3/19K protein of adenovirus type 2 consists of three separate amino acid
segments at the carboxy terminus. J. Cell Biol. 111: 1803–1810.
22. Li, S., H. O. Sjo¨gren, U. Hellman, R. F. Pettersson, and P. Wang. 1997. Cloning
and functional characterization of a subunit of the transporter associated with
antigen processing. Proc. Natl. Acad. Sci. USA 94: 8708–8713.
23. Sofra, V., S. Mansour, M. Liu, B. Gao, E. Primpidou, P. Wang, and S. Li. 2009.
Antigen-loaded ER microsomes from APC induce potent immune responses
against viral infection. Eur. J. Immunol. 39: 85–95.
24. Mizukoshi, E., J. Sidney, B. Livingston, M. Ghany, J. H. Hoofnagle, A. Sette,
and B. Rehermann. 2004. Cellular immune responses to the hepatitis B virus
polymerase. J. Immunol. 173: 5863–5871.
25. Crasto, C. J., and J. A. Feng. 2000. LINKER: a program to generate linker
sequences for fusion proteins. Protein Eng. 13: 309–312.
26. Li, S., K. M. Paulsson, S. Chen, H. O. Sjo¨gren, and P. Wang. 2000. Tapasin is
required for efficient peptide binding to transporter associated with antigen
processing. J. Biol. Chem. 275: 1581–1586.
1542 IL-2–nano-APC ENHANCES RESPONSES OF HBV-RESPONDING T CELLS
 o
n
 A
pril 16, 2012
w
w
w
.jimmunol.org
D
ow
nloaded from
 
27. Sadegh-Nasseri, S., S. Natarajan, C. L. Chou, I. Z. Hartman, K. Narayan, and
A. Kim. 2010. Conformational heterogeneity of MHC class II induced upon
binding to different peptides is a key regulator in antigen presentation and epi-
tope selection. Immunol. Res. 47: 56–64.
28. Malek, T. R., and I. Castro. 2010. Interleukin-2 receptor signaling: at the in-
terface between tolerance and immunity. Immunity 33: 153–165.
29. Boni, C., P. Fisicaro, C. Valdatta, B. Amadei, P. Di Vincenzo, T. Giuberti,
D. Laccabue, A. Zerbini, A. Cavalli, G. Missale, et al. 2007. Characterization of
hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J.
Virol. 81: 4215–4225.
30. Yang, P. L., A. Althage, J. Chung, H. Maier, S. Wieland, M. Isogawa, and
F. V. Chisari. 2010. Immune effectors required for hepatitis B virus clearance.
Proc. Natl. Acad. Sci. USA 107: 798–802.
31. Fooksman, D. R., S. Vardhana, G. Vasiliver-Shamis, J. Liese, D. A. Blair,
J. Waite, C. Sacrista´n, G. D. Victora, A. Zanin-Zhorov, and M. L. Dustin. 2010.
Functional anatomy of T cell activation and synapse formation. Annu. Rev.
Immunol. 28: 79–105.
32. Cho, J. H., H. O. Kim, C. D. Surh, and J. Sprent. 2010. T cell receptor-dependent
regulation of lipid rafts controls naive CD8+ T cell homeostasis. Immunity 32:
214–226.
33. Nandedkar, T. D. 2009. Nanovaccines: recent developments in vaccination. J.
Biosci. 34: 995–1003.
34. Geijtenbeek, T. B., S. J. van Vliet, A. Engering, B. A. ’t Hart, and Y. van Kooyk.
2004. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu.
Rev. Immunol. 22: 33–54.
35. Bensinger, S. J., P. T. Walsh, J. Zhang, M. Carroll, R. Parsons, J. C. Rathmell,
C. B. Thompson, M. A. Burchill, M. A. Farrar, and L. A. Turka. 2004. Distinct
IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J. Immunol.
172: 5287–5296.
36. Adachi, K., and M. M. Davis. 2011. T-cell receptor ligation induces distinct
signaling pathways in naive vs. antigen-experienced T cells. Proc. Natl. Acad.
Sci. USA 108: 1549–1554.
37. Keir, M. E., M. J. Butte, G. J. Freeman, and A. H. Sharpe. 2008. PD-1 and its
ligands in tolerance and immunity. Annu. Rev. Immunol. 26: 677–704.
The Journal of Immunology 1543
 o
n
 A
pril 16, 2012
w
w
w
.jimmunol.org
D
ow
nloaded from
 
Supplementary data Fig. 1. Summary of CD8 T cell responses from two clinical
studies of HLA A2 positive chronic HBV patients induced by HBVA2-nanoAPC or
IL-2-HBVA2-nanoAPC. Unstimualted PBMC from same patient served as
controls.
Controls          HBVA2-nano    IL-2-HBVA2-nano
%
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N
+
Shanghai
QM
 o
n
 A
pril 16, 2012
w
w
w
.jimmunol.org
D
ow
nloaded from
 
Supplementary data Table 1. Patient characterization and CD8 T cell response
induced by nanoAPC for each patient from QM study.
Subject ALT HBeAg Viral load Sex Age IL-2M-I M-I Control 
Low viral 
load (IU/liter) (log) CD8+IFN+(%) 
Q1 39 N 5.28 F 36 5.9 3.1 0.1
Q2 37 N 3.27 M 44 0.8 0.3 0.1
Q3 24 N 4.58 M 69 0.8 0.1 0
Q4 53 N 5.98 M 23 10.1 0.7 0.2
Q5 24 N 5.84 M 42 0.5 0.4 0
Q6 36 N 4.67 F 44 3.7 0.3 0.3
Q7 127 N 4.63 M 26 1.5 0.3 0.4
Q8 211 N 5.22 M 33 4.2 2.3 0.1
Q9 97 P 4.05 F 56 0.3 0.1 0
Q10 206 N 5.27 M 51 16.1 5.4 0.2
Q11 79 N 5.58 M 52 0.5 0.3 0
Q12 44 N 5.11 M 42 0.7 0.3 0
Q13 83 N 4.49 M 57 0 0 0
Average  81.54 P/N=1/12 4.92 F/M=3/10 44.23
High viral 
load
Q14 32 P 7.99 F 35 0.1 0 0
Q15 65 N 7.14 F 58 7.3 0.2 0.2
Q16 30 P 7.45 M 17 0.1 0 0.1
Q17 45 P 7.31 M 18 12.3 3 0.3
Q18 202 N 8.37 F 27 0.1 0.1 0
Q19 31 P 9.96 M 28 4.5 0.5 0.1
Q20 169 N 6.65 F 36 14.2 6.2 0.2
Average  82 P/N=4/3 7.84 F/M=4/3 31.29
Total 
Average  81.7 P/N=5/15 5.94 F/M=7/13 39.7
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Supplementary data Table 2. Patient characterization and CD8 T cell response
induced by nanoAPC for each patient from Shanghai study.
Subject ALT HBeAg Viral load Sex Age IL-2M-I M-I Control 
Low viral 
load (IU/liter) (log) CD8+IFN+ (%) 
F1 430 P 4.68 M 33 11.4 4.5 0.3
F2 121 N 5.79 M 37 1.7 1.4 0.1
F3 42 N 5.21 M 44 1.3 1.3 0.3
F4 73 N 5.58 M 23 1.4 1.2 0.3
F5 362 P 4.31 M 32 2.6 0.7 0
F6 140 N 5.38 M 40 12.4 1.1 0
F7 170 P 5.42 M 27 7.8 0.5 0
F8 120 P 5.49 M 29 3.6 3.3 0
F9 278 P 5.83 M 40 4.9 2.3 0.3
F10 40 P 5.87 M 25 0.9 1.5 0
F11 423 P 5.63 M 33 2.5 0.8 0.2
Average 199.91 P/N=7/4 5.38 F/M=0/11 33
High viral 
load
F1 2 135 P 7.23 F 52 0.5 0.3 0
F13 110 P 7.54 M 22 4 2.5 0.1
F14 143 N 7.03 F 32 3.5 2 0.1
F15 188 N 6.13 M 19 1.8 1.6 0
F16 194 P 7.05 F 41 3.5 1.5 0.1
F17 267 N 9.13 M 22 1 1 0
F18 126 P 6.23 M 19 1 0.3 0
F19 20 P 7.04 F 40 1.4 0.5 0
F20 313 N 6.32 M 38 1 0.9 0.1
F21 212 P 9.12 M 47 1.5 0.2 0
F22 122 P 7.15 M 32 1.7 1.2 0.1
F23 35 N 7.24 M 20 4.2 1.3 0.3
F24 23 N 7.24 F 37 1.1 0.8 0.2
F25 46 N 6.09 F 38 0.8 0.3 0.8
F26 310 N 7.61 M 34 4 0.4 0.1
F27 76 N 7.14 M 46 0.6 0 0.1
F28 211 N 7.54 M 33 1 0.6 0.1
F29 79 N 6.23 F 52 3.7 0.2 0
F30 35 P 6.34 M 26 4 2 0
F31 46 P 7.38 M 18 2.1 1.1 0.3
F32 80 P 7.24 F 27 5.6 0.9 0
F33 43 P 7.23 M 18 4.7 3.9 0.2
F34 86 P 7.42 M 30 2.8 0.9 0.3
F35 47 P 7.86 M 41 0.9 0.9 0.1
F36 42 P 6.1 M 28 0.7 0.6 0
F37 140 P 6.5 M 32 0.3 0.1 0
Average 120.35 P/N=15/11 7.12 F/M=8/18 32.46
Total
Average 141.11 P/N=22/15 6.61 F/M=8/29 32.64
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Subject ALT HBeAg 
Viral 
load Sex Age IL-2M-II M-II Control 
Low viral 
load (IU/liter) (log) CD4+IFN+ (%) 
Q1 39 N 5.28 F 36 2.6 0.5 0
Q3 24 N 4.58 M 69 1.4 0.2 0.1
Q5 24 N 5.84 M 42 1.9 0.5 0
Q9 97 P 4.05 F 56 4.6 2.2 0.1
F4 73 N 5.58 M 23 0.9 0.8 0
F5 362 P 4.31 M 32 0.6 0.2 0
F8 120 P 5.49 M 29 0.9 0.6 0.1
F10 40 P 5.87 M 25 1.7 0.3 0
Average 97.38 P/N=4/4 5.13 F/M=2/6 39
High viral 
load
Q19  31 P 9.96 M 28 4.3 0.8 0.4
F12 135 P  7.23 F 52 0.6 0.2 0.2
F13 110 P 7.54 M 22 3.6 1.5 0
F14 143 N 7.03 F 32 5.6 2.9 0.1
F18 126 P 6.23 M 19 0.9 0.2 0
F19 20 P 7.04 F 40 1 0.3 0
F20 313 N 6.32 M 38 0.7 0.6 0
F21 212 P 9.12 M 47 0.5 0.2 0
F23 35 N 7.24 M 20 1.9 0.5 0.1
F24 23 N 7.24 F 37 0.5 0.3 0
F25 46 N 6.09 F 38 0.7 0.1 0.1
F26 310 N 7.61 M 34 3.9 1.9 0.2
F27 76 N 7.14 M 46 0.3 0.5 0.1
F28 211 N 7.54 M 33 2.7 3 0.2
F29 79 N 6.23 F 52 1.4 1.7 0
F30 35 P 6.34 M 26 0.8 0.1 0.1
F31 46 P 7.38 M 18 3.4 3.2 0
F35 47 P 7.86 M 41 2.9 2.7 0.3
F36 42 P 6.1 M 28 3.5 2.4 0.1
F37 140 P 6.5 M 32 0.1 0.1 0
Average 109 P/N=11/9 7.19 F/M=6/14 34.15
Total
Average 108.15 P/N=15/13 6.65 F/M=8/20 35.52
Supplementary data Table 3. Patient characterization and CD4 T cell response
induced by nanoAPC for each patient included in this study.
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